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ABSTRACT.
Experiments aimed at e luc idating  the id e n t i ty  o f antigenic metabolites 
of p ra c to lo l ,  using in v i t ro  generated practo lo l metabolites and 
sera from practo lo l pa tien ts , were unsuccessful as none of the sera 
tested contained measurable concentrations of antimetabolite a n t i ­
bodies. Collaborative experiments with workers who had o r ig in a l ly  
established the technique also fa i le d  to detect such antibodies. I t  
was concluded, a f te r  fo llow  up studies, tha t the active sera must 
have been used up or damaged during the o r ig ina l inves tiga tions .
Rabbits and guinea-pigs, in jected with the prote in bound practo lo l 
metabolites did not respond by synthesising antjmetabolite antibod­
ies. The probable reason fo r  the lack of response was the low concen­
t ra t io n  of hapten binding (1 metabolite molecule/6  prote in molecules).
A ra t io  o f at least 10:1 is normally used in such experiments and 
ra t ios  o f greater than 100:1 are not uncommon.
Neither in v i t r o  generated metabolites o f practo lo l nor chemical ana­
logues, had any e f fe c t  on human skin f ib ro b la s t  growth or collagen 
synthesis in v i t r o . In contrast, p ra c to lo l,  propranolol and paracetamol 
all inh ib ited  these f ib rob la s ts  functions in a dose re la ted fashion. 
Cells from uninvolved skin o f a psoriasis pa tient were more se n s it ­
ive to the in h ib i to ry  actions o f the two 3-receptor blocking drugs 
than f ib ro b la s ts  obtained from a control volunteer but were less sen­
s i t iv e  to paracetamol ind ica ting  a va r ia t ion  in the response to 
3-receptor blocking drugs and tha t such changes in s e n s i t iv i t y  need 
not be para lle led by chemically re la ted compounds such as paracetamol. 
Practolol was not taken up by the f ib ro b la s ts  to any great extent
ind ica ting  tha t i t s  s i te  o f action was the plasma membrane. Uptake 
o f leucine was in h ib ite d  to the same extent as collagen synthesis 
suggesting that practo lo l may in te r fe re  with protein synthesis by 
l im i t in g  substrate a v a i la b i l i t y .
In v i t r o  morphological studies are consistent w ith the idea tha t the 
three drugs act by d i f fe re n t  mechanisms although fu r th e r  studies are 
necessary to confirm th is .
The fo llow ing conclusions can be drawn from the experimental f ind ings .
- The side effec ts  o f practo lo l are more l ik e ly  to have been due 
to the parent molecule than to a metabolite.
- The action o f practo lo l is l i k e ly  to have been an in h ib i to ry ,  
rather than a s tim u la tory , one.
- Susceptible patients have an increased s e n s i t iv i t y  to practo lo l 
which could be re flec ted in the response o f f ib ro b la s ts  from 
such patients in v i t ro .
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CHAPTER 1.
INTRODUCTION TO THE THESIS
INTRODUCTION
The terms adrenergic and cho linerg ic were introduced by Dale (1933) 
to describe nerve f ib res  tha t release, respective ly , a sympathetic 
transm itte r and ace ty lcholine, but the terms have since been extended 
to include the corresponding neurotransmitter receptors.
Langley (1905) suggested that there were two types o f t issue recep­
to r ,  exc ita to ry  and in h ib i to ry .  This concept was supported by Dale 
(1906) who showed tha t an ergot preparation paralysed the s tim u la to r 
actions o f the adrenergic system without a ffec t ing  in h ib i to ry  impul­
ses. The concept of independent receptors received support from Ahlqu is t 
(1948) who investigated the e f fe c t  o f f iv e  catecholamines on adrenergic 
actions and showed tha t although they were q u a l i ta t iv e ly  s im ila r  
there were qu an tita t ive  differences. He explained th is  f ind ing  by 
suggesting that the two receptors had d i f fe re n t  a f f in i t i e s  fo r  the 
compounds tested. The order o f potency fo r  one set o f responses was, 
adrenaline, nor-adrenaline, methylnor-adrenaline and isoprenaline. This 
potency order correlated with contraction o f the rabb it u terine myomet­
rium, dog and rabb it uterus in s i tu  and fo r  in h ib i t io n  o f atropine ind ­
uced gut contractions. The second class o f responses, ty p i f ie d  by 
vasod ila tion , in h ib i t io n  o f myometrial contraction and a pos it ive  iono- 
tro p ic  e f fe c t  had a catecholamine potency order o f isop rena line , adren­
a l ine , methyl adrenaline, methyl nor-adrenaline and nor-adrenaline. 
Ahlquist designated the receptors as alpha (a) and beta (B) respective ly  
and emphasised that the c la s s i f ic a t io n  was based on agonist potency.
The adrenergic receptor blocking agents ava ilab le at tha t time acted 
only at a-receptors and th is  lead to c o n f l ic t in g  reports on th e i r  s i te  
o f action and e f f ic ie n c y , (Ahlquist 1967).
The use o f di-chloroisoprenaline (Powell and S la ter 1958), a compound 
which was shown to block 3-adrenergic functions, f i n a l l y  established 
the two receptor concept. Later work by Lands et al (1967), Furchgott 
(1967), Levy (1966) and Moran (1966) demonstrated tha t the 3-receptor 
could be divided in to  subtypes. Stimulation o f 3i-receptors produced 
e ffec ts  on the heart and 1ipo lys is  w h i ls t  s tim u la tion o f 32-receptors 
produced changes in bronchiolar and blood vessel tone. Furchgott (1967) 
studied the a f f in i t y  constants o f various tissue receptors fo r  pro- 
netholol and concluded that the 3-receptor could be even fu r th e r  sub­
divided. Bristow et al (1970) extended Furchgotts work and measured 
the receptor a f f in i t i e s  o f the 3-receptor blocking drugs propranolol 
and p rac to lo l.  They found tha t the a f f in i t y  constant fo r  the blocking 
action o f practo lo l on the heart v/as f i f te e n  tim es'greater than fo r  
tracheal muscle and s ix  hundred and s ix ty  times greater than fo r  a o r t ic  
muscle. They in terpreted these quan tita t ive  differences as evidence 
fo r  the presence o f 3-receptor subtypes in the tissues studied. 
Furchgott (1972) discussed the problems involved in measuring the a f ­
f i n i t y  constants o f 3-receptors fo r  agonists and antagonists. For ex­
ample sympathetic nerves ac t ive ly  accumulate nor-adrenaline w h i ls t  
propranolol can in te r fe re  with i t s  uptake. S im ila r ly  measurement o f 
the blood drug level may give a value unrelated to the free drug con­
c e n t ra t io n - i f  binding to plasma proteins occurs. The d i f f i c u l t i e s  in ­
volved in c lass ify ing  3-receptor subtypes are fu r th e r  underlined by the 
f ind ing  that schemes based on a comparison o f agonist potency do not 
wholly agree with those derived from a comparison of antagonist ac t ion , 
(Bristow et al 1970, Furchgott 1972). Despite the doubt surrounding 
the d iv e rs i ty  o f 3-receptor subtypes, the two receptor concept has 
proved useful in defin ing tissue s e le c t iv i t y  o f 3-adrenergic receptor 
blocking drugs.
Structure function re la tionsh ips of beta adrenergic receptor blocking
drugs.
The discovery of d ich lorisoprenaline (Powell and S later 1958) stimu­
lated the development of other 3-receptor blocking drugs and resulted 
in a number o f compounds with a wide spectrum of pharmacological actions. 
For example propranolol ( f i g l , l ) ,  a non spe c if ic  3-receptor blocking drug, 
was shown to possess membrane s ta b i l is in g  a c t iv i t y  (Prichard 1978) w h i ls t  
practo lo l ( f ig  1,1), which is spec if ic  fo r  3 i - re ce p to rs , has no membrane 
s ta b i l is in g  a c t iv i t y  but does posses in t r in s ic  sympathomimetic ac t­
i v i t y ,  (Prichard 1978). These associated properties provided the basis 
fo r  a system of c lass ify ing  the drugs and can be corre lated w ith 
functional groups on the molecule, (F itzgera ld  1969, Prichard 1978).
Most 3-receptor blocking drugs are analogues o f isoprenaline ( f i g l , l ) .
The 3-receptor s p e c i f ic i t y  has been shown to reside with the iso ­
propyl substitu ted secondary amine while the a f f in i t y  is  re la ted to 
the size and degree o f branching o f the a lky l side chain, (Goodman 
and Gilman 1975 , Dollery et al 1969). This re la t ionsh ip  also applies 
to 3-blocking drugs based on pronethalol ( f i g 1,1) and d ich lo ro isoprena line , 
( f i g l , l ) . Hydroxyl sub s titu t io n  at the 3-carbon confers sterio isom- 
erism on the molecule resu lt ing  in D and L forms of which the L 
form is  the morefKarmacologically active . This applies to agonists 
and antagonists. Antagonist and agonist properties have been shown 
to be dependent on the type o f su b s t itu t io n  on the benzene nucleus.
For example isoprena line ,.a  potent agonist, has hydroxyl groups sub­
s t i tu te d  at the 3 and 4 positions w h i ls t  d ich lo ro isopro te reno l, an 
antagonist, has chlorine atoms substitu ted across the same carbon atoms.
Figure 1, 1.
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C lin ica l uses o f beta-receptor blocking drugs.
The 3-receptor blocking drugs have been used to t re a t  a va r ie ty  of 
c l in ic a l  cond it ions, ( table 1,1). but the main therapeutic use is  fo r  
the treatment of cardiovascular disease, p a r t ic u la r ly  hypertension 
where long term treatment resu lts  in a gradual reduction in blood 
pressure, (Prichard 1964, Prichard and Gil lam 1969). The mechan­
ism by which the blood pressureis reduced is not known. Various 
hypotheses have been put forward to account fo r  th is  hypotensive 
e f fe c t  including an action on the central nervous system, a block­
ade of adrenergic neurones, a lte ra t io ns  in renin leve ls , an action 
on the barroceptors and an e f fe c t  secondary to cardiac output 
such as a reduction in plasma volume. There is  evidence fo r  and 
against each o f these but probably a l l  are involved to varying 
degrees,(Prichard 1978).
Adverse side e ffec ts  o f treatment with beta blocking drugs
Adverse side e ffec ts  common to beta blocking drugs.
A ll  3-blocking drugs in use are capable o f giv ing r ise  to adverse 
e ffec ts  (Sanders 1978) the severity  o f which can be influenced by the 
dose, 3-receptor s p e c i f ic i t y ,  presence or absence o f in t r in s ic  a c t iv i t y  
and physical properties such as l i p id  s o lu b i l i t y  (Prichard 1978, 
Carruthers 1980), Side e ffec ts  are reported by 40-50% of a l l  patients 
on 3-blocking drugs (Dany et al 1979), although reducing the dose or 
changing to another drug can a l le v ia te  the symptoms (Zacharias et al 
1972). About 20% of patients have to be withdrawn from treatment 
( Petrie et al 1976) w h i ls t  with others the side e ffec ts  are dose 
l im i t in g  or can be to lerated (Dany et al 1979, Prichard 1978,
Zacharias et al 1972). Deliberate or massive overdoses are seldom
Table 1.
Current therapeutic uses fo r  beta receptor blocking drugs.
Angina pectoris
Hypertension
Cardiac arrhythmias
Thyrotoxicosis
Hypertrophic cardiomyopathy
Schizophrenia w
Anxiety state
Phaeochromocytoma 
Tetralogy o f F a l lo t  
Parkinson’ s disease 
Dissecting a o rt ic  aneurysm 
V io l i n i s t ’ s bow tremor 
Glaucoma
Familial benign tremor
(data modified from M il la r-C ra ig  1979 and van Joost et al 1979).
fa ta l  (Dukes 1979).Practo lo l (9gm) and metoprolol (lOgm) have been 
taken without causing death (Faverel-Garrigues et al 1977) although 
large oral doses o f 3-blocking drugs can prove le th a l ,  eg oxprenolol 
(4.5gm) and sota lo l (3gm) (Faverel-Garrigues e t al 1977, Montagna and 
Groppi 1980).
*
Drug induced side e ffec ts  can be divided in to  two types, those re s u l t ­
in g  from an exacerbation o f the drugs normal pharmacological action 
and those apparently unrelated to the drugs pharmacology. A summary 
o f these side e ffec ts  are given in  table 1 , 2 .
1 - Adverse_side_effects_related_to_the_pharmacology_gf_beta_-_receptor
i
kl29king_drugs
Blockade o f 3-receptors can re su lt  in a va r ie ty  o f e ffec ts  including 
a general decrease in cardiac function , an increase in peripheral 
vascular resistance, bronchioconstriction and metabolic e f fe c ts ,  
(Prichard 1978). These are usually not serious as long as care is  
taken in prescribing a p a r t ic u la r  drug fo r  a pa tien t. Adverse cardiac 
e ffec ts  such as bradycardia and hypertension are seen in about 4% o f 
practo lo l patients and between 1.5 and 6% of those on propranolol, 
(Dany et al 1979). Up to 60% o f patients on propranolol, 20% on 
oxprenolol and 35% on atenolol have been reported to su ffe r  from cold 
extrem ities due to increased vascular resistance (Roberts e t al 1976). 
Various other complaints such as ch i lb la in s  and Raynaud’ s syndrome are 
not uncommon but extreme reactions resu lt ing  in gangrene are rare, 
(O’ Rourke et al 1979, Vale and Jefferys 1978). P rac to lo l,  metoprolol 
and atenolol cause few side e ffec ts  in asthmatic patients (V i ls v ik  and 
Schaanning 1976, Formgren 1976). Those reactions tha t do occur are 
eas ily  reversed by administration o f  a 3-receptor agonist (Boye and 
Vale 1977). Propranolol is  contraindicated in asthma however (Dolery
Table 1, 2.
Summary o f adverse e ffec ts  associated with g-receptor blocker 
treatment
Adverse reactions related to the degree o f 3-blockade.
-------- ' - T - - - ^
yo2il20 • ( 2- 7%)
Heart fa i lu re ,  hypertension,
Bronchiospasm 
Hygoglycaemia 
y§§22l2r_§ff§2*§-(40%)
in te rm it te n t c laud ica tion , cold extremeties, Renauds phenomenon.
Adverse side effec ts  unrelated (?) to 3-blockade.
Neuromuscular_reactions^ (1-16%)
muscular weakness, ha lluc ina t ions , dreams, somnolence, insomnia, 
depression.
Ind igestion, diarrhoea, constipation.
Adverse side e ffec ts  associated mainly with practo lo l adm in is tra tion . 
Skin_effects (5.6% Waal-Manning 1975)
Psoriasiform changes, ex fo l ia te  de rm a tit is , ezematous, l icheno id , LE-
Raftery 1974)
922l2T_2ff§222i(1-4% Waal-Manning 1975)
Photophobia, g r i t t y  fe e l in g ,  reduced tear f low , conjunctival f ib ro s is  
corneal perforation .
( I t  has also been reported tha t the combined incidence o f skin and 
ocular e ffects  is  about 10%, (Jachuck et al 1977)).
l ik e
,
Table 1, 2. continued.
Sclerosing p e r i to n i t is .
Q^her_ react i 20§ ^ )*
Pleural reaction, pericard ia l reaction, l i v e r  and kidney damage, 
auditory impairment, u lceration o f the mouth and nasal passages.
The to ta l number o f patients reported to have suffered adverse 
side effec ts  due to practo lo l was 1,300 as o f 1983. Patient exposure 
to practo lo l was about 1 m i l l io n  pa tien t years, (Cruickshank 1983).
(Percent values fo r  the general e ffec ts  o f 3-receptor blocking drugs 
are taken,or calcu lated, from the references given in the te x t )
et al 1969). Both glycogenolysis and l ip id  metabolism can be d is ­
turbed by 3-receptor blockade. Disruption o f glycogenolysis may res­
u l t  in hypoglycaemia although th is  occurs in frequently  (Prichard
1978). Insu lin  induced hypoglycaemia can be enhanced however, p a r t ic ­
u la r ly  by those drugs with membrane s ta b i l is in g  properties and l i t t l e  
3-receptor s p e c i f ic i t y  (Deacon et al 1977). An increase in blood 
t r ig ly c e r id e s , but not glucose or cholesterol leve ls , has been rep­
orted during metoprolol, a teno lo l,  pindolol and propranolol therapy 
(Shaw et al 1978) although other authors have not been able to con­
firm  th is  change (Nilsson et al 1977).
2. Effects unrelated to the pharmacological action of beta-receptor_______       —_—____L _ __ _ _ _ _ ______ —__  * __             — _____ _
b]ocking_drugs.
A number o f reactions,apparently unrelated to the pharmacology of 
3-receptor blocking drugs,can be seen with a l l  members o f the group, 
w h i ls t  other reactions occur ra re ly  or are apparently associated with 
a p a r t ic u la r  drug. L ip id  soluble compounds such as propran­
o lo l ,  pindolol and oxprenolol enter the C.N.S. re la t iv e ly  eas ily  and 
can give r ise  to a number o f psychotic disturbances such as nightmares, 
v iv id  dreams, ha lluc inations and muscular weakness (Robinson 1978). 
Isolated examples occure with most 3-receptor blocking drugs 
(Berglund 1977, Ashton 1976). Estimates of the number o f patients 
affected vary. For example Dany e t al (1979) compared publications 
which showed tha t between 0.6 and 4.3% o f patients on propranolol had 
trouble sleeping. Gastro intestina l complaints are common and in d i ­
gestion, diarrhoea, nausea, cramps and constipation have been assoc­
iated with a l l  3-blocking drugs although treatment ra re ly  needs to 
be discontinued (Robinson 1978). I t  is  not always possible to gauge 
accurately the numbers o f patients affected as the methods o f obta in­
ing information can bias the resu lts  (Dany et al 1979, Roberts e t al
1976). Estimates o f the percentage o f patients taking propranolol 
chron ica lly  who su ffe r  from in te s t in a l complaints vary from 0 . 9% 
to 11.2% (Dany et al 1979).
Occasional and s ingular adverse reactions have been reported fo r
a l l  the drugs in use, fo r  example hyperpigmentation associated with
<
oxprenolol (Hcirrower and Strong 1977). In some cases a causal 
re la tionsh ip  has been established by challenging with the drug but 
th is  is  not always the case and some reports re ly  on the coin­
cidence of drug and e f fe c t .  The most serious and s ig n if ic a n t  series 
o f adverse e ffec ts  occured as a re su lt  o f practo lo l adm inistra tion.
Isolated reaction found with other 8-blocking drugs w i l l  be discussed 
in re la tionsh ip  with the practo lo l e f fe c t  as there is concern tha t 
they could also give r ise  to aspects o f the practo lo l syndrome (Scowen 
1978, Sutherland and Wilson 1976).
Adverse side e ffec ts  associated mostly with practo lo l adm in is tra tion . 
Practolol was introduced in 1970 as a BiSpecific  antagonist.
During i t s  c l in ic a l  t r i a l s  no adverse e ffects  were noted although 
only small numbers o f patients were treated fo r  short periods o f 
time (George et al 1970, Sandler and Clayton 1970) Soon a f te r  i t s  
in troduction however Wiseman (1971) and Zacharias (1972) described 
a v a r ity  of skin rashes associated with i t s  use and in 1973 a p ract­
o lo l induced systemic lupus erythematosus-type syndrome was reported
(Raftery and Denman 1973, Assem and Banks 1973). During the next
year i t  became apparent tha t a complex o f adverse reactions could be 
caused by practo lo l invo lv ing the sk in , eyes and serosal surfaces.
The term "oculomucocutaneous syndrome" was suggested by Wright (1975) 
to cover the var ie ty  of lesions reported. Symptoms included a p so r i­
asiform skin eruption (Fe lix  et al 1974), u lceration o f the mouth and nasal
passages, impairment o f hearing and vis ion (Wright 1975) and a 
po lyseros it is  which resulted in e ith e r f ib ro s is  or effus ion in to  
the serous cav ity . More recently reports o f l i v e r  damage (Brown et 
al 1978) and damage to the lungs (Marshall e t al 1977b) and Kidneys 
(Farr et al 1975) have been published. The reactions out!ined above 
occured both s ing ly  and in combination and are now discussed in 
more d e ta i l .
A Skin_effects.
Practolol re lated e f fe c ts .
Fe lix  et al ^ 1974) described 21 practo lo l patients seen over a 
period o f two years with e ith e r psoriasiform (14 patients) excematous 
(1 pa tien t) lichenoid (2 patients) lupus erythematosus l ik e  (1 pat­
ien t)  eruptions or e x fo l ia t iv e  derm atit is  (3 pa tien ts ). The rashes 
cleared on withdrawal of the drug and reappeared a f te r  oral challenge. 
The development and h isto logy o f the psoriasiform lesion is  thought 
to best ty p i fy  the practo'lol reaction although h is to log ica l find ings 
were most marked in those patients with the lichenoid type eruption. 
The rash developed over a period o f months s ta r t in g  w ith a scaling 
and thickening o f the skin o f the palms and soles, associated with 
p s o r ia s is - l ike  plaques over the knees, elbows and other bony prom­
inences. I t  la te r  spread to other areas o f the limbs and then to the 
trunk,as an erythematous rash with scaly edges. The h is to log ica l 
appearance was s im ila r  in each case, varying only in degree depending 
on the lesion. There was a marked epidermal atrophy and c o l lo id  
bodies could be seen migrating from the epidermis to the outer horn^ 
layer. There was patchy swelling o f the basement membrane, which was 
disrupted in some places. Deposits o f immunoglobulin (Ig)G,IgM and 
complement fac to r  C3 were found at the dermo-epidermal junc tion  in
6 out o f 8 patients examined and antinuclear antibodies (ANA) in the 
serum of 5 out o f 18 patients investigated. Only one pa tien t tested 
fo r  ANA had a psoriasiform rash however.
Effects associated with other beta blocking drugs.
Rashes have been associated with a l l  3-blocking drugs in use (Scowen 
1978, Neumann and van Joost 1981), but i t  is  not certa in tha t these 
represent examples o f the practo lo l induced rashes as noneof these 
patients developed the cha rac te r is t ic  thickening o f the palms and soles 
described by Fe lix  et al (1974). The h isto logy of some lesions how­
ever is  s im ila r  to tha t found with practo lo l induced eruptions.
Damage to the epidermis resu lt ing  in i t s  th inn ing , epidermal oedema,
1iq u it ra c t iv e  degeneration and foc i o f 1iq u it ra c t iv e  damage have been 
described in a va r ie ty  o f rashes associated with oxprenolol (Gange and 
Levene 1979, Holt and Waddington 1978) labeto lo l (F in lay and 
Waddington 1978, Savage et al 1978, Gange and Wilson-Jones 1978) and 
propranolol (Cochran et al 1976). More im portantly , degenerating and 
necrotic ce l ls  associated with c o l lo id  body formation have also been 
described in the epidermis o f patients on the above drugs, a f ind ing  
considered to be cha rac te r is t ic  o f the practo lo l induced rashes 
(Fe lix  et al 1974). F ib r in  and fibrinogen deposits were detected at 
the dermo-epidermal junction  in the labeto lo l pa tien t o f Fin lay and 
Waddington (1978) and Savage et al (1978) respective ly and IgM and 
complement were s im i la r ly  detected by Holt and Waddington (1978) in 
th e i r  oxprenolol treated patient*.The pa tien t o f Gange and Levene 
(1979) was found to have c irc u la t in g  antibodies to an epidermal 
in te rc e l lu la r  substance but i t s  s p e c i f ic i t y  was not fu r th e r  de ter­
mined to see i f  i t  resembled the pemphigus in te rc e l lu la r  antibody 
or tha t described by Amos et al (1975) which was strongly associated 
w ith practo lo l induced ocular damage.
The h isto logy o f 3-blocking drug induced lesions seems to be d im ila r  
(Holt and Waddington 1978) and the evidence suggests tha t non-pract- 
o lo l drugs can occasionally give r ise  to a rash with a cha ra c te r is t ic  
histopathology d i f fe r in g  from the appearance of the practo lo l induced 
lesion only in degree.
JL  _0_c_uJ_ar_ A f/_ e_c_t_s_.
Practolol re lated e f fe c ts .
In 1975 Wright described 27 patients su ffe r ing  from ocular e ffec ts . 
These started ty p ic a l ly  with an " i tch y  foreign body"sensation in 
the eyes followed by a reduction in tear f low , lysozyme and secret­
ory IgA content o f the tears were also reduced, which resulted in 
a cha rac te r is t ic  conjunctival f ib ro s is  and scarring. In some patients 
corneal opacities and u lceration developed. ANAs were present in 
the serum of a l l  patients and 25 had c irc u la t in g  antibodies to 
the in te rc e l lu la r  region o f the epidermis. This autoantibody d if fe re d  
in s p e c i f ic i ty  from a s im ila r  pemphigus autoantibody (Amos e t al 
1975). In contrast o n ly -1 out o f 3 patients reported by Fe lix  (1974) 
had both ANA and eye trouble. Rahi et al (1976) described in de ta i l  
the histopathology o f practo lo l induced ocular to x ic i t y  in 6 pa tien ts , 
including 2 necropsy cases. They reported destruction o f the lacr im ­
al gland, thickening and acanthosis o f the conjunctival epithelium 
and loss o f goblet c e l ls .  These chronic inflammatory changes resulted 
in the f ib ro s is  o f the underlying stroma. The corneal epithelium 
was less obviously a f f l ic te d  but e p i th e l ia l  and stromal u lcera tion  
lead to perforation in 2 cases. Immunoglobulin was found bound to 
e p ith e l ia l  ce l l  membranes and in the subcapsular e p i th e l ia l  region 
o f the lens but complement f ix a t io n  could not be demonstrated in 
e ith e r case.
Effects associated w ith other beta blocking drugs.
Occurence o f dry eyes have been reported with a l l  3-blocking 
drugs (Scowen 1978). Dollery et al (1977) reported tha t 25% o f a 
to ta l o f 483 patients seen,who had been taking various 3-blocking 
drugs, complained o f a g r i t t y  fe e l in g ,  sore or red eyes and/or photo- 
phobia. Fraunfelder (1976) l is te d  the side e ffects  o f propranolol as 
invo lv ing the eyelids and conjunctiva. Reports purporting to describe 
incidences s im ila r  to the practo lo l syndrome are rare. Bevis e t al 
(1975) reported a pa tien t w ith propranolol induced ocular changes 
and Knapp and Galloway (1975) Holt and Waddington (1975) and Clayden 
(1975) have reported adverse e ffec ts  a f te r  administration o f oxprenolol. 
The top ica l administration o f atenolol has been reported to give r ise  
to conjunctiv itis  and reduced tear secretions (Rebeller and Mureau
1979) and metoprolol to conjunctival oedema, hyperaemia and p e r i ­
ocular derm atit is  (van Joost et al 1979). The s ign if icance o f any o f 
these reports is  unclear and i t  is  too soon to assess i f  the changes 
observed a f te r  top ical treatment could re su lt  in more serious damage 
as th is  is  a re la t iv e ly  new use fo r  3-blocking drugs.
In the absence o f a d e f in i t iv e  report i t  would seem u n like ly  tha t 
oral 3-blocker therapy, using drugs other than p ra c to lo l,  would 
re su lt  in serious ocular damage.
C Sclerosing p e r i to n i t is .
Practolol related e f fe c ts .
Id iopath ic  sclerosing p e r i to n i t is  is  a condition ra re ly  seen and 
Geisthovel and Kalfhaus (1965) have reviewed the l i te ra tu re  from 
1942 when p la s t ic  p e r i to n i t is  was f i r s t  described by Hartmann.
Brown et al (1974) described 3 female patients with d is t in c t  rad io ­
log ica l features showing d i la t io n  confined to the small bowclbut 
extending from the duodenum to the ileum. At laparotomy the v iscera l
and parie ta l peritoneum were seen to be thickened, with massive 
peritoneal adhesions. The re troperitoneal space was not affected. 
H is to lo g ica l ly  the thickening was seen to be due to a non-specific 
inflammatory response,with a layer o f compact,laminated,fibrosis 
beneath the mesothelium composed o f collagen bundles. There was no 
sign o f tubercu li or foreign p a rt ic le s .  The histo logy d if fe re d  from 
id iopath ic  and methysergide associated re troperitoneal f ib ro s is  in 
tha t the deep adipose tissue and large blood vessels were not effected. 
Biopsies obtained from patients who underwent a second operation fo r  
removal o f the peritoneal adhesions showed that a vigorous, granu­
la t io n ,  tissue response had developed with a f ib r inous exudate ever- 
ly ing  the mesothelial surface. Later scanning electron microscopic 
and h is to log ica l studies suggested that the mesothelium had in fa c t  
been destroyed in patients with sclerosing p e r i to n i t is ,  (Myllarniemi 
and Lappaniemi 1981). As the association between practo lo l and the 
sclerosing condition was not d e f in i te  the authors carried out a 
survey,via the Committee on Safety o f Medicines, which revealed four 
s im ila r  cases. Other reports followed describing the ch a ra c te r is t ic  
peritoneal adhesions and histology,(Meyboom. 1975, Windsor e t al 
1975 and Marshall et al 1977a) Withdrawal o f the drug did not prev­
ent the development of the f ib r o t i c  condition which could express 
i t s e l f  8 months or 12 months or even 18 months a f te r  a pa tien t had 
stopped taking p ra c to lo l,  (Brown etal 1974, Hailey and Goodman 1975, 
Allan and Cade 1975). Approximately 25% o f ind iv iduals  w ith s c le r ­
osing p e r i to n i t is  suffered from inflammation o f other serosal mem­
branes , (Harty 1978). Pleural e ffus ions, jo in t  e ffus ion s ,p leu r­
isy and c o n s tr i t iv e  p e r ic a rd i t is  have also been reported to occur, in 
association with the sclerosing condition (Flemming and H ick ling 1975,
MacKay and Axford 1976, Fraser and Irv ine  1976, Dyer and Vorley 1975). 
Dermatitis and con junc tiv it is  occured in over 50% of such pa tients . 
Marshall et al (1977b) reported in de ta il on 6 patients who devel­
oped resp ira tory  disease a f te r  surgical treatment fo r  sclerosing 
p e r i to n i t is .  Findings included extensive f ib r o t ic  pleural thickening 
and lesions fn the lung parenchyma. Radiological changes always 
occured during practo lo l administration but, as with the p e r i to n i t is  
(Marshall et al 1977a), these could preceed c l in ic a l  symptoms by as 
much as 20 months (0-20 months, mean 9.3months). In some cases dyspnoea 
was s t i 11 increasing several years a f te r  the pleural th ickening was 
diagnosed. . Laminated collagen bundles and signs of a mild in flam ­
matory reaction were found in biopsies o f the thickened pleural 
t issue , almost iden tica l in appearance to specimens from patients 
with sclerosing p e r i to n i t is .
Effects associated with other beta blocking drugs.
Marshall et al (1977a) have presented evidence tha t appears to im p l i ­
cate other 3-blocking drugs in the formation o f small bowel abnorm­
a l i t i e s .  They studied 54 patients who had been on 3-blocking drugs 
fo r  more than a year, using a rad io log ica l technique. 2 patients 
on p ra c to lo l,  2 patients on propranolol and 3 patients on oxprenolol 
had s im ila r  rad io log ica l small bowel abnormalities and 1 pa tien t who 
remained on propranolol fo r  a fu r th e r  6 months developed abdominal 
pain and nausea. Radiological investigations revealed tha t the changes 
had progressed in th is  pa tien t. On withdrawal o f the drug(s) the 
signs regressed. In contrast Marigold e t al (1982) could f in d  no ind­
ications^ in a group of 32 patients taking propranolol (25) and 
oxprenolol (7 ), o f s im ila r  rad io log ica l changes. Oxprenolol and t im ­
o lo l have both been associated with sclerosing p e r i to n i t is ,  (Kennedy 
and Ducrow 1977, Baxter-Smith et al 1978) but a causal re la t io n ­
ship is  doubtful and Nancarrow (1978) suggested that the lesions 
were more compatible with e ith e r a secondary p e r i to n i t is  or an id io ­
pathic collagen disease. Clark and Terris  (1983) however reported 
tha t metoprolol caused sclerosing p e r i to n i t is  in a female pa tien t 
who had been taking the drug fo r  2 years. Findings on laparotomy 
were consistent with those described by Brown et al (1974) fo r  p ract­
o lo l induced changes. Harty (1978) described a patient who devel­
oped itchy  eyes, a p u r i t ic  scaly eruption on his legs and fee t and 
asc ites, over a period o f 2 or 3 months, w h i ls t  taking propranolol.
The small bowel was found to be encased in a dense fibrous tissue. 
Histology o f the peritoneal biopsy showed an intense f ib ro p la s t ic  
and inflammatory response tha t extended to the mesothelial l in in g  
and affected the mesenteric adipose tissue. The h isto logy o f the 
lesion was d i f fe re n t  from tha t described fo r  practo lo l as the adipose 
tissue was involved. The fa c t tha t the patient had taken propranolol 
fo r  such a short time, in  conjunction with other drugs, makes i t  
un l ike ly  tha t the disease was due to the 8 -blocking drug. A case o f 
sclerosing p e r i to n i t is  in a man who had been taking propranolol fo r  
2 years was reported by Ahmed (1981) so that iso lated cases may 
occur . There are 2 reports o f re troperitoneal f ib ro s is  in  patients 
who had taken atenolol fo r  9 months (Doherty e t al 1978) and 1\ months 
(Johnson and McFarland 1980). The histo logy o f drug induced (eg methy- 
sergide) and id iopa th ic  retoperitoneal f ib ro s is  are the same (Graham 
et al 1966) so tha t i t  was not possible from biopsies to be sure i f  
atenolol was the causative agent or not. The patient o f Johnson and 
McFarland (1980) had been hypertensive fo r  5 years before an operation 
to free his r ig h t  ureter. A fte r  th is  treatment his blood pressure 
returned to normal. This change led Gavin et al (1980) to suggest
tha t the hypertension had been caused by the re troperitoneal f i b ­
ro s is ,  although they did not comment on the fac t that the pa tien t 
would have had to have had the f ib r o t ic  condition fo r  5 years.
Timolol and metoprolol have also been associated with re troperitonea l 
f ib ro s is  (Rimmer et al 1983, Thomson and Julian 1983). Bullimore 
(1980), using*data published by the Committee on Safety o f Medicine, 
suggested tha t 8-blocking drugs predominated in causing re t ro p e r i t ­
oneal f ib ro s is  and tha t some members o f th is  series o f drugs are more 
active than others in th is  respect. Castle et al (1980) however 
quoted a persgnal comunication reporting tha t 16 patients who had 
changed from practo lo l to atenolol 6 years previously had not only 
lo s t  symptoms o f the oculomucocuaneous syndrome but had no signs of 
a f ib r o t i c  lesion.
A case o f pulmonary f ib ro s is  occuring in a pa tien t who had taken 
pindolol fo r  7 years was reported by Musk and Pollard (1979). H is t­
ology was s im ila r  to tha t described fo r  practo lo l induced pulmon­
ary f ib ro s is  (Erwtman e t al 1977).
Sclerosing conditiqns are rare with 8“ blocking drugs other than prac t­
o lo l and i t  is  d i f f i c u l t  to ru le  out the coincidence o f drug therapy 
and id iopa th ic  disease. The various aspects of discussions on the 
incidence of drug induced f ib ros ing  e ffec ts  are ty p i f ie d  by the 
correspondence of Bullimore (1980) and Castle e t al (1980) over the pos­
s i b i l i t y  of atenolol induced re troperitoneal f ib ro s is .
D Systemic Lupus Erythematosus (SLE).
Practolol re lated e f fe c ts .
Raftery §nd Denman (1973) described 3 patients with a r th ra lg ia ,  fever 
and rashes. They had raised erythrocyte sedimentation rates, lupus 
erythematosus ce lls  and ANA but no antibodies to native deoxyribo-
nucleic acid (DNA). Serum complement levels and gamma globulin  
levels were normal and there was no evidence o f renal involvement. 
A fte r  withdrawal o f the drug the c l in ic a l  symptoms improved but 
s tero id  treatment was needed before the ANA dropped and the lupus 
ce l ls  disapeared. The c l in ic a l  appearance and laboratory f ind ings 
were consisteht w ith a diagnosis o f drug induced SLE.
Effects associated with other beta blocking drugs.
Both pindolol and labeta lo l have been reported to induce a SLE 
syndrome (Bensaid et al 1979, G r i f f i t h s  and Richardson 1979, Brown 
et al 1981). Labetalol is  also associated with the presence o f a n t i -  
mitochondrial antibodies (AMA). Douglas-Wilson et al reported tha t 
7 out of 90 patients (8%) on labeta lo l had AMA t i t r e s  o f between 1/8 
and 1/126 w h ils t  only 0.7% o f untreated hypertensives and 0.6% of 
patients treated with other 3-blocking drugs had a pos it ive  t i t r e .
The AMA usually appeared months a f te r  commencing treatment w ith 
labeta lo l but did not appear to be associated with any abnormality 
o f the sk in , l i v e r  or pericardium although the presence o f AMA was 
reported to be strongly co-related with b i l ia r y  c irrh os is  (90%) and, 
to a lesser extent, autoimmune diseases (8%).
Summary.
There is evidence tha t some reactions associated with the practo lo l 
syndrome can occasionally occur w ith other 3-adrenergic receptor 
blocking drugs. These can cause skin lesions, the h isto logy o f which 
is s im ila r  to those conditions observed in practo lo l treated pa tien ts , 
(F in lay and Waddington 1978, Gange and Levene 1979). Propranolol
and oxprenolol can induce ocular e ffec ts  s im ila r  to those induced 
by practo lo l but d i f fe r in g  in in te n s ity .  Reports o f sclerosing reactions 
associated with non practo lo l 3-receptor blocking drugs are rare and 
causal re la tionships were not well established although 3-adrenergic 
receptor blockade may be associated with an increased r is k  o f re tro -  
peritoneal f i& ros is  (Bullimore 1980). No drug however has given r ise  
to the cha rac te r is t ic  pattern o f adverse reactions observed with pract­
o lo l and a l l  the evidence available suggests tha t i t  is  unique in 
th is  respect. Some patients have been reported to cross react with 
other 3-receptor blocking drugs on trans fe r from practo lo l (Furhoff 
et al 1976, Assem 1975) but these reports would not appear to be 
typ ica l o f such patients ( Fe lix  et al 1975, Furhoff et al 1976) and 
would not appear to j u s t i f y  a lte r in g  the opinion expressed above.
Possible mechanisms of the practo lo l induced adverse e ffec ts .
Pharmacological mechanisms.
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Several authors have suggested tha t a pharmacological mechanism may 
be involved in the adverse e ffec ts  associated with practo lo l admin­
i s t r a t io n , ( fo r  a summary o f these see table 1,2). Nistrup-Madsun and 
S0ndergaard (1977) suggested tha t the psoriasiform eruption seen in 
such patients was the re su lt  o f 3-blockade which resulted in a 
d isruption of^the balance between cyc lic  adenosine Si^'-monophosphate 
(cAMP) and c y c l ic  guanine 3;5'-monophosphate (cGMP) which 1e«£ to  a 
loss of control of f ib ro b la s t  growth and a p ro l i fe ra t iv e  response.
Human f ib rob la s ts  in cu ltu re  (Rao et al 1971, Berg et al 1981) and 
human keratinocytes (Harper and Flaxman 1975) w i l l  respond to cate­
chol iwturves with an increase in cAMP content which resu lts  in 
m ito t ic  in h ib i t io n ,  possibly at the G^  phase o f the ce l l  cycle 
(Harper et al 1974). Propranolol, but not p ra c to lo l,  can block th is  
in h ib i t io n  suggesting that the receptor involved has 32s ra ther than 
3X, cha rac te r is t ics , (Voorhees et al 1974). Propranolol has also been 
shown to block the in h ib i t io n  o f collagen synthesis induced by iso- 
prenaline in acute (6h) in v i t r o  experiments, (Berg et al 1981). Cells 
incubated with isoprenaline fo r  longer periods however (72h) became 
desensitised and there was no in h ib i t io n  o f collagen synthesis and no 
increase in cAMP leve ls ,  (Saltzman 1982).
B_ Effects_on_the_skin
There is-some evidence tha t to p ic a l ly  applied 3-blockers can have a 
d ire c t  action on apparently normal skin in v ivo . For example Gaylarde 
et al (1978) demonstrated that propranolol could induce psoriasiform
changes in guinea-pig skin and van Joost et al (1979) tha t glaucoma 
patients treated to p ic a l ly  w ith metoprolol or atenolol developed 
derm atit is . Existing or in c ip ie n t lesions can be exacerbated by 
3-b locker therapy. Wiley and Weinstein (1977) demonstrated tha t in t ra -  
dermal in jec t ions  o f propranolol induced a s ix  fo ld  increase in the 
p ro l i te ra t io n 'o f  skin in an uninvolved area o f a psoriasis pa tien t 
and van Joost and Srnitt (1981) tha t a pa tien t who developed derm­
a t i t i s  a f te r  oral administration of propranolol had a pos it ive  ep i- 
cutaneous te s t to propranolol, atenolol and oxprenolol. The s ig n i f ­
icance o f these reports with regard to the practo lo l syndrome is  not 
c lear however as top ica l or intradermal challange with practo lo l fa i le d  
to produce psoriasiform changes in patients who gave such a reaction
to oral adm in istra tion , (F e i l ix  et al 1974, Mikkelsen et al 1975).
A number o f 3-blocking drugs can also exacerbate ex is ting  lesions 
a f te r  oral adm in is tra tion , practo lo l (S0ndergaard e t al 1976,V1
Ridley 1.974), oxprenolol (Cumberpatch 1974) and labeta lo l (Staughton 
et al 1980). Dunn et al. (1975) described a pa tien t in which practo lo l
caused expression o f anti cedent Sjogrens syndrome.
A  Effects_pn_secretpry_organs^
Daily in jec t ions  o f propranolol have been shown to induce a decrease 
in weight,and ce ll s iz e ,o f  ra t  submaxillary glands, in some cases with 
the formation o f atrophic f igu res , (Fukuda 1968). S im ilar changes 
were also reported to occur a f te r  oral adm in is tra tion , (Smith and 
Butler 1978). These authors also reported that there was a loss 
o f secretions from the parotid and submaxillary glands.and i n f i l ­
t ra t io n  o f  lymphocytes around the duct and parenchyma with resu ltan t 
destruction o f the e p ith e l ia l  c e l ls .  Some animals also developed 
granulomas on the serosal surface o f the colon and duodenum and
changes in the in te s t in a l serosa. These changes were only observed 
a f te r  s ix  to eighteen months so tha t propranolol would have to be 
taken fo r  a long period by humans before any s im ila r  e f fe c t  would 
be expected. Tanaka et al (1983) have shown tha t practo lo l can in ­
duce a reduction in tear flow in beagles given the drug o ra l ly .
%
Lymphocyte i n f i l t r a t i o n  in to  the lacrymal gland was also observed.
As only two animals per dose were used however these find ings need 
to be confirmed. Practolol accumulates in the lacrymal gland (Scales 
and Cosgrove 1970) so that i t  is  possible tha t damage to th is  gland 
observed in humans (Rahi et al 1976) could have been due to a 
d ire c t  e f fe c t  on the 3-receptors. Recently Okine e ta l (1982) have 
reported tha t oral administration o f p ra c to lo l,  but not propranolol, 
acebutalol, atenolol or pronetha lo l, inh ib ited  the synthesis o f 
gas tro in tes tina l mucosal glycoprotein synthesis in the ra t .  I t  was 
suggested by the authors tha t an impaired formation o f mucus could, 
in tu rn , re su lt  in in te s t in a l adhesion and dry eyes. This f in d in g ,  
together with tha t o f Tanaka et al (1983), would suggest tha t p ra t- 
o lo l is capable, in some circumstances, o f inducing changes which, 
i f  they occured in humans, could re su lt  in the adverse e ffec ts  found. 
However the lack o f any adverse e ffec ts  in animals, including the 
ra t and beagle, fed practo lo l chron ica lly  makes the in te rp re ta t io n  
o f the above reports d i f f i c u l t  (Scales and Cosgrove 1970).
P_ §ffe c ts_ o n _ ]eukocyte_]ysosomal_enzYme_release^
Brown et al (1974) suggested that the sclerosing p e r i to n i t is  could 
be due to a stim ulation o f leucocyte lysosomal enzyme release which 
could, if i tu rn , cause tissue damage and in i t i a t e  an inflammatory 
reaction. Release o f 3-glucuronidase (GUR) from human leukocytes 
is  enhanced by phagocytosis o f immune complexes (L ichtenstein and
Margolis 1968, Weissmann et al 1971a,Ignarro e t al 1974), cGMP 
and agents causing an increase in cGMP (Zurie r e t al 1974). Enzyme 
release is  depressed and the above increase blocked by cAMP and chem­
ic a ls ,  such as 8-agonists, which stimulate cAMP formation, (Zurie r 
et al 1974, Weissmann et al 1971a). Propranolol reduces the blocking 
action o f cAM^  and 8-agonists but has no d ire c t  e f fe c t  i t s e l f ,
(Zurie r et al 1974). Human lymphocytes and f ib rob la s ts  are thought 
to have 82 ra ther than 81 receptors, (Conolly and Greenacre 1977, 
Voorhees et al 1974). There appears to be no paper published des­
cr ib ing  the 87receptor subclass of human macrophages but ra t  macro­
phages have been reported to posses 82 receptors, (Schenkelaars and 
Bonta 1984). Using carrageenin e l ic i te d  ce lls  they showed tha t the 
s tim ulation o f GUR secretion by leukotriene could be blocked by 
isoprenaline and tha t th is  block could be reversed by propranolol 
but not by p rac to lo l.  Neither practo lo l nor propranolol had any 
d ire c t  e f fe c t  on GUR release.
I t  seems u n like ly  therefore that practo lo l would have any e f fe c t ,  
d ire c t or in d ire c t ,  on lysosomal enzyme release. This view is  sup­
ported by the find ing  that practo lo l can stimulate cAMP formation by 
human lymphocytes in v i t r o , (Lima and Turner 1981). I t  appears th a t,  
at least in the above model, practo lo l is  a p a r t ia l  agonist and 
would be expected, i f  anything, to depress GUR release via the 
increase in cAMP synthesis.
E Effects on the immune system.
In 1971 A llison  et al proposed tha t B -ce lls , capable o f synthesising 
autoanttbodies, were under the control o f a suppressor T -ce ll pop­
u la tion. This concept le ^  Raftery and Denman (1973) to
suggest tha t 3-blockade could d i f f e r e n t ia l l y  in te r fe re  with th is  group
o f regulatory lymphocytes allowing expression o f autoantibodies 
and development o f a lupus type syndrome. Patients with active SLE 
have an impaired antigen spec if ic  T-suppressor ce ll  a c t iv i t y ,
(Gladman et al 1980). Further, anti DNA antibody production by B-cells  
from SLE patients in v i t ro  can be prevented by allogeneic normal,
c
but not SLE, *T-cells, (Clough et al 1980). S im ilar extensive lymph­
ocyte function tests have not been carried out using ce l ls  from 
practo lo l patients so that i t  is  not possible to say i f  T -ce ll are 
p re fe re n t ia l ly  suppressed in adversely affected patients. There are 
data available which show tha t adrenergic agents can modulate 
lymphocyte metabolism, p ro l i fe ra t io n  and function , (Strom et al 
1972, Hadden et al 1972) and tha t these changes could be blocked by 
B2-receptor blocking drugs, (Conolly and Greenacre 1977). Propranolol has 
been shown to enhance IgE formation in the rabb it (Homer and Cain 
1979), t o ta l ,  but not antigen sp e c if ic ,  IgE formation in the ra t ,
(Pauwels et al 1980) and antibody formation to heterogenous prote in  
in the ra t (Benner et a.l 1968) and mouse (Nakazawa et al 1976).
Buckley and McGregor (1977) also reported tha t propranolol increased 
the number of survivors and decreased the duration of disease in ethanol 
suppressed rats infected with type I I I  pneumococci. As these e ffec ts  
are probably mediated via 32 receptors (Conolly and Greenacre 1977) i t  
is  un like ly  tha t practo lo l would have a s im ila r  e f fe c t  unless, l ik e  
the stim ula tion of growth in psoriasis pa tien ts , there was a pre­
disposing fac to r. Bjorkholm et al (1980) suggested tha t ischemic heart 
disease could be associated with an immunological disrangement.
This concept received support from the work o f Takeichi et al (1980). 
These workers reported tha t spontaneously hypertensive rats have a 
reduced number o f thymocytes at b i r th  and a depressed T -ce ll
dependent immune response, a condition which worsens with age.
I t  is  not certa in  as yet i f  the immune changes and the hypertension 
are fu n c t io n a lly  re lated.
A var ie ty  o f autoantibodies have been found in the sera o f practo lo l 
patients. I t  is  possible therefore that these patients had a suppressor 
ce l l  defect, feehan et al (1976) found antibodies to the nucleus, 
thyro id , thyrog lobu lin , smooth muscle, sa liva ry  duct, immunoglobulin, 
gas tr ic  parie ta l c e l ls ,  an in te rc e l lu la r  substance and basement 
membranes, mostly in patients who had been taking the drug fo r  
more than one^year or who had adverse e ffec ts .  In te rc e l lu la r  a n t i ­
bodies and ANA were commonly associated with ocular damage, (Amos 
et al 1975). Rahi et al (1976) detected immunoglobulin deposits 
between the conjunctival epithelium and in the lens and Fe lix  et a l (1974) 
reported the presence o f IgG,IgM and complement at the dermo-epid- 
ermal junction in some patients su ffe ring  from skin rashes. S im ilar 
deposits in the dermo-epidermal junction o f skin from patients with 
practolo l-associated psoriasiform changes were detected by Dahl et al 
(1975). Whilst there appears to be a re la tionsh ip  between practo lo l 
and the presence of autoantibodies there is  no c lear re la t ionsh ip  
between the presence o f autoantibodies and the d if fe ren t side e f ­
fects . A summary o f the various findingsare given in table 1,3.
There is  l i t t l e  evidence to suggest tha t e ith e r the immunoglobulin 
deposits or autoantibodies were cyto tox ic . Rahi et al (1976) came to 
the conclusion tha t the deposits in the lens and e p ith e l ia l  t issue 
were formed as a resu lt o f tissue damage rather than being responsible 
fo r  the damage. Amos e t al (1975) suggested tha t the in te rc e l lu la r  
antibody could be binding non-spec if ica lly  and tha t there was in ­
s u f f ic ie n t  evidence to ascribe cytotoxic properties to i t .
Table 1, 3.
Corelation o f immunological parameters w ith adverse e ffec ts  induced
by p rac to lo l.
autoantibody. disease type proportion po s it ive .
4
in te rce l 1u la r. eye or eye and skin 
les ions .
<
2/15
27/29
sclerosing p e r i to n i t is 2/3
*
no e f fe c t  but long term 
practo lo l treatment 3/9
controls 0/35
Anti nuclear practo lo l treated with 
lesions 11/22, 1/5, 9/18,
practo lo l treated without 
side effec ts 9/46, 4/9
controls 15/100, 9/208, 1/35
smooth muscle practolo l treated with 
lesions 5/22, 0/5,2/18
practo lo l treated without 
lesions 3/46,1/9
controls 16/100, 7/208, 0/35
parie ta l ce ll practo lo l treated with 
lesions 0/22, 3/5, 2/18
practo lo l treated without 
lesions 4/46, 0/9
controls 3/100, 12/208, 0/35
Data are taken from Davies, 1979, 1980
S im ila r ly  the high incidence o f ANA found in some patients would 
appear to be secondary to tissue damage and not causally re lated 
(Wilson et al 1978, Raftery et al 1973).
Behan et al (1976) tested d i f fe re n t  aspects o f the immune system in 
practo lo l patients to see i f  there was any evidence of a dysfunction. 
Those patients who had adverse e ffects  and those who had been taking 
practo lo l fo r  long periods (greater than 12 months) showed a s im ila r  
pattern o f responses which d if fe red  from the control group and from 
patients who had taken practo lo l fo r  short periods. The former 
group of patients showed a decreased skin response to Candida and 
streptok inase/stre ’ptodornase, decreased lymphocyte protein synthesis 
and a depressed lymphocyte transformation response to mitogenic stim­
u la t ion , s im ila r  in some respects to the find ings o f Takeichi et al 
(1980) using hypertensive ra ts . Amos and Brigden (1976) could not 
confirm the impaired transformation response however and suggested 
that th is  was due to differences in the control patients used by the 
two groups. Pugh et al .(1976) followed the lymphocyte a c t iv i t y  in 
practolo l patients over a course o f treatment and concluded tha t ab­
normalities in lymphocyte response to mitogens did not precede the 
formation o f autoantibodies but did re f le c t  disease a c t iv i t y  in 
general. I t  appears l i k e ly  therefore tha t practo lo l has no d ire c t  
e f fe c t  on the immune system.
Summary.
There is  s u f f ic ie n t  data available to show tha t propranolol can 
a f fe c t  ce l ls  o f the sk in , sa liva ry  glands and the immune system. 
P racto lo l, in most systems where i t  has been tested, is  w ithout 
a c t iv i t y  as would be expected as most ce l ls  appear to posses 32
receptors. Two recent reports however have shown that practo lo l can 
e f fe c t  the a c t iv i t y  o f the lacrymal gland and in h ib i t  in te s t in a l 
glycoprotein synthesis, the la t te r  e f fe c t  being spec if ic  fo r  p ract­
o lo l ,  (Tanaka et al 1983, Okine et al 1982). As has already been stated, 
practo lo l is unique in 'th e  severity  and range o f i t s  side e ffects  
in man. I t  is unlikely tha t practo lo l caused these adverse changes 
via a pharmacological mechanism as propranolol, active in a va r ie ty  
o f systems, does not give r ise  to the pattern o f reactions observed 
with p rac to lo l.  Further, extensive feeding t r ia ls  using albino and 
black mice, beagles, marmosets and hamsters have fa i le d  to show any 
relevant changes, (Case et al 1978). A d ire c t  tox ic  e f fe c t  would, 
based on the above data, also appear to.be un like ly .  I t  is  necessary 
therefore to postulate an id iosyncra t ic  mechanism, possibly due to 
differences in metabolism in susceptible patients or, to a drug 
induced hypersens it iv ity  reaction. (A comparison o f the b io log ica l 
e ffec ts  o f practo lo l and propranolol are given in table 1, 4 .)
Possible id iosyncra t ic  mechanisms.
A AeAaA°Jj-SOLp_tPJActoJoJ.
!4
Reeves et al (1978) investigated the metabolism of C-practolol in
a healthy volunteer, 2 patients who had been on practo lo l without
experiencing any adverse e ffec ts  and 6 patients who had developed
rashes, 1 o f whom had ocular problems as w e ll.  No gross differences
%
cotild be found in the metabolism of practo lo l labelled in the r ing or 
acetyl group. Most o f the drug was excreted in the urine (80-90%), 
the m a jority  w ith in  3 days (74-90%). Small amounts o f polar metab­
o l i te s  were found (3-13%), possibly including the glucuronide, but 
certa in l i k e ly  metabolites, the desacetyl and 3-hydroxy forms, could
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Table 1, 4.
A comparison o f some o f the b io log ica l e ffec ts  o f practo lo l and 
propranolol.
e f fe c t  o f practo lo l in 
the model.
model used. e f fe c t  o f propranolol 
in the model.
human f ib ro b la s t  none
and keratinocyte 
cAMP synthesis in 
the presence o f 
catecholamines.
human f ib ro b la s t  not done
collagen synthesis 
in h ib i t io n  by iso- 
prenalin (6h)
skin p ro l i te ra t io n  not done
e ffe c t  o f challenge none 
on psoriasis sk in ,
(topical or id )
in h ib i to ry
e ffe c t on ra t  
submaxillary gland
e ffe c t  on beagle 
lacrymal gland
e ffe c t  on ra t  in ­
te s t in a l glycoprotein 
synthesis.
leucocyte lysosomal 
enzyme release in 
the presence o f 
3-adrenergic agonists
not done
decreased secretions
in h ib i to ry  when given 
o ra l ly
not done
ra t macrophaqe GUR 
release in the pres­
ence o f LT,s. no e ffe c t
Rabbit and ra t
IgE synthesis not done
reverses the in h ib i t io n .
stimulates growth o f 
guinea-pig skin.
p ro l i fe ra t iv e  response.
causes decrease in size 
and secretions
not done
no e f fe c t
reverses the in h ib i t io n  
due to the increase in cAMP
protects against the in h ib ­
i to r y  action o f 3- adrenerg' 
agonists.
enhances i t s  formation.
Results are a summary o f those discussed in the te x t .
not be id e n t i f ie d .  Deacetylation did occur and accounted fo r  
approximately 5% o f the metabolism of p ra c to lo l ,  s im ila r  to that 
found in the ra t  and beagle. The metabolic fa te o f practo lo l in 
various species is  outlined in f i g . 1. 2.
Plasma levels o f practo lo l were o f the order o f lug/ml a f te r  3h and 
decayed mono-exponentially with a h a lf  l i f e  o f 12-16h. Saliva levels 
varied from 0.45-2.0ug/ml and decreased at the same rate as serum 
leve ls . The authors concluded that i f  the mechanism leading to the 
adverse reactions involved differences in metabolies o f k ine tics  
then these must be re la t iv e ly  small and not read ily  demonstrable 
Individual phase I or phase I I  metabolites were not id e n t i f ie d  
however in the plasma or urine so tha t there could have been 
differences which were not detected.
Reeves et al (1979) investigated the metabolism o f practo lo l in the 
marmoset, hamster, ra t ,  mouse, guinea-pig and rabb it.  The marmoset 
showed extensive deacetylation (57%) and the hamster appeared to p re f­
e re n t ia l ly  synthesise the 3-hydroxy metabolite (11%) ora conjugate 
o f 3-hydroxy p rac to lo l.  The other species metabolised the drug s im i la r ly  
to man. I t  is  u n l ike ly  tha t gross differences in the metabolism of 
p ra c to lo l ,  as re flec ted  by analysis of ur ine, faeces and expired a i r ,  
can be used to pred ic t s u s c e p t ib i l i ty  to practo lo l as these animals 
exhibited none of the signs associated with the practo lo l syndrome
during chronic feeding studies (Case et al 1978). Scales and Cosgrove (1970)
%
reported that enterohepatic c irc u la t io n  played an important part in 
the metabolism o f practo lo l in the dog, ra t  and mouse and Reeves e t al 
(1979) tha t desacetyl practolo l could become reacetylated to p racto lo l 
in the rabb it.  There are mechanisms therefore which would allow 
extensive metabolism of the drug, which may re su lt  in s ig n if ic a n t
Figure 1, 2.
Possible pathways of practolol metabolism 
showing interspecies variations.
enterohepatic circulation  
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differences in humans, which would not be detected during routine 
ana ly tica l procedures.
A va r ie ty  o f animal species have been used in to x ic i t y ^ t r ia ls  and 
some have been shown to metabolise practo lo l extensively. In no 
case however has an untoward e f fe c t ,  re lated to the practo lo l syn­
drome, been reDorted. Drug metabolism in practo lo l patients with 
and without side e ffec ts  and a control was very s im ila r  (Reeves et 
al 1978) and th is  information, together w ith the animal data, sug­
gests tha t practo lo l does not give r ise  to p a r t ic u la r  metabolites 
which are responsible fo r  the adverse reactions.
B_ Drug_ hypersen si t i v j  ty_ re ac ti oru
The a lte rna tive  to an ind iosyncra tic  response due to differences in 
drug metabolism is  a drug induced hypersens it iv ity  reaction. There 
are certa in c h a ra c te r is t ic s ,o f  a drug induced a l le rg ic  reaction,which 
suggest such a diagnosis. A fte r the primary exposure a la te n t period 
is  required before a reaction is seen. This is  not the case a f te r  sub­
sequent ones. The reaction occurs in a m inority  o f patients and is 
not l in e a r ly  re lated to dosage or to pharmacological properties of 
the chemical (F i l ip e k  1979). These requirements are typ ica l o f the
r
practo lo l induced e ffec ts . Such reactions are usually o f four main 
types (Gel! and Coombs 1968), Type I ,  anaphylactic, IgE mediated;
Type I I ,  cy to tox ic , IgG mediated; type I I I  Arthus and type IV, ce l l  
mediated, delayed. The practo lo l reaction does not seem to f i t  in to  
any o f these categories (Amos et al 1978). Neverthe\eS5 some signs 
o f immunological a c t iv i t y  were seen in  oracto lo l pa tien ts , p a r t icu ­
la r ly  the lupus syndrome described by Fe lix  et al (1974) and the auto­
antibodies reported by Amos et al (1975) and Behan et al (1976). In 
order to d e f in i te ly  show tha t practolo l can cause a hyp erse ns it iv i ty  
reaction i t  is necessary to demonstrate a spec if ic  in te rac tion  between
the drug, or a metabolite, and e ith e r sensitised lymphocytes or drug 
spec if ic  antibodies. Assem (1975) reported tha t 2 out o f 3
practo lo l patients and 1 o f 2 propranolol patients had.a pos it ive  
lymphocyte transformation te s t  to lug/ml p ra c to lo l ;  one o f the pract­
o lo l patients also giv ing a pos it ive  response to lug/ml propranolol.
A number o f authors have t r ie d  to repeat these experiments using 
p ra c to lo l,  practolo l/a lbumin complexes, desacetyl practo lo l linked 
to sheep red blood ce lls  and two possible metabolites o f practo lo l 
but without success, (Behan et al 1976, Amos and Brigden 1976, Amos 
1979). Raftery and Denman (1973) were equally unsuccessful in detecting 
antibody receptors to practo lo l on lymphocytes obtained from pract­
o lo l patients. I t  is  not altogether suprising tha t immunological 
investigations using the parent molecule should be negative. In order 
to provoke an immunological response a chemical should have a molec­
u la r weight o f at least 6000 or, i f  not, be f i rm ly  bound to some 
macromolecule forming a hapten/carrier complex, (Landsteiner and 
Jacobs 1936). Most drugs have a molecular weight below 6000, fo r  ex­
ample practo lo l (264) and p e n ic i l l in  BT (346) and must therefore form 
such high molecular weight complexes during t h e i r rmetabolism in order 
to provoke an immune response. Drug antibodies have been reported fo r  
hydralazine (Heine and Friedman 1962) and procainamide (Russell and 
Z i f f  1968) but a survey by Nakatsu and Scully (1980), using a double
antibody technique, fa i le d  to reveal IgG antibodies to acetyl s a l ic y l ic
%
acid, erythromycin, l idnocain , te t ra c y c l in ,  p e n ic i l l in ,  a m p ic i l l in  
or procainamide. This lack o f success could have been due to the fa c t  
that they did not look fo r  IgM antibodies, the most common class o f 
drug antibody (Whittingham and MacKay 1976) or to the fa c t  tha t hapten/ 
ca r r ie r  complexes were e ithe r not formed or the hapten was not bound
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at a concentration s u f f ic ie n t  to provoke an immune response. I t  was 
o r ig in a l ly  thought tha t the hapten/protein bond had to be covalent but 
Plescia and Palczik (1964) and Boyd and Pert (1968) have published 
data suggesting tha t strong associates are s u f f ic ie n t  fo r  the production 
of antibodies to small b io log ica l molecules although i t  is  not c lear 
i f  th is  concept also applies to drugs. The presence and s p e c i f ic i t y  
o f drug antibodies are usually investigated using model compounds.
This is  not a problem i f  the parent molecule is  the antigen but can 
pose a problem i f  the active species is  a metabolite as the metabolism 
of the drug may not have been studied, the active form may be present 
in small amounts,or be unstable, and therefore not detected,or model 
compound may not be ava ilab le . In order to overcome these d i f f i c u l t i e s  
with p ra c to lo l ,Amos et al (1977, 1978) used an ingenious system to 
generate metabolites o f practo lo l in v i t r o  and then trap them using a 
scavenger macromolecule. Practolol metabolites were generated by in c ­
ubating the drug in v i t r o  with a microsomal mixed functional oxidase 
system iso lated from ra t  or hamster l iv e rs .  In one set o f experiments 
the metabolites produced were allowed to couple to non-agglutinating 
rabb it antibodies to human 0 red blood ce l ls  which were then used to
p*
passively sensitise  human 0 red blood c e l ls .  This reagent was then
titrated against practo lo l patients serum in an agglu tination assay.
(Amos e t al 1977). In a second series o f experiments practo lo l metab-
125o l i te s  were allowed to couple to I-human serum albumin (HSA) which
*
was* then used in a modified Farr assay, (Amos et al 1978). This idea 
was based on the work o f Orton and Lowery (1981) who showed tha t
radio!abelled metabolites of p ra c to lo l,  generated in v i t r o , would bind 
to microsomal protein and tha t th is  binding could be blocked by HSA 
which scavenged the metabolites. Amos e t al (1977) demonstrated tha t 
antimetabolite antibodies o f the IgM class were present in the sera
o f practo lo l patients with severe adverse side e ffec ts  but not 
control sera. They then went on to further characterise the s p e c i f ic i ty  
o f the antibody and to asses i t s  s ign if icance , (Amos e t .a l  1977, Amos 
1979). The presence o f the antimetabolite antibody could not be r e l ­
ated to any p a r t ic u la r  manifestation o f the oculomucocultaneous syndrome 
but there did appear to be an inverse re la tionsh ip  between the antimetab­
o l i t e  antibody and the in te rc e l lu la r  antibody and the sclerosing cond­
i t io n .  They also showed tha t i f  susceptible patients were challenged 
with practo lo l the level o f the antimetabolite antibody rose rap id ly  
to levels seen at the h ight o f the adverse reaction, behaviour typ ica l 
o f a secondary a l le rg ic  reaction, (Amos et al 1978). The authors sug­
gested tha t the antibody was produced early  in the development o f the 
adverse reaction and th a t,  as the damage became more severe, i t  bound 
to antigenic determinants on the tissue, ie tissue bound metabolite.
This would also explain the low antimetabolite t i t r e  in patients with 
autoantibodies. The resu lts  reported by Amos et al (1977), Amos (1979) 
and Orton and Lov/ery (1981) are summarised in table 1,5.
Although the s ign if icance o f ' th e  above f ind ings , w ith regard to the 
practolo l syndrome, are not c lea r, i t  is  apparent ^hat practo lo l could, 
in v ivo , give r ise  to metabolites which bound to macromolecules to 
form haptens. This binding could have induced a novel type o f hyper­
s e n s i t iv i t y  reaction as suggested by Amos et al (1978), or d i re c t ly
caused tissue damage. In e ith e r case i t  is conceivable tha t a bu ild  up
%
of the tissue bound metabolite would be necessary to invoke e ith e r 
an immune response or overt tissue damage. Lindup et al (1979) have 
reported a' time and concentration dependent accumulation o f radio­
a c t iv i t y  in the eye, skin and small in te s t in e  o f male hamsters fed rad io- 
labelled p ra c to lo l,  ie tissues most associated with the adverse e ffec ts
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Table 1, 5.
A summary o f the biochemical (prote in binding) and immunological 
(antimetabolite/antibody binding) studies aimed at e luc idating  the 
s tructure o f the antigenic metabolite.
treatment protein
binding
Farr assay 
binding.
A) treatment o f the animal
1 chronic practo lo l administration no e ffe c t not done
2 phenobarbitone l i v e r  induction no e ffe c t no e f fe c t
3 3-methylcholanthrene l iv e r  induction 4- binding 4 binding
B) additions to the microsomal incubation.
1 NADPH necessary necessary
2 glutath ione 4- binding 4 binding
3 tricyclopropene oxide1 no e ffe c t no e f fe c t
4 b is -(p -n itro p h e n y l) phosphate2 4 binding not done
5 sodium f lu o r id e 3 variable variable
C) effect o f practo lo l analogues.
1 desacetyl notr done 4 binding4
2 3-hydroxy n no e f fe c t
3 propane d io l H no e f fe c t5
4 practolo l n 4 binding
5 paracetamol n 4 binding
>
*
Data are taken from Amos et al (1977), Amos (1979) and Orton and 
Lowery (1981) ! epoxyhydratase in h ib i to r .  2deacetylation in h ib i to r ,  
S tim u la tes N-hydroxylation. ^ In h ib i t io n  also seen with the agg lu tina tion  
assay, i n h ib i t i o n  seen with the agg lu tination assay.
in man. Most, 80%, o f the a c t iv i t y  was due to practo lo l i t s e l f  w h i ls t  
the remaining 20% was not characterised. I t  is  possible tha t such an 
accumulation in tissues in susceptible patients could provoke an 
adverse reaction.
Research needs.
A cha rac te r is t ic  o f the practo lo l syndrome is  the extensive f ib ro s is  
o f the peritoneum and other mucosal membranes, (see section on the 
adverse effec ts  due to p ra c to lo l) .  I t  is  possible that th is  f ib ros ing  
response is  due to a metabolite o f practo lo l acting d ire c t ly  on the 
ce ll to promote i t s  growth and/or synthesis o f collagen. Support fo r  
th is  proposal comes from the work o f Shafer (i960. 1961). He showed 
that diphenylhydantoin, in vivo and in v i t r o , and some o f i t s  metab­
o l i te s  2£ v jlLO j stimulated the rate o f growth and synthesis o f c o l l ­
agen by human skin f ib ro b la s ts .  Fibroblasts have been used to study, 
in v i t r o , the e f fe c t  o f a va r ie ty  o f d i f fe re n t  lesions o f both genetic 
and chemical o r ig in ,  (Le Roy e t al 1974, Buckingham et al 1978, V is t ica  
et al 1977,Hunt et al 1979, Hassell and G ilbe rt 1983). Stimulation 
(Shapiro 1958) and in h ib i t io n  (Richards et al 1975) of various func­
tions have been demonstrated. This approach appeared to be a va lid  
one fo r  investiga ting  the possible mechanism by which p ra c to lo l ,  and/or 
i t s  metabolites, could have induced the f ib ros ing  reactions associated
with i t s  administration. As a f i r s t  step i t  was decided to t r y  and char-
%
acterise , chemically,the nature of the metabolite(s) reacting with 
spec if ic  antibodies in the sera o f adversely effected patients using 
the methods described by Amos et al (1978). This compound(s) could 
then be used in in v i t ro  experiments aimed at evaluating the co n tr ib ­
ution o f f ib ro b la s t  e ffec ts  to the practo lo l syndrome.
EXPERIMENTS TO FURTHER CHARACTERISE THE CHEMICAL
NATURE OF THE ANTIGENIC METABOLITES OF PRACTOLOL 
USING AN IMMUNOLOGICAL APPROACH.
CHAPTER 2.
EXPERIMENTS AIMED AT EVALUATING PREVIOUSLY PUBLISHED 
METHODS OF DETECTING ANTIBODIES TO PRACTOLOL METABOLITES
AND CONFIRMING EARLIER RESULTS.
INTRODUCTION
Amos et al (1977, 1978) demonstrated, in the serum o f adversely e ffe c ­
ted pa tien ts , antibodies to i n ' v i t r o  generated, protein bound, metab­
o l i te s  o f practo lo l (the antigen complex). Although the s ign if icance
(
of th is  f ind ing , with regard to the pathogenesis o f the oculomucocut- 
aneous syndrome, is  not c lear the fac t tha t practo lo l could be met­
abolised in vivo to reactive metabolites, capable o f binding to mac­
romolecules to form haptens, might be an important step in the mech­
anism by which practo lo l exerted i t s  adverse reactions, be i t  via a novel 
form o f  hype rsens it iv ity  reaction (Amos e t al 1978) or a d ire c t  tox ic  
e f fe c t  due to macromolecule binding. Amos et al (1977) p a r t ia l ly  
characterised the chemical nature o f an antigenic metabolite using 
a competitive binding assay. In the system f i r s t  used by Amos et al
(1977) practo lo l metabolites were bound to non-agglutinating a n t i ­
bodies tohuman Ored blood ce lls  (HRBC). These were then used to pass­
ive ly  sensitise  HRBC which were f i r s t  incubated with patients sera and 
then anti human immunoglobulin. Agglutination was observed i f  the pat­
ients sera contained antimetabolite antibodies. When competitive binding 
assays were performed patients sera were f i r s t  incubated w ith chem­
ica l analoges o f practo lo l before being incubated with the sensitised 
SRBC. The greater the s im i la r i t y  between the chemical analogue and the 
metabolite bound to the anti SRBC antibody the greater the In h ib i t io n  
o f agg lu tination . P rac to lo l,  des-acetyl practo lo l and des-isopropyl 
practo lo l p a r t ly  inh ib ited  agglu tination but preincubation o f pat­
ients sera with the antigen complex resulted in almost to ta l  a b o l i t io n .  
Such competitive binding assays could also be used with the rad io- 
immunological approach la te r  used by Amos et al (1978).
Complete e luc idation o f the chemical s tructure o f these reactive 
metabolites would be important as the p u r if ie d  chemical, or a sim­
ple precursor, could then be used in studies aimed at unravelling 
the mechanism by which practolo l induced such severe changes in 
some patients. The aim o f the experiments described in th is  section 
was to confirm the resu lts  o f Amos e t al (1978) and Amos (1979).
This involved evaluating both the methodology available fo r  preparing 
the antigen complex and the assays fo r  detecting and measuring bind­
ing o f th is  to antibodies in the patients sera. At the same time i t  
was necessary to  ensure tha t the assay methods could also be used to 
estimate the levels o f anti metabolite antibodies present in any pa rt­
ic u la r  patients serum and tha t the assays could be used in compet­
i t i v e  binding experiments aimed at id e n t i fy in g  the chemical s t ru c t ­
ure o f the antigenic metabolite(s).
METHODS.
A Princip les o f methods.
Evaluation o f methods used to generate the antigen complex.
Synthesis o f the antigen metabolite complex as described by Amos e t al
(1978) involved two steps. F i r s t  preparation o f the hamster l i v e r  
microsomes and second, generation and iso la t io n  of practo lo l metab­
o l i te s  bound to a c a r r ie r  protein (Human serum albumin(HSA)).
The a c t iv i t y  o f the microsomal preparation used in the experiments 
was demonstrated by fo llow ing the de-ethylation o f 7-ethoxycoumarin 
to 7-hydroxycoumarin, (Lake e t al 1979).
In order to show that practo lo l metabolites bound to the c a r r ie r  molec­
ule (HSA), incubations were carried out using radio labelled p ra c to lo l.
Covalent binding o f practo lo l metabolites to HSA was then measured 
14by assaying C a c t iv i t y  associated with the protein a f te r  solvent
extraction or exhaustive equil ib rium  d ia lys is  o f HSA iso lated from the 
14the microsome/ C practo lo l incubation system. Recently the merits
o f solvent extraction  and exhaustive equil ib rium  d ia lys is  as methods
(
fo r  assessing covalent binding have been investigated by Sun and Dent 
(1980). The standard technique involves p re c ip ita t in g  the protein 
from the medium using 10% tr ic h lo ra c e t ic  acid (TCA), removing assoc­
ia ted, but unbound, ra d io a c t iv i ty  by solvent extraction and measuring 
the bound residual a c t iv i t y  in the protein p e l le t .  This method has 
several drawbacks. F i r s t  low molecular weight molecules may not 
p rec ip ita te  with TCA. Second, l ip id s -a re  extracted by many organic 
solvents which could lead to a low apparent binding i f  the drug bound 
to a l i p id  compartment., fo r  example halothane (Van Dyke and Gandolf 
1974). Lastly covalent bonds may be cleaved during acid or base t re a t ­
ment o f the TCA prec ip ita ted p e l le t ,  (G i l le t te  and Pohl 1977). Sun 
and Dent (1980) suggested tha t equil ib rium  d ia lys is  gave a more acc­
urate estimation o f covalent binding and reported tha t values obtained 
by them fo r  binding to ce l ls  and microsomes was 2-7 times higher when 
the analysis was performed by this technique than by solvent extrac­
t io n . As the solvent extraction method had been used by Orton and 
Lowery (1981) to demonstrate binding o f practo lo l metabolites to mic­
rosomes we also used th is  method, as well as equilib rium  d ia ly s is ,  
to assess covalent binding so that a comparison o f the values obtained 
could be made.
Evaluation o f the methods used to measure antigen/antibody binding.
Amos et al (1978) detected antibodies to the antigen complex using 
a modified Farr assay (Farr 1958). The.specific antibody in the pat­
ients serum bound to the metabolite covalently bound to a radiolab- 
125el led c a r r ie r  ( I HSA). Separation o f antibody bound and unbound
t
antigen complex was performed by s a l t  p re c ip ita t io n  o f the gamma 
globulin  fra c t io n .  Only antibody bound metabolite was precip­
ita ted  and , with i t ,  the radio!abelled c a r r ie r  prote in . The radio­
a c t iv i t y  in  the washed p e l le t  was a measure o f the degree o f antigen/ 
antibody binding. Ammonium sulphate is  usually used to s a l t  out the 
gamma g lobulin  f ra c t io n ,  a 50% solu tion (w/v) p re c ip ita t in g  a l l  pro­
te in  bar the albumin f ra c t io n ,  (Cohn et al 1940).Other chemicals 
can be used, fo r  example sodium sulphate or ammonium acetate, but 
are not used rou tine ly . In the system described by Amos et al (1978) 
protein (serum or gamma g lobu lin ) was not added to the assay. This is 
often recommended to ensure a good p re c ip ita t io n  on addition o f the 
p re c ip ita t in g  agent, p a r t ic u la r ly  when the concentration o f antibody 
in the serum is low (Hunter 1978). In order to assess the importance 
o f the factors discussed above, and the r e l i a b i l i t y  o f the o r ig in a l 
method in my hands, i t  was decided to use a model system to evaluate 
not only the Farr assay but also other assay systems which could be 
used. Idea lly  i t  is necessary to have a characterised, rad io !abe lled , 
antigen and spec if ic  antisera in order to establish such binding 
assays. Neither o f these was ava ilab le fo r  the present study as both
the antigen and antibody were the subject o f the investiga tion .
125I t  was decided to use I HSA and anti HSA sera to evaluate the 
proposed assay systems. Several modifications o f the Farr assay were
used, reducing the incubation volume or adding protein to the inc­
ubations, to ensure a good p rec ip ita t ion  on addition o f the ammonium 
sulphate.
Besides the Farr assay, the Cross Linked Antibody (Keck 1978) and the 
Staphylococcus aureus (Jonsson and Kronvall 1974, Kessler 1975) meth­
ods were a lso 'inves tiga ted . The former employed an inso lub il ized  
crosslinked gamma g lobulin  f ra c t io n ,  formed a f te r  sodium sulphate 
p re c ip ita t io n . This has the advantage that bound antigen can eas ily  
be separated from unbound antigen and i t  minimises the r is k  o f carry­
ing over radioactive HSA, fo r  example during a p re c ip ita t io n  step.
The la t te r  method u t i l is e s  the a f f in i t y  o f protein A, a major ce ll  
wall component o f most s tra ins o f Staphylococcus aureus, fo r  the Fc 
part o f some immunoglobulin molecules. The bacteria act as an immuno- 
absorbant with a high absorbing capacity and bind rap id ly  to antigen/ 
antibody complexes. The bound antigen can eas ily  be separated from 
the free form by cen tr ifuga tion  o f the bacteria , (Kessler 1975). The 
a f f in i t y  o f protein A varies fo r  d i f fe re n t  mammalian species. In 
humans 90% of IgG^ and IgG^ is  bound but hardly any o f the IgM or 
IgA classes or the IgG^ sub class (K fonvall and-Williams 1969). I f  
the antimetabolite antibody was of the IgM class as suggested by Amos 
et al (1977) then a marked difference would be expected in  binding to 
patients serum using th is  method compared with the other methods.
_B Practical de ta ils  of the methods.
Preparation o f the microsomes.
Hamsters were k i l le d  by cervical d is loca tion , the l iv e rs  removed and, 
a f te r  removal o f the gall bladders, placed in a beaker containing 
Tris (50mM)/KCl (154mM) bu ffer,ph7 .4. Livers from several animals
were pooled, washed once in the bu ffe r , b lo tted dry, and homogenised 
in 4 volumes (w/v) o f Tris/KCl bu ffe r using a Teflon/glass motorised 
Potter type homogeniser. The homogenate was cen tr i f iged  in 50ml poly­
carbonate tubes at 10,000g using a MSE Highspeed 18 at 4°C fo r  20min. 
The postmitochondrial supernatant (PMS) obtained was transfered to 
25ml polycarbonate (MSE) tubes and spun at 105,000g fo r  60min at 4°C 
in a MSE Superspeed 50TC centrifuge. The supernatant was discarded and 
the p e l le t  washed once before being suspended in a small volume of 
Tris/KCl bu ffe r. The microsomes were stored on ice u n t i l  needed.
Protein estimation
Microsomes (0.5ml) were dissolved in 9.5ml o f 0.1N sodium hydroxide 
and a liquots fu r th e r d ilu ted  to 1/100 and 1/200. Standard solutions 
o f bovine serum albumin (BSA) were made up in 0.1N sodium hydroxide 
to cover the range 0 to lOOyg/ml. Solution A (5ml) (100ml o f 2% 
sodium carbonate, 1ml 1% cupric sulphate, 1ml 2% potassium sodium 
ta r t ra te )  was added to 1ml a liquots o f the protein so lu tion in a 20ml 
glass centrifuge tube, vortex mixed and l e f t  a t room temperature fo r  
a fu ther lOmin. Solution B(0.5ml)(Folin-Ciacalteaux reagent) was added, 
the so lu tion vortex mixed and l e f t  at room temperature fo r  30min a f te r  
which i t s  absorbance was read at 720nm using a Cecil 272 l in e a r  read­
out spectrophotometer. A graph of absorbance against ygBSA was con­
structed and the concentration of microsomal protein read o f f  i t .  The 
o r ig ina l microsomal preparation was then d ilu ted  to the required con­
centration.
The de-ethylation o f 7-ethoxycoumarin.
A 2 mMolar stock so lu tion o f 7-ethoxycoumarin was prepared by b o il in g  
22.8mg in 60 ml o f Tris/KCl bu ffe r. The solu tion was readjusted to 60ml 
on cooling.A O.SmMolar standard so lu tion o f 7-hydroxycoumarin was 
prepared by d issolv ing 40.5mg in 20ml ethanol and making up the
i
volume to 500ml with d is t i l l e d  water. This was fu r th e r d ilu ted  to 
0.1 mMolar with d is t i l l e d  water fo r  use during the assay. 1ml o f co­
factors containing lu n i t  is o c i t ra te  dehydrogenase (ICDH), 15y moles 
i s o c i t r i c  acid (ICA), 1 ymole NADP and 10 ymoles o f magnesium sulphate, 
was added to 0.w5ml of microsomes in Severil tubes placed in a shaking 
water bath at 37^C. A fte r 5min preincubation 0.5ml o f 2mMolar 7-ethoxy­
coumarin was added and incubated fo r  the desired time. The tubes were 
then placed on ice and protein prec ip ita ted  by mixing in 1ml o f 5%
(w/v) zinc sulphate and 1ml saturated barium hydroxide. A fte r  lOmin 
the p rec ip ita te  was spun down at 1500g fo r  15min at 4^C in a MSE .
Cool spin centrifuge. Levels o f 7-hydroxycoumarin in the supernatant 
were measured d i re c t ly  using a perkin-Elmer MPFgg fluoresence spect­
rophotometer (exc ita t ion  wavelength 380nni, emission wavelength 425nm) 
and comparing the sample fluorescence with tha t obtained fo r  a standard 
so lu tion.
Preparation o f p ra c to lo l/p ro te in  complexes.
Microsomal protein (5mg), 1ml o f 10mMolar practolo l and 12mg HSA in 
Tris/KCl bu ffe r and bu ffe r (to  4ml) were added to 25 ml conical f lasks 
on ice. The flasks were placed in a shaking water bath set a t 37^C and 
incubated J x r  5min before adding 1ml o f cofactors,(NADPH regenerating 
system, 0.5mM NADP, 15mM ISA, 5 units ISDH). The incubation was allowed 
to proceed fo r  the required length o f time a f te r  which the microsomes
were spun down as described previously. The supernatants were placed
in glass s c in t i l l a n t  v ia ls  and stored at -20°C u n t i l  needed.
To separate bound practo lo l metabolites from other low molecular
weight components the supernatant was eluted down a lcmx30cm G-25
sephadex column by means o f phosphate buffered saline (PBA) ph 7.2
<
using a LKB p e r is ta l t ic  pump (0.8x10 speed, 7ml fra c t io n s ) .  Fractions 
were collected in glass te s t tubes using a LKB 7000 U ltrarac. Protein 
levels were monitored continuously using a LKB Uvicord I I  (280nm).
The frac tions  corresponding to those in which HSA eluted were concen­
tra ted under pressure by 50% using a UM-10 Diaflow f i l t e r  and th is  
solution was used as the radio labelled antigen in antigen/antibody
binding studies.Radiolabelled practolo l (lyCi ring labelled pract-
125olo l plus cold practo lo l to 2mM) or I HSA were added as required.
14Measurement of . C practo lo l protein binding to human serum albumin. 
§2l  ex tract i on_methodJ,
Equal volumes o f the p ra c to lo l/p ro te in  complex and 10% TCA in d is t ­
i l l e d  water were vortex mixed in a 20ml glass centrifuge tube.and the 
p rec ip ita te  spun down at lOOOg fo r  5min at 18°C using a MSE Cool spin 
centrifuge. The supernatant was discarded and the p rec ip ita te  extrac­
ted s ix  times with 5ml o f d ie thyl ether. The p rec ip ita te  was then
dissolved in 2ml o f 0.1 N sodium hydroxide and aliquots taken to .
14to carry out a protein estimation and to determine C a c t iv i t y .
The protein was reprec ip ita ted with 4ml o f 10% TCA, centrifuged to 
give a p e l le t ,  washed once in d ie thyl ether,and protein and ^C  lev ­
els measured as before. I f  the spec if ic  a c t iv i t y  was not constant f u r ­
ther extractions were carried out u n t i l  no fu ther changes occured.
^99 j  ]  j  i r J  i/IP_ dj p] ^  s i s_ me t  hod_.
A volume o f supernatant was dialysed against 4x41 PBS in a 51
conical f lask  placed on a magnetic s t i r r e r  in a 4°C cold room. The
14buffer was changed ever 48hrs. The protein concentration and C ac t­
i v i t y  were measured a t ' th e  end o f 6 and 8 days. I f  the spe c if ic  ac t­
i v i t y  was not constant the supernatant was dialysed fu r th e r.
Preparation o f serum samples.
Serum from practo lo l treated patients was provided by Dr. Amos (ICI 
Parmaceuticals d iv is io n ,  A lderly  Edge, Macclesfield, Cheshire). 
Guinea-pig serum was prepared from blood taken from ear veins and 
control human serum from blood obtained, from the cub ita l vein. The 
blood was collected in e ith e r p la s t ic  universal containers or LP  ^
p la s t ic  tubes ,depending onthe.volume o f blood, and incubated at 37°C 
fo r  2h. The c lo ts  were then eased from the sides o f the tubes and the 
tubes placed in a fr idge  at 4°C overnight. The serum was separated out 
by cen tr ifug ing at lOOOg fo r  20min at room temperature using a MSE 
bench cen tr ifuge, aliqaoted (500yl) and stored at -20°C. Sera to be 
used in antibody/antigen binding studies were f i r s t  heat inactivated 
at 57°C in a water bath fo r  45min and then d ilu ted  i f  necessary.
Antibody/antigen binding assays.
M pdj f j  ed_ Fa r  r_ ass ays_.
%
Method 1. A 20yl a liquo t o f serum was added to lOOyl o f rad io labelled 
antigen solution in a 2.0ml glass te s t tube. The so lu tion was mixed 
and incubated fo r  2h at 37°C and 2h at 4°C with occasional mixing. A
0.4ml a liquo t o f PBS and 0.52ml o f a saturated aqueous solu tion o f 
ammonium sulphate, ph 7.2, w^e added, vortex mixed and the so lu tion . 
l e f t  at room temperature fo r  15min to allow the precipitate to form. 
This was then centrifuged down fo r  40min at 1500g and room temperature 
using an MSE bench centrifuge. The supernatant was discarded and the 
p rec ip ita te  washed twice with 1ml o f a 40% aqueous solu tion o f amm­
onium sulphate. R ad ioactiv ity  was e ith e r counted d ire c t ly  in a Packard 
auto gamma s c in t i l la t io n  spectophotometer 5230 or the p rec ip ita te  
was dissolved in 1ml of ce llusolve overnight at 37°C, put in a s c in t ­
i l l a t i o n  v ia l ^containing 10ml o f Dimilune s c in t i l la n t  and counted 
using a Packard T ri-carb  l iq u id  s c in t i l la t io n  spectrophotometer.
Method 2. This assay is  s im ila r  to the one described above with the 
difference that PBS was not added to the serum and antigen solutions 
a f te r  the 2h incubation at 4°C. Instead 120yl o f a saturated ammonium 
sulphate so lu tion was added and the assay continued as above.
Method 3. Serum (50y l),  antigen solu tion ( 50yl) 0.1% BSA in PBS (50yl) 
and normal guinea-pig serum (20y l)  were mixed in LP  ^ stoppered tubes 
and vortex mixed. A fte r a 2h incubation period at 37°C and 2h at 4°C 
170yl o f a saturated ammonium sulphate so lu tion was added and the 
solutions mixed. The p rec ip ita te  formed was then treated as p re v i­
ously described.
The cross linked antibody method.
The method used is  based on tha t o f Keck (1978). The gamma g lobulin  
fra c t ion  o f a serum sample was prec ip ita ted by mixing with 2 volumes 
o f 27% aqueous so lu tion o f sodium sulphate in a LP  ^ p la s t ic  tube. A f t ­
er cen tr ifuga tion  at lOOOg fo r  5min at room temperature the p e l le t  
was dissolved in 1 volume of borate buffered saline containing 0 . 2%
bovine gamma globulin  (BGG) and d ilu ted  out in to  LP  ^ tubes using the 
same bu ffe r. The protein was reprec ip ita ted with 2 volumes o f 27% sod­
ium sulphate containing 5y l/ ml o f 25% glutaraldehyde so lu tion . The 
tubes were l e f t  at room temperature fo r  5min and excess glutaraldehyde 
neutralised by adding 1ml o f 1% ethylene diamine. A fte r spinning down,
f
the p rec ip ita te  was washed twice with the borate/BGG bu ffe r and 50yl 
o f antigen solu tion added. The tubes were then capped, the p re c ip i t ­
ate suspended by vortex mixing and incubated fo r  48h at 4°C clipped 
to a ro ta t ing  disc set at an angle o f 45°, (12 revo lu tion/m in). The 
p rec ip ita te  was then washed three times with the borate/BGG buffer 
and counted fo r  ra d io a c t iv i ty .
Staphlococcus aureus-Protein A assay.
Preparation o f bac te r ia .
The bacteria l absorbant was prepared by the method o f Jonsson and 
Kronwall (1974) as modified by Keseler (1975). One loop o f Cowan 
I s tra in  of Staphlococcus aureus was added to 11 o f aerated penassy 
broth,supplemented with 5mg/ml casein, 2.5mg/ml yeast ex trac t, 2.0mg 
/ml thiamine, 2.5mg/ml 3-glycerophosphate and 4.0 g/ml n ia c in , in  a 
41 conical f lask  and incubated fo r  24h at 37°C. The bacteria were 
spun down a t 2000g at room temperature fo r  20min using a MSE Cool- 
spin, washed twice in PBS/10% sodium azide bu ffer (ph 7.2) and sus­
pended at 10% (w/v) in PBS/azide bu ffer containing 1.5% formalin.
The ce lls  were then incubated fo r  l jh  at room temperature, washed 
once in PBS/azide bu ffe r and resuspended to 10% (w/v). The bacteria 
were placed in a large volumetric f lask  to form a th in  layer on the 
bottom, heated at 80°C fo r  5min and then cooled rap id ly  on ice. They 
were then spun down, washed twice in PBS/azide bu ffe r and resuspended
to 10% (w/v). The reagent was stored at 4°C u n t i l  needed.
Within 24h o f being used a volume o f ce l ls  was spun down and incu­
bated in a T riton  X 100 bu ffe r , (0.5% Triton  X 100, 150mM sodium 
ch lo ride , 5mM EDTA, 50mM T r is ,  0.2% sodium azide ph 7.4) at room 
temperature fo r  15min. They were then washed once in the t r i t o n  bu ffe r
r
and resuspended at 10% (w/v) in the same buffer containing O.lmg/ml 
ovalbumin and 5mM potassium iodide.
Assay procedure.
Serum (20yl) and antigen solu tion (lOOyl) were added to 1.5ml poly­
propylene centrifuge tubes, vortex mixed and incubated fo r  2h at 37°C 
and 2h at 4°C. An a liquo t o f the bacteria l reagent (300yl) was added 
to each tube, the contents mixed and the ce lls  spun down using a 
Beckman Microfuge (8730g,5min,room temperature). The p e l le t  was washed 
twice in tr iton/ovalbumin bu ffer and the ra d io a c t iv i ty  counted using 
a Packard auto gamma s c in t i l l a t io n  spectrophotometer.
RESULTS
Determination o f hamster l i v e r  microsomal metabolising a c t i v i t y . 
Hamster l i v e r  microsomes were prepared as described in the Methods 
Section. Microsomal a c t iv i t y  was demonstrated by assaying fo r  the 
de-ethylation o f 7-ethoxycoumarin to 7-hydroxycoumarin using the meth­
od of Lake et al (1979). Formation o f 7-hydroxycoumarin was l in e a r  
over the f i r s t  2min and increased with microsomal protein concentra­
tion ( f i g . 2 , 1 - 2 ) .A c t iv i ty  was equivalent to 65nmoles 7-hydroxy­
coumarin .formed/ mg microsomal pro te in / min.
Figure 2 , 1.
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The e f fe c t  of increasing protein concentration on the de­
ethyl a t i  on o f 7-hydroxycoumarin using hamster l i v e r  micros­
omes. a  = 2min incubation. o= 5min incubation and ©= lOmin 
incubation. (Results are the mean + SD, n=3)
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The e ffe c t of increasing the incubation time on the de-ethylation 
o f 7 etjioxycoumarin using hamster l i v e r  microsomes. 
a  = lOyg pro te in , 0 =  30yg protein and © = 50pg protein .
(Results are the mean + SD, n=3).
Measurement o f practo lo l metabolite binding to human serum albumin.
14A mixture of HSA and C practo lo l was passed down a sephadex G25 
column and the e f f lu e n t monitored at 280nm. Fractions ( 4x10 speed)
50 drop fra c t ions ) were then counted fo r  ra d io a c t iv i ty .  Almost a l l  
the a c t iv i t y  was located in frac tions  15-20, corresponding to those 
frac tions in which practo lo l eluted. The small amount o f absorbtion 
at 280nm seen was due to practo lo l i t s e l f .  HSA eluted in frac tions  
6-11.( f ig .  2, 3 .) .
14Practolol (2mM, 1 ci C p rac to lo l)  was incubated with hamster l i v e r  
microsomes and 12mg HSA fo r  30min, with or w ithout cofactors. The mic­
rosomes were sedimented by cen tr ifuga tion  and the supernatant eluted 
down a sephadex G25 column, (0.8x10 speed, 100 drop fra c t io n s ) .
Two peaks were observed ( f ig .  2, 4) and the frac t ions  making up the 
f i r s t  one, corresponding to HSA, were pooled and concentrated under
pressure,using a UM 10 diaflow f i l t e r ,  to about h a lf  the o r ig ina l
14volume. Protein bound C a c t iv i t y  was measured a f te r  solvent ex trac tion  
or exhaustive equilib rium  d ia lys is  o f the concentrated protein f ra c ­
t ion .
When covalent binding was measured by exhaustive equilibrium d ia lys is  
0.54nMol/mg protein was found to have bound in the absence o f co fact­
ors and 3.08nMol in the presence o f cofactors, an increase o f 470%. 
corresponding values obtained a f te r  solvent extraction were O.lnMol and 
l . l ln M o l ,  lower than those obtained by exhaustive equilib rium  d ia ly s is  
although the percentage increase observed was much greater ( 1000%) 
due la rge ly  to the lower control values obtained by solvent ex trac t ion .
Figure 2, 3.
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14The e lu tion  p ro f i le  o f HSA and C practo lo l mixture eluted down 
a G25 sephadex column.(The e lu ting  bu ffe r was PBS ph 7.4, speed 
4x10, frac tions  50 drops.The frac tions  were monitored at 280nm ( o )
and counted fo r  r a d i o a c t i v i t y  ( ©) ) •
Figure 2 , 4.
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The separation o f HSA bound metabolites o f practolo l from the 
incubation mixture using a G 25 sephadex column.
(The e lu t ing  so lu tion was PBS, ph 7.4. speed 0.8x10, fra c t io n  
volumes 7ml. The e f f lu e n t was monitored at 280nm).
The assesment o f d i f fe re n t  radioimmuno assays fo r  detecting
antibodies to practo lo l metabolites using a model system.
The modified Farr assay.
A comparison o f d i f fe re n t  modified Farr assays.
The r e l i a b i l i t y  o f the three d i f fe re n t  modifications was compared 
(see Methods Section) using radio labelled HSA (1/8 d i lu t io n /  6 . 5yg 
assay) and sheep anti HSA (1/10 d i lu t io n ) .A l l  three modifications 
proved to be equally e ffe c t ive  in d iscrim inating between sp e c if ic  a n t i -  
sera and heat inactivated control sera (table 2 , 1 ) .  The system used 
by Amos et al (1978) proved, in my hands,to be unre liab le  as the prec­
ip i ta te  formed on addition o f ammonium sulphate did not always give 
a good p e l le t  on cen tr ifuga tion . I t  was therefore decided to use method 
3_ (see Methods Section) rou tine ly  as i t  gave the most reproducable 
resu lts .
A_compari_son_of the_ab_iJ i ty  o f_di/_ferent_ chemi cal s _t_o_ precip i tate_ 
the pamma_ _gl obulj n_ fract i on _of_serum.
A comparison was made o f the a b i l i t y  o f 50% ammonium sulphate, 27%
sodium sulphate and a saturated so lu tion o f ammonium acetate in ethanol
125to se le c t ive ly  p rac ip ita te  I HSA bound to anti HSA serum. Amm­
onium sulphate and sodium sulphate were considerably more e f fe c t iv e
125in p re c ip ita t in g  bound I HSA than ammonium ace ta te ,(tab le  2 , 2 ) .
A 50% solu tion o f ammonium sulphate gave the lowest control values 
when heat inactivated human serum was used. The re la t iv e  increase in 
ra d io a c t iv i ty  in the protein p e l le t  comparing control and experimental 
sera was*660% using ammonium sulphate, 264% using sodium sulphate and 
131% with ammonium acetate.
Table 2, 1.
A comparison o f the a b i l i t y  o f three d i f fe re n t  modifications o f 
the Farr assay to discrim inate between nonspecific and sp e c if ic  sera 
against human serum albumin.
(
*
modified Farr assay control serum (dpm) sheep anti human serum
albumin (dpm)
method 1 3,359+549 45,600+3,400
method 2 3,289+702 41,200+4,000
method 3 . 3,310+665 40,600+3,175
(Results are the mean + SD, n=3. dpm = d is in t ig ra t io n s /m in . )
The fo llow ing modifications to the methods described e a r l ie r  were made 
to ensure tha t the concentrations o f antibody and antigen were the same 
in each assay. Methods 1 and 2 :-  50 y l o f HSA was used and the to ta l 
volume made up to 170pl with PBS. Appropriate a lte ra t ions  to the volumes 
o f subsequent reagents used were also made. Method 3 :-  20pl o f antisera 
were used and 30pl o f PBS added to make the volume up to 50pl.
Table 2, 2 .
A comparison o f the a b i l i t y  o f sodium sulphate, ammonium sulphate
and ammonium acetate to p rec ip ita te  the gamma globulin f ra c t io n  o f sera.
p re c ip ita t in g  agent control serum (dpm) sheep anti human serum 
albumin (dpm)
50% ammonium sulphate 18,000+1,100 137,000+0.600
27% sodium sulphate 36,300+2.300 132,000+21,000
ammonium acetate in
ethanol * 38,500+4,300 89,000+13,000
(Results are the mean + SD, n=3, sera were d ilu ted  1/5 and HSA 1/ 8 ) 
Modified Farr assay, method 3. was used.
125Titration curve fo r  horse anti human serum against I HSA using 
a modified Farr assay, Method 3.
Horse anti human serum was s e r ia l ly  d ilu ted  and incubated with a fixed 
125concentration o f I HSA (1/8 d i lu t io n ,  6.5 yg/assay). A reduction 
, 125in prec ip ita ted I w ith increasing serum d i lu t io n  was found using 
the spec if ic  anti serum but minimal binding when heat inactivated 
human serum was used, ( f i g 2 9 5).
Results of _a_competitiv_e_bin_ding_a_s_say_using Farr assay, Method _3.
The a b i l i t y  o f the method to be used in competitive binding assays was
studied by adding increasing amounts o f uniabelled HSA or bovine
125serum albumin (BSA) to tubes containing I HSA (6. 5pg/assay) and 
undiluted horse anti human serum. The tubes were incubated fo r  2h at 
37°C and overnight at 4°C. The assay was then performed as normal.
BSA over the range 0.20-1.0mg/assay induced a s l ig h t  increase in a n t i ­
body/antigen binding w h i ls t  HSA, over the same concentration range, 
reduced antibody binding in a concentration dependent manner, ( f i g  2 , 6 ).
The cross linked antibody method.
125J l t r a t i  on _c_urve _f o r _ho_r_se_a n t i_huma_n_ serum_ agaj ns t _ HSA._
125 I HSA bound to horse anti human serum but not to heat inactivated 
control serum , ( f i g  2, 7 ).
Staphlococcus aureus Protein A method.
Quantitation o f the d i lu t io n  o f bacteria l suspension needed to 
give optimal antigen/antibody recovery.
The bacteria l suspension was d ilu ted  in T riton  bu ffer containing
ovalbumin and potassium iodide and d i f fe re n t  volumes added to 1ml tubes 
125containing I HSA and anti sera which had been preincubated fo r  2h
Figure 2, 5.
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125T it ra t io n  curve fo r  horse anti human serum against I HSA using 
modified Farr assay, method 3. (Results are the mean + SD, n=3.
HSA d i lu t io n  1 / 8 ) . # =  horse anti human serum. 0 = control serum.
Figure 2, 6.
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Competitive binding assay using modified Farr assay, method 3. 1?{-
( Results are the mean + SD, n=3. Horse anti human serum 1/20 d i lu t io n .  I 
HSA 1/8 d i lu t io n )  o=~unlabelled BSA and © = unlabelled HSA.
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125T it ra t io n  curve fo r  horse anti human serum against HSA using the 
cross linked antibody method. (Results are the mean + SD, n=3. 125hSA 
d i lu t io n  was 1/ 8 ). 0 = control sera. ©= horse anti human serum.
at 37°C and 2h at 4°C. Specific and control binding, using d i f fe re n t  
volumes o f the bacteria l suspension, was measured as described 
in the Methods Section. Optimal binding (sp ec if ic  vs con tro l)  was found 
using 300ylofthe neat suspension (10%w/v) and th is  was used fo r  sub­
sequent assays, (tab le 2, 3 ) .
IItr§tion_of_s'heep_anti_human_serum_a]bumin_using_the_Staph]ocgccus
jyr§y§_ Protein,  ^ method..
Specific binding to the sheep anti HSA dropped rap id ly  with increasing 
serum d i lu t io n .  Binding to control serum was very low, ( f i g  2, 8 ).
15 s _o^_ a_ cpmpeti t  i ve_bi ndi ng_ass_a_y_ us i ng_ the_ §taphl°coccus_ aureus 
.P CQte in _A .method..
Unlabelled HSA added to a 1/20 d i lu t io n  o f sheep anti HSA in h ib ite d  
binding o f the rad io labelled protein in a dose re lated fa sh io n ,(0 . 2- 1.0 
mg/assay) BSA s i ig h t ly  enhanced I HSA binding, ( f i g  2, 9) .
A comparison o f the a n t ig e n ic i ty  o f the rad io labelled and unlabelled
human serum albumin samples used in the competitive binding assays.
I t  was noted that high concentrations o f unlabelled HSA (0.2-l.Omg/
assay) were needed to reduce the binding o f antibody to the radio-
labelled antigen, (6.5 pg/assay). I t  appeared tha t the rad io labe lled
HSA was more antigenic than the unlabelled HSA. This p o s s ib i l i t y
was tested by carrying out a double d if fu s io n  experiment against
sheep anti HSA. A fte r 2 days p re c ip ita t io n  lines were observed w ith a
1251/512 d i lu t io n  o f ■“ I HSA but only at a d i lu t io n  o f 1/128 w ith the 
unlabelled antigen.
Table 2, 3.
Experiment to determine the concentration o f Staph!ococcus aureus
giving optimal antibody/antigen recovery.
volume o f bacteria added control serum (dpm) sheep anti HSA 
(dpm) c o n tro lx l00experim.
10yl 1,325+1,200 271,700+71,100 0.5%
50yl 1,700+ 600 235,800+51,700 0.7%
lOOyl 2,800+ 300 191,700+25,600 1.5%
200yl „ 4,800+2,400 340,500+36,000 1.4%
300yl 4,200+1,300 345,700+43,200 ( 1.2%
125(Results are the mean + SD, n=3) Sera were not d ilu ted . HSA was d i lu ted  
1/ 8 .
Figure 2, 8.
- 3
' dpm x 10
400 i
300 -
200  -
100
1 11.0 1
5 10 20 40 80
serum d i lu t io n
125T it ra t io n  o f sheep anti human serum albumin against HSA using the 
Staphlococcus protein A method.
(Results are the mean + SD, n=3. ^H S A  was d ilu ted  1/ 8 ).
Control serum = 0  . sheep anti human serum albumin =© .
Figure 2, 9.
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Competitive binding assay using the Staph!ococcus aureus prote in A 
method. (Results are the mean + SD, n=3. sheep anti human serum was 
d ilu ted  1/20. 125hsA 1/8 .) Unlabelled HSA =© . unlabelled BSA = 0  .
Analysis o f serum from practo lo l treated patients fo r  antibodies to
in v i t ro  generated practolo l metabolites.
Protein bound metabolites of practo lo l were generated as described 
previously and, a f te r  iso la t io n  and concentration, used as the a n t i ­
gen complex in Farr, cross linked gamma g lobulin  and Staplococcus
(
aureus assays.'The resu lts  obtained using sera from 12 d i f fe re n t  pat­
ients are given in table 2, 4. Some o f the pa tients , (7 ), had already 
been shown to contain antimetabolite antibodies by Amos e t al (person­
al communication) at a t i t r e  o f 1/10. I t  was not generally possible 
to use the same samples as Amos et al but th e i r  f ind ings , using serum 
from the same patients are given fo r  comparison where possible.
No d ifference in binding between control and experimental serum 
samples could be detected or between the antigen complex generated in 
the presence o f cofactors or the absence o f cofactors using any o f the 
assays. Differences in the percentage binding between the three assays 
used were seen. The Farr assay gave the highest binding values but 
these ra re ly  exceeded 5%. o f the to ta l counts added. The cross linked 
antibody method gave s l ig h t ly  lower values fo r  antigen binding and the 
Staplococcus aureus protein A method the lowest binding values, less 
than 1%.
DISCUSSION
The aim o f the experiments described in th is  Chapter was to evaluate 
the methods used in generating the p ra c to lo l/p ro te in  complex and the 
assays fo r  measuring bind to spec if ic  antibodies present in the serum 
of adversely e ffected patients.
The a c t iv i t y  o f the microsomal mixed functional oxidase system was
Table 2, 4.
Results o f binding assays obtained with the modified Farr assay.
cross linked antibody assay and the Staphjlococcus aureus assay using 
patients sera and the practo lo l metabolite antigen complex.
4
Serum sampled % binding Result o f Amos et a l.
(7o binding)
_________________ Test_antigen______control antigen_______________________
Farr assay. 
S896/74 (LW) 2.5 3.3
S122/75 (AD) 3.7 3.7 20,
S762/74 (BL) 2.9 3.2
i
25
S818/74 (BL) 2.4 1.7
S935/74 (MU) 2.1 1.9
S123/75 (BO) 2.2 2.0
S840/74 (Me) 1.8 2.0
S127/74 (MA) 1.7 1.9 30
control A 3.9 3.0
control B 2.3 1.6
Cross linked antibody method 
S909/74 (RE) 1.0 1.2 12
S935/74 (MU) 1.8 1.6
S157/75 (AD) 1.4 1.5
S123/75 (BO) 1.5 1,3
S896/74 (LW) 2.0 2.3
N88699 (130) 2.9 2.6
control A 2.7 2.6
control B 1.7 1.7
Table 2, 4. continued.
Staphlococcus aureus method.
N88699 (GO) 0.23 0.29
S157/57 (AD) 0.30 0.29
S818/74 (BL) ' 0.33 0.16
S47/75 (CA) 0.32 0.51 25
S102/75 (MUL) 0.41 0.38 16.5
S935/74 (MU) 0.35 0.36
S195/75 (ST) . 0.27 0.29 34, 15.6
control A 0.39 0.40
control B 0.30 0.40
Results are the mean o f duplicate assays.
The sera had been stored at BIBRA. Each sample was given a number 
at the time i t  was taken by Dr Amos. The results  o f assays performed, 
using serum from the same patient,by Amos et al are given when ava ilab le 
A na lys is  was performed on the same sample.
demonstrated using the de-ethylation o f 7-ethoxycoumarin as an ind­
ica to r of microsomal enzyme a c t iv i t y .  Formation o f m etabolite /prote in
14complexes was confirmed by measuring covalent binding of C-practo- 
lo l  to HSA,added to the incubation system,after solvent or exhaustive 
equilib rium  d ia lys is  extraction o f the iso lated HSA fra c t io n .  Cova­
len t binding to%HSA was about 3 fo ld  higher a f te r  exhaustive d ia lys is  
extraction than a f te r  solvent ex trac tion . This find ing  is  in agreement w ith 
an e a r l ie r  report o f Sun and Dent (1980). They showed tha t covalent 
binding values were between 2 and 7 times greater a f te r  exhaustive 
d ia lys is  tha t a f te r  solvent ex trac tion . The large increase in binding 
in the presence o f cofactors indicates that much o f the covalently 
bound a c t iv i t y  was due to practo lo l metabolites. The value o f l . l ln m o l 
/mg protein obtained a f te r  solvent extraction is  in good agreement with 
the value published by Orton and Lowery (1977). They reported binding 
o f 1.49nmol/mg microsomal protein using s im ila r  incubation conditions. 
Addition of 12.5mg HSA to the incubation in h ib ite d  binding by 96%, 
presumably by scavenging the active metabolites formed. A value of 
about 1.43nmol/mg HSA would therefore be expected i f  a l l  the metabol­
ites  became bound to HSA, approximately 30% more than was found in 
th is  study. I t  is  not possible to compare the resu lts  gained in the 
experiment described above with the resu lts  obtained by Amos et al 
as they did not measure metabolite binding.
I t  was not possible to va lidate the various binding assays using known
antigents or antibodies as characterisation o f these parameters was
125the goal o f th is  pro jec t. Commercial anti sera against HSA and I HSA 
were therefore used as a model system. Using th is  approach i t  was dem­
onstrated that high spec if ic  binding, but low binding to control sera,
125occured with a l l  the assays evaluated and tha t binding of HSA could
be blocked by unlabelled HSA but not by BSA.
Using a l l  three techniques, sera from patients who had been treated 
with practo lo l were analysed fo r  the presence of antibodies against the 
antigen complex, including sera from patients known to have had a 
pos it ive  t i t r e  at some time. None o f the sera tested gave a pos it ive  
re su lt  but because i t  was not possible to use the same serum samples 
used by Amos et al i t  was not possible to compare resu lts  d i re c t ly .  
Several explanations fo r  the lack o f binding suggest themselves. F i r s t  
i t  is possible that the methods used to generate the antigen complex 
were inadequate. This would seem un like ly  as the method used in these 
studies were the same as those used successfully by Amos et al (1978) 
and,in some cases,the antigen complex was prepared by the workers who 
had taken part in the o r ig ina l studies. Second, the sera could have 
deteriorated during storage. This period was as long as 5 years in 
some cases and, as the sera had not been a liquoted, some samples, par­
t ic u la r ly  the more in te res ting  ones, had been frozen and thawed several 
times, (e ithe r on purpose or accidently when the deepfreeze broke 
down). Third, i t  was possible that a l l  the active sera had been used 
in the o r ig ina l studies and only inactive sera was l e f t .  Further stud­
ies were undertaken to evaluate these p o s s ib i l i t ie s .
CHAPTER 3.
INVESTIGATIONS TO DETERMINE POSSIBLE REASONS WHY 
ANTIBODIES TO IN VITRO GENERATED PRACTOLOL METABOLITES 
COULD NOT BE DETECTED IN THE SERUM OF PRACTOLOL
TREATED PATIENTS.
INTRODUCTION
The methods necessary to generate antigen complexes .and assay fo r  
spec if ic  antibodies to these in the serum o f practo lo l treated 
patients were evaluated in Chapter 2. Using these methods however 
no metabolite antibodies could be detected, even using serum from 
patients previously shown to have synthesised such antibodies by Amos 
et a l . I t  was suggested tha t e ith e r the methods used were inadequate 
or tha t the sera used was, fo r  some reason, inac tive . These p o s s ib i l ­
i t ie s  were evaluated. In order to control fo r  methodological errors 
co llabora tive  experiemnts were performed with Dr. B.Lake and Ms 0 
A r t is  BSc, workers who had performed the o r ig ina l experiments with 
Dr. Amos,(1978). In one experiment sera which had been stored at The 
B r i t is h  Biologica l Research Association (BIBRA) were used and in a sec­
ond sera were obtained from ICI Macclesfield. This enabled both a com­
parison o f the methodology and of serum samples stored at d i f fe re n t  
laboratories.
As a check on the s ta b i l i t y  o f the sera, samples were analysed fo r  
th e ir  autoantibody t i t r e ,  using guinea-pig oesophageal r ings , and com­
pared with t i t r e s  obtained o r ig in a l ly  using sera collected at about the 
same time.
Amos et al (1977) had suggested that there could be a negative re la ­
t ionship between autoantibody t i t r e  and the presence of antimetabolite  
antibodies. A number o f serum samples were chosen at random and tested 
fo r  autoantibodies. I t  was intended to perform Farr assays on those 
samplesWhich were negative at a 1/10 d i lu t io n .
METHODS
Methods used in th is  Chapter fo r  the generation o f the antigen complex 
and detection, by Farr assay, o f antimetabolite antibodies were the 
same as those described in Chapter 2.
Measurement o-f autoantibodies.
A guinea-pig oesophagus was dissected out and pieces frozen onto a 
cryostat chuck placed in a cardice/acetone freezing mixture. Sections, 
5-6ym, were cut using a Bright microtome and freeze fixed onto 76x26mm 
glass microscope slides and l e f t  in the microtome u n t i l  needed.
Before s ta in ing the s lides were put in racks suspended in 500ml PBS 
in a glass tank placed on a magnetic s t i r r e r  and washed fo r  lh . They 
were then removed, drained o f excess bu ffe r and placed in a damp box. 
The seruftto be used (0.4ml o f the required d i lu t io n )  was placed on 
each s lide  and l e f t  fo r  30min. The seru#\was then drained, the s lides 
washed fo r  lh in a change o f bu ffe r before being replaced in  the damp 
box. The sections were then counter stained fo r  30min using 0.4ml o f 
1/10 d i lu t io n  of FITC labelled sheep anti human IgG. A fte r a f in a l  
wash fo r  lh in a change o f bu ffe r the s lides were drained and mounted 
in buffered glycerol under a glass covers!ip . The sections were exam­
ined using a Zeiss fluorescent microscope set fo r  exc ita t ion  at 450- 
500nm (optimal wavelength 490nm) and the fluorescence ca lib ra ted using 
an a rb ita ry  scale with reference to a control from which serum had 
been ommitted, ( s l ig h t  + to ++++).
RESULTS
Results o f co llabora tive  experiments.
There was no d ifference in binding between te s t  antigen (incubations 
carried out with cofactors)- and the control antigen (cofactors omit­
ted) when sera' stored at BIBRA was used in the f i r s t  co llabora tive  
experiment,(table 3, 1), using e ith e r the technique o f E l l i o t t  or tha t 
of Lake and A r t is .  S im ila r ly  no d ifference in binding between control 
and patients sera was observed. Binding values obtained by Lake and 
A r t is  were very low (0.2% or less) and d if fe red  'from values previously 
reported which varied from about l%-85% (Amos et al 1978).
In the second co llabora tive  experiment sera from both BIBRA and ICI 
were used. This allowed a d ire c t  comparison to be made of both the 
techniques and the e f fe c t  o f storage on the sera stored at BIBRA. 
Binding values reported th is  time by Lake and Artis varied between 2 
and 14% w h ils t  values obtained by E l l i o t t  were comparable to those 
obtained during the f i r s t  set o f analysis, (tab le 3, 2). I t  can be seen 
from the assay of anti HSA vs the antigen complex however tha t the 
method employed by Lake and A r t is  is  not reproducible eg the standard 
deviation fo r  tha t assay was up to +90%. This makes i t  very d i f f i c u l t  
to assess the s ign if icance of the resu lts . For example the apparent 
s ig n if ic a n t  binding o f seromfrom pa tien t TO to the antigen complex.
The reason fo r  the large d ifference in percentage binding found by 
Lake and A r t is  between the two experiments is not known. No d i f f e r ­
ence between te s t and control antigens could be detected. Sera obtained 
from BIBRA and ICI bound the antigen complex to about the same .extent 
ind ica ting  tha t storage conditions at BIBRA had not contributed spec­
i f i c a l l y  to any deterioration o f the serum samples.
Table 3, 1.
The resu lts  o f a co llabora tive  experiment aimed at detecting anti 
metabolite antibodies in the serum of practo lo l treated patients 
using sera stored at BIBRA.
Serum sample % Binding
Lake/Artis El 1i o t t
Test Control 
antigen antigen
Test
antigen
Control
antigen
S102/75 (MUL) 0.10 0.08 1.7 2.0
S818/74 (BL) 0.10 0.08 1.7 1.9
S935/74 (MU) 0.19 0.08 1.7 2.0
S47/75 (CA) 0.08 0.08 2.2 1.9
S195/75 (ST) 0.16 0.07 1.9 1.7
control A 0.22 0.16 1.6 1.9
control B 0.14 0.07 1.2 1.9
The antigen complex was prepared by Dr Lake. Sera which had been 
stored at BIBRA (-20°C) were analysed fo r  antimetabolite anti 
bodies by Ms A r t is  (modified Farr assay, Amos e t al 1978) and 6. 
E l l i o t t  (Farr assay method 3). Results are o f s ing le assays.
Table 3, 2.
The resu lts  o f a co llabora tive  experiment aimed at detecting anti
metabolite antibodies in  the serum o f practo lo l treated patients 
using sera stored at BIBRA and ICI.
 *___________________________________________________
Serum samp’le D ilu t ion  %Binding
Lake/Artis E l l i o t t
Test
antigen
Control
antigen
Test
antigen
Control
antigen
Anti HSA 1/10 21+19 24+21 27.5+4.0 31.5+2.:
(Sheep) 1/00 4.0+3.4 9+1.0 5.5+0.2 6.4+0.2
S886/74 (TO) 1/10 14.65 6.43 1.4 2.3
7/11/74 14.89 5.05 1.7 1.8
N:A (MUL) 1/10 --------------------- ----------------- — —
B62882 8.43 6.95 1.6 1.5
S47/75 (CA) 1/10 4.73 3.24 1.6 1.6
17195 3.75 5.91 1.5 1.7
S130/75 (BR) 1/10 3.38 2.79 1.4 1.7
G5648 8.49 4.85 1.6 2.1
S195/75 (ST) 1/10 4.15 4.54 2.0 2.1
G65931 7.57 3.95 1.6 1.8
S18/75 (MC) . 1/10 7.01 3.14 2.0 1.9
17/11/75 7.84 5.26 2.2 2.0
S162/75 (HI) 1/10 4.60 4.32 1.5 1.5
G67176 5.10 5.74 1.7 1.6
The antigen complex was prepared by Dr Lake. Sera which had been 
stored at BIBRA or ICI ( - 2 0 ° C )  were analysed fo r  antimetabolite 
antibodies by Ms A r t is  and G .E l l io t t .  Sera which had been stored 
at BIBRA are given f i r s t  each time. Results are o f s ingle analyses 
apart from the assays of sheep anti HSA versus the antigen complex 
which were carried out in duplicate (mean+ sd.)
Analysis of sera from patients treated with practo lo l to id e n t i fy
samples with an autoantibody t i t r e  of less than 1/10.
Autoantibody levels were measured in the sera o f 17 patients chosen 
at random, including 4 patients where se r ia l samples were ava ilab le , 
(tab le 3, 3 ). A l l  had ,a t i t r e  o f at least + at a 1/10 d i lu t io n  using 
FITC labelled sheep anti human IgG serum. An antibody to an in te r c e l l ­
u la r antigen was found in the serum of a l l  patients tested and a 
nuclear antibody in the serum of about 50% o f the pa tien ts , ( f ig  3, 1 
and 2).There was some evidence tha t the autoantibody t i t r e  changed 
with time when sera from pa tien t BL was used but no apparent changes 
when sera from patients MUL,RE or RY were used. Due to the presence 
of autoantibodies in a l l  the sera tested Farr assays were not per­
formed.
A comparison of autoantibody t i t r e s  in stored sera with those 
obtained soon a f te r  c o l le c t io n .
In order to investigate-the p o s s ib i l i ty  that the sera may have lo s t  
th e ir  a c t iv i t y  during storage the autoantibody t i t r e  was measured in 
6 serum samples and compared with the t i t r e  reported at the time o f 
co llec t ion  by Dr Amos. Dr Amos also standardised the scale used to 
assessthe re la t iv e  response, + to ++++. None o f the samples analysed 
had a t i t r e  o f greater than + at 1/80 d i lu t io n .  Most o f the patients 
had a t i t r e  of at least 1/320 when the analysis was performed soon 
a f te r  the blood was taken, (tab le 3, 4).
The binding of  an t ibod ies  in the serum of  a p rac to lo l  t r e a t e d  
p a t i e n t  (S924/74,  1/10 d i l u t i o n )  to the i n t e r c e l 1u la r  region of  
a xenogenic t i s s u e  (guinea-pig oesophagus).  Counter sta in ing was 
c a r r i e d  out using FITC l abe l l ed  sheep antihuman IgG.
Figur e 3,  2.
Binding of an t ibod ies  in the serum of a p rac to lo l  t r e a t e d  p a t i e n t  
(S122/75,  1/10 d i l u t i o n )  to the nucleus of a xenogenic t i s s u e .  
Condit ions as f o r  f i g .  3, 1.
Table 3, 3.
An analysis o f autoantibodies present in the sera of p racto lo l
treated patients using guinea-pig oesophagus r in g s .
Serum samples. Code Date obtained Binding(1/10 d i lu t io n ) .
% in te rc e l lu la r nuclear
MUL1 S745/74
S949/74
S103/75
S169/75
21/10/74
19/12/74
5/2/75
6/5/75
+
+
+±
+
+
+
+
+
BL 1 S762/74
S24/75
S124/75
?
8 / i/75 
14/3/75
+++
++++
++
+
RE 1 S773/74
S909/74
S105/75
28/10/74
6/12/74
6/2/75
++
+++
++
RY 1 S924/74
S90/75
S135/75
S142/75
12/12/74
30/1/75
25/2/75
8/4/75
++++
++++
+++±
+++± +
BO S795/74 23/10/74 + ±
RO S63/75 ? ++
LA S168/75 6/5/75 +++ ±
MA 1 S127/75 17/3/75 ++
JE S752/74 21/10/74 +±
AL S846/74 ? + . +±
MC S724/74 7/10/74 ++++ ++
AD1 S122/75 ? + +++
LY S65/75 9/12/74 + ++
CR S186/75 12/5/75 +
MAC S748/74 21/10/74 ++± ++
CAR S70 9/12/74 ++
MUR S71/75 2/1/75 + +++
Binding o f serum,from practo lo l treated pa tien ts , to a xenogenic t issue , 
(guinea-pig oesophagus). Counter s ta in ing was performed using sheep anti 
human IgG. FITC labelled. 1= oatient shown to have antimetabolite  a n t i ­
bodies at some time.
Table 3, 4 .
A comparison of autoantibody t i t r e s  in the serum of practo lo l 
treated patients with those values reported when f i r s t  analysed
serum sample. binding at 1/80 d i lu t io n o r ig ina l t i t r e
S886/74 (TO) s l ig h t  + none
S124/75 (MUL) 1 + 1/320
S195/75 (ST) " + 1/640
S18/75 (Me) " + 1/640
S130/75 (BR) 1 + 1/320
S126/75 (HI) " t 1/1280
Binding of serum from practo lo l treated patients to a xenogenic 
tissue (guinea-pig oesophagus). Counter sta in ing was carried out 
using FITC labelled sheep anti human IgG.
DISCUSSION
The co llabora tive experiments carried out in cooperation with Dr.B.
Lake and J .A r t is  demonstrated that the results  given in Chapter 2
were not fa lse negatives. The second experiment also showed tha t 
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there was l i t t l e  d ifference between sera stored at BIBRA and ICI.
Whilst i t  was s t i l l  possible tha t the sera had become deactivated 
during storage i t  appeared to be un like ly  that non-standard storage 
conditions had contributed to th is  process.The most in te res ting  f in d ­
ing to emerge, from the two co llabora tive  experiments was the d i f f e r ­
ences in antigen binding obtained using the o r ig ina l method. In the 
f i r s t  experiment (tab le  3, 1) binding values v/ere less than 0.5% 
where as in the second experiment (table 3, 2) i t  varied between 3 and 
15%. Antigen binding o f greater than 10% was o r ig in a l ly  accepted as 
being necessary to demonstrate the presence o f spec if ic  antibodies 
(Amos et al 1978). Only one patient of the seven tested in  the second 
experiment had a t i t r e .  o f greater than 10%, (pa tien t TO),although four 
of the patients had been shown to have synthesised antimetabolite a n t i ­
bodies previously,(MUL, CA, BR, and ST). There was however considerable 
va r ia t ion , not only between the two experiments but also between dup­
lica tes  (+90% when anti HSA sera was incubated w ith the antigen complex) 
which makes i t  d i f f i c u l t  to in te rp re t  th is  f ind ing .
I t  was possible that a l l  the serum containing antimetabolite a n t i ­
bodies had been used up by the o r ig ina l investiga to rs . A method fo r  
test ing  fo r  active sera was indicated by the proposal o f Amos et al 
(1978) that there might be an inverse re la tionsh ip  between au toanti­
body levels and the presence of antimetabolite antibodies. A number 
of samples were therefore analysed fo r  autoantibodies using a d i lu t io n
of 1/10. I t  was intended to use any sera which were negative at th is  
d i lu t io n  in Farr assays. Unfortunately a l l  the sera tested were pos it ive  
and were not analysed fo r  the presence o f antimetabolite antibodies.
In order to investigate the idea that the samples had deteriorated 
during storage autoantibody t i t r e s  o f stored sera were compared with the 
t i t r e s  obtained soon a f te r  they were co llected. As can be seen from 
table 3, 4 .,  none o f the sera bound strongly to guinea-pig oesophagus 
rings at a 1/80 d i lu t io n  where as a l l  the sera had t i t r e s  o f  1/320 
or greater at the time o f co l le c t io n . I t  is  possible therefore tha t the 
samples had deteriorated during storage.
The most probable reason fo r  the negative resu lts  obtained in these 
studies is  tha t the active sera had a l l  been used up in the o r ig ina l 
studies. Although autoantibody t i t r e s  appear to be maintained in v iv o , 
(see table 3, 3.) anti metabolite antibodies f luc tua te  g rea tly  w ith in  
a short time period. Amos et al (1977) fo r  example reported tha t th is  
a c t iv i t y  dropped by 65% and 75% in two patients in a one month period. 
With such a short time .in which to c o l le c t  active sera i t  is  probable 
that many samples obtained would be inactive  and that the small number 
of active samples available would be rap id ly  used up. In view o f the 
fac t that no fu r th e r serum samples from practo lo l patients would be 
forthcoming i t  was not considered f r u i t f u l  1 to pursue the problem 
any fu r the r.
Incidences of adverse e ffects  associated with drug adm in is tra tion , such 
as the practo lo l syndrome, can, p o te n t ia l ly ,  provide a great deal o f 
information, not only on the mechanism of the drug induced reaction but 
also on the way in which normal control processes, such as the immune 
system, are regulated. I t  is important therefore tha t samples obtained 
from treated patients are stored p roperly , fo r  example at -70°C or
f'reeze dryed with a preservative. Samples should ce r ta in ly  be aliquoted 
as soon as possible and not repeatedly thawed and refrozen.
I t  is  also important tha t samples known to contain the reported act­
i v i t y  are not used up so tha t workers wishing to confirm, or extend," 
the o r ig ina l observations have a pos it ive  control with which to work.
CHAPTER 4.
EXPERIMENTS AIMED AT RAISING ANTIBODIES TO IN VITRO 
GENERATED METABOLITES OF PRACTOLOL IN ANIMALS.
INTRODUCTION.
I t  had not proved possible to characterise, chemically, the nature 
o f the antigenic practo lo l metabolites using sera obtained from 
patients treated with practo lo l (chapters 2 and 3). A d i f fe re n t  
approach to the problem is to raise antibodies to in v i t r o  gener­
ated metabolites o f p ra c to lo l , using animals, and use these antibodies 
to define the s tructure o f the immunologically active product(s).
Antibodies to protein bound practo lo l had been raised in rabbits  by 
Chuong et al (1977a) As there were no reports o f antibodies being 
raised to in v i t r o  generated metabolites i t  was decided to fo llow  the 
immunization schedule described by Chuong et al (1977a) in these experiments. 
Rabbits (4) and guinea-pigs (5) were in jected with metabolite/microsome
complex and the formation of antibodies followed by e ith e r skin te s t -
14ing or by carrying out modified Farr assays (method 3) using C pract-
125olo l or the HSA/metabolite complexTletabolites binding to microsomal 
protein are probably iden tica l w ith those which bind to HSA. This 
approach therefore allowed the HSA/metabolite complex to be used 
as the antigen in the Farr assays,as described prev ious ly ,and preempted 
problems associated with the generation o f antibodies to the c a r r ie r  
protein in jected in to  the animals. Amos et al (1977) had reported tha t 
practo lo l p a r t ia l ly  inh ib ited  binding o f the HSA/ metabolite complex 
to antibodies in human sera. I t  was probable therefore tha t ^C  p rac t­
o lo l would also bind to antibodies against m e ta b o l i te s , i f  only w ith a 
reduced a f f in i t y .
METHODS.
HSA/metabol i t e  complexes were generated as described in chapter 2. 
Microsome/metabolite complexes were formed in the same way with the 
exception that HSA was not added to the incubation system:
4
Immunisation schedule.
The niicrosomal/metabolite system was homogenised with complete Freunds 
adjuvent using a motorised, g la ss / te f lo n ,  Potter type homogeniser to 
give a f in a l  concentration o f Img prote in /m l. New Zealand White rabbits  
(2.5-3.0 kg)were in jected at m u lt ip le  s ites  in the leg muscles with a 
to ta l of 2mg (10x0.2ml) o f the adjuvant/ antigen mixture and then 
every week fo r  5 more weeks with 4x0.5ml subcutaneously. Blood samples 
were taken from the ear veins lOdays a f te r  the la s t  in je c t io n  and serum 
isolated as described in chapter 2.
Albino guinea-pigs (400-500g) were in jected with a to ta l o f 0.5mg 
protein (50pl in each hind footpad and 4x0.1ml subcutaneously) fo r  the 
f i r s t  in je c t io n  and then weekly fo r  5 weeks with 5x0.lml subcutaneously. 
Blood samples were taken from the ear veins 10 days a f te r  the la s t  in ­
je c t io n  and serum iso la ted.
\
I f  the resu lts  of the tests fo r  antimetabolite antibodies were neg­
ative the animals were l e f t  fo r  6 months and the schedule repeated. 
Analysis o f serum fo r  antibodies against practo lo l metabolites.
14Either the HSA/metabolite complex or C practo lo l was used as the 
antigen in the modified Farr assay. Serum was heat inactivated before 
being used and d ilu ted  1/10 with PBS.
Procedure fo r  skin te s t in g .
The flanks o f the animals were shaved and 0.2ml o f each tes t a n t i ­
gen in jected in trade rm a lly . Each in je c t io n  s i te  was numbered using 
a water proof f e l t  t i p  pen. The skin thickness at each s i te  was measured
a fte r  2, 6 and 23h using a Pocotest d ia l gauge. The antigen te s t  so l-  
%
utions were as fo llow s, 1x10 M p ra c to lo l ,  microsomal preparation (lmg/ml) 
d ilu ted 1/10 with Tris/HCl bu ffe r ,  0.5 units/ml ICDH (1/10 d i lu t io n ) ,  
and the HSA/metabolite complex. Results are given as the skin thickness 
at the s i te  o f antigen in je c t io n  minus the thickness at the s i te  o f 
Tris/HCl bu ffe r (mm).
RESULTS.
Experiments aimed at detecting antibody production to practo lo l 
metabolites in rabbits and guinea-pigs using a modified Farr assay.
None of the serum samples from the four rabbits or f ive  guinea-pigs 
contained antibodies to the HSA/metabolite complex or p racto lo l 
a t a ■1/10 d i lu t io n  (table 4, 1 .) .  when assayed a f te r  the f i r s t  series 
of in jec t ions . A fte r the second series there was s t i l l  no detectable 
a c t iv i t y ,  (data not given).
Experiments aimed at detecting antimetabolite antibodies by skin te s t in g .
None o f the animals tested showed any signs o f reacting to intradermal 
in jec t ions  o f the HSA/metabolite complex or practo lo l at any o f the 
time periods. A ll the animals reacted to the microsomal preparation 
and, most s trong ly , to ICDH. Maximum changes in skin thickness were 
found a f te r  about 6-7h. Results fo r  the rabbits are given in tab le 4,
2 and fo r  the guinea-pigs in table 4, 3. S im ilar values were ob ta i-  
ed a f te r  the second series of in je c t io n s , (data not given).
Table 4, 1.
Binding o f rabb it and guinea-pig sera to the HSA/metabolite complex
-
and to C practo lo l using a modified Farr assay.
animal
%
125HSA/metabolite complex 
% binding.
14C practo lo l 
% binding.
rabbits.
1 4.9 2.8
2 5.6 3.3
3 6.0 2.9
4 3.7 3.4
controls
1 5.4 4.7
2 3.1 2.5
guinea-pigs
1 6.0 3.3
2 6.7 2.5
3 5.2 3.7
4 3.6 2.9
5 3.8 3.0
controls
1 4.6 3.3
2 5.4 3.7
Results are the mean o f duplicate assays fo r  each animal. 
1/10 serum d i lu t io n .
Table 4, 2.
Results o f skin tes t carried out on New Zealand White rabb its .
animal. skin thickness (mm), tes t minus control values.
ICDH microsomal
preparation
metabolite/HSA 
complex
practo lo l
re su lt  ■a fte r  2h.
1 3.2 1.8 0.2 0.1
2 2.7 1.9 0.1 0.2
3 3.0 2.1 0.3 0.1
4 1.8 1.8 0.1 0.0
control animals
1 0.5 0.6 0.1 0.2
2 0.0 0.2 0.0 0.0
results a f te r  6h
1 3.2 1.9 0.1 0.0
2 2.8 1.6 0.0 0.0
3 2.9 1.3 0.1 0.0
4 2.5 1.8 0.0 0.0
control animals
1 0.4 0.1 0.0 0.1
2 0.0 0.2 0.0 0.0
results a f te r  23h
1 2.0 0.8 0.0 0.0
2 1.9 1.2 0.0 0.0
3 2.2 1.0 0.0 0.0
4 . 1.8 0.9 0.0 0.0
control animals.
1 0.6 0.4 0.1 0.0
o<L 0.0 0.0 0.0 0.0
Table 4, 3.
Results of skin tests carried out on albino guinea-pigs.
animal skin thickness (mm), tes t minus control values.
"ICDH microsomal metabolite/HSA practo lo l
» preparation complex
resu lt a f te r  2h
1 1.6 0.2 0.1 0.0
2 2.4 0.2 0.2 0.3
3 2.0 0.8 0.1 0.0
4 2.5 0.5 0.3 0.1
5 1.1 0.3 0.1 0.0
control animals
1 0.4 0.2 0.2 0.0
2 0.8 0.5 0.1 0.1
results a f te r  7h
1 2.9 1.3 0.0 0.0
2 4.5 2.1 0.2 0.5
3 2.9 0.9 0.0 0.2
4 2.9 1.4 0.1 0.1
5 2.9 0.2 0.0 0.0
control animals
1 0.0 0.3 0.0 0.0
2 0.0 0.2 0.0 0.0
results a f te r  24h
1 1*8 0.1 0.0 0.0
2 2.1 1.3 0.2 0.0
3 1.3 0.0 0.0 0.0
4 1.5 0.0 0.0 0.0
5 0.6 0.0 0.0 0.0
Table 4, 3. continued.
animal skin thickness (mm) tes t minus control value.
ICDH. microsomal
preparation
metabolite/HSA
complex
practo lo l
control animals
1 0.1 0.2 0.0 0.0
2 0.7 0.4 0.0 0.0
DISCUSSION.
None o f the animals immunised with the microsome/metabolite complex
synthesised antibodies spe c if ic  fo r  e ith e r practo lo l or i t s  metabolites
using the in je c t io n  schedule o f Chuong et al (1977a). A response to 
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microsomal p ro te in , and to a much greater extent ICDH, was observed 
in a l l  animals when challenged intradermally ind ica ting  tha t the anim­
als were responding to the in jec t io ns .
The negative response to the metabolite haptens is  probably not a fa lse
re su lt  due to the in a b i l i t y  of the methods used to detect antimetabolite
antibodies. I t  is  presumed tha t the metabolites which bound to microsomes
are identica l to those scavenged by HSA so that antibodies to the
microsomal bound metabolites would be expected to bind to HSA bound
metabolites. This proposal is  fu r th e r supported by the lack o f binding 
14between C practo lo l and antibodies in the experimental sera. Amos 
et al (1977) demonstrated tha t practo lo l could, p a r t ia l ly ,  in h ib i t  
binding between patients, sera and the antigen complex suggesting some 
cross re a c t iv i ty .  I t  is also l i k e ly  tha t the metabolite(s) was 
antigenic as antibodies to practo lo l were raised by Chuong e t al (1977a) 
and such metabolites presumably induced an immune reaction in susceptible 
practo lo l patients. The most l i k e ly  explanation fo r  the lack o f a n t i ­
metabolite antibodies is  tha t the hapten density on the c a r r ie r  mol­
ecule was too low to induce an immune response. Maximum binding of 
practo lo l metabolites to HSA was 3.3nmol/mg protein (chapter 2). Ass­
uming a molecular weight fo r  HSA o f 50,000 th is  is  equivalent to 3.3nmol/ 
20 nmol HSA, ie 1 molecule o f practo lo l : 6 molecules of HSA. I t  is 
possible tha t bonds other than covalent ones are s u f f ic ie n t  to induce 
an immune; response to a hapten/protein c a r r ie r  and that during the assay 
to measure covalent binding these bonds were broken.
Values from covalent binding assays may, therefore, give an a r t i f i c i a l l y
low number o f antigenic determinants. I t  would appear u n like ly  how­
ever tha t so mild a process as equilibrium  d ia lys is  would
d isrupt linkages capable o f binding a hapten to a protein s u f f ic ie n t ly  
strongly to provoke an immune response.
Chuong et al (1977a) used p ra c to lo l/p ro te in  complexes with a d rug /ca rr ie r  
ra t io  of between 40:1 and 140:1 (calculated from th e ir  data and not 
the values given), when ra is ing  antibodies to practolo l and ra t ios  o f 
between 100:1 and 300:1 when ra is ing  antibodies to a sp ir in /p ro te in  
conjugates (1977 b). S im ila r ly  van Weenmen and Schuurs (1972) raised 
antibodies to oestradiol and oe s tr io l using hapten/carrier ra t ios  of 
up to 40:1. Thus i t  would appear tha t the ra t io  o f practo lo l metabolites 
to c a r r ie r  protein used in these experiments was a fac to r o f at least 
100-200 too low when compared with ra t ios  used to generate antibodies 
to s im ila r, low  molecular weight,compounds.
PART 2.
*
EXPERIMENTS TO INVESTIGATE THE EFFECT OF PRACTOLOL, IN VITRO 
GENERATED METABOLITES OF PRACTOLOL AND CHEMICAL ANALOGUES ON 
HUMAN-SKIN FIBROBLAST FUNCTIONS.
INTRODUCTION.
Amos et al (1977,1978) had demonstrated tha t the sera o f patients 
taking p ra c to lo l ,and who developed adverse reactions as a re s u lt ,  
contained antibodies to in v i t r o  generated metabolites o f p rac to lo l.
I t  appears that metabolites o f practo lo l could, in v ivo , form hap­
tens. These antigenic metabolites could have induced a novel type of 
hypersens it iv ity  reaction , as suggested by Amos e t al (1978), or have 
had a d ire c t  e f fe c t  on ce l l  (eg f ib ro b la s t)  function. Some support fo r  the
la t te r  concept comes from the work o f Lindup e t al (1979). They
14demonstrated tha t C a c t iv i t y  accumulated in the eye, skin and small 
in tes t ine  o f hamsters fed radioactive p ra c to lo l,  ie tissues associated 
with adverse e ffec ts  in humans. Both the parent compound (80-84% of 
recovered a c t iv i ty )  and metabolites were detected. As f ib ro s is  is such 
a major feature o f the practo lo l syndrome i t  was decided to invest­
igate the e f fe c t  o f p ra c to lo l ,  in v i t r o  generated metabolites o f p ract­
olo l and some chemical analogues on f ib ro b la s t  functions.
As discussed in Part 1, i t  had not proved possible to f u l l y  charact­
erise the chemical nature of the practo lo l metabolite(s) which provoked 
the immune response in adversely affected patients. Preliminary evid­
ence suggested that the metabolite could have been formed by N-hydroxy- 
la t io n  o f practo lo l or desacetyl practo lo l (Orton and Lowery 1981,
Amos 1979). Some chemical analogues o f p ra c to lo l,  including desacetyl 
practolo l and 3-hydroxy p ra c to lo l ,  possible metabolites in v iv o , (Reeves 
et al 1978), were available from IC I, Macclesfield however and i t  
was decided to compare the a c t iv i t y  of these compounds with practo lo l 
and in v i t ro  generated practo lo l metabolites in the systems chosen.
The chemical structures o f the practo lo l analogues are given on page8a/8b. 
Propranolol, a 3i and 32 receptor blocking drug, was used to control fo r
effects  mediated via 3-receptors and paracetamol as a control fo r  
the acetmido/benzene r ing system o f p ra c to lo l.
Two f ib ro b la s t  functions were chosen as being suitable fo r  in v e s t i ­
gation, ce l l  growth and collagen synthesis. A number of authors have 
shown tha t chemicals, drugs and enviromental po llu tan ts , can cxffect 
these parameters with both stim ulatory and in h ib i to ry  e ffec ts  being 
reported. Shafer (1960, 1961) demonstrated that diphenylhydantoin in 
vivo and in v i t r o , and some o f i t s  metabolites in v i t r o , stimulated 
f ib ro b la s t  growth w h ils t  lead (V is t ica  et al 1977) inh ib ited  both ce l l  
growth and col lagen synthesise and potassium para-aminobenzoate (P r ie s t ly  and 
Brown 1979) inh ib ited  ce ll growth but not collagen deposition.
Philips (1974) and Fry and Bridges (1977) also used changes in the rate 
o f f ib ro b la s t  growth as an ind ica to r o f c y to to x ic i ty .
Besides a d ire c t  e f fe c t  upon f ib ro b la s t  function i t  is  possible tha t 
the active chemical had an in d ire c t  e f fe c t  via an intermediary e ffe c to r  
ce ll such as the macrophage. Heppleston and Styles (1967), Burrel and 
Anderson (1973), Nourse .et al (1975) and A llison  et al (1977) have shown that 
macrophages can synthesis and secrete a fibrogenic fac to r when stimulated 
with mineral dusts such as s i l i c a .  I t  was envisaged that exposing f i b ­
roblasts to the supernatant or ce l l  contents o f macrophages incubated 
with the various chemicals would allow th is  p o s s ib i l i ty  to be invest­
igated.
Practolol has been reported to exacerbate ex is t ing  lesions (see in t ro d ­
uction). and the adverse e ffec ts  o f p ra c to lo l,  ie  f ib r o s is ,psoriasis 
type eruptions, can be thought o f as p ro l i fe ra t iv e .  I t  was decided 
therefore to use f ib rob la s ts  from an uninvolved area o f a psorias is pat­
ien t (PS^), also a p ro l i fe ra t iv e  condition, as well as from a healthy 
donnor (DT^P^) to see i f  there were any differences in the in v i t r o  res­
ponse of the two ce ll types to the chemicals used.
CHAPTER 5.
THE EFFECT OF PRACTOLOL, IN VITRO GENERATED METABOLITES 
OF PRACTOLOL AND CHEMICAL ANALOGUES ON THE RATE OF GROWTH 
OF HUNAN SKIN FIBROBLASTS IN VITRO.
INTRODUCTION
As has already been stated in the in troduction to Part 2, changes 
in ce ll growth have been used to monitor the e ffec ts  of d rugs ,po ll­
utants and ind us tr ia l chemicals and to investigate  the genetic basis 
of diseases involv ing p ro l i fe ra t iv e  events such as a r t h r i t i s  and 
psorias is , (Hassell and G ilbe rt  1983, Hunt et al 1979, Ponec et al 
1977, P ries tley  and Brown 1979, Nourse e t al 1975, P ries tley  1980, 
Goldberg et al 1980, Rowe et al 1977). I t  is  possible tha t p ra c to lo l,  
or one o f i t s  m etabolites, had a stimulatory e f fe c t  on f ib ro b la s t  
growth which could, in v iv o , re su lt  in a f ib ros ing  reaction.
METHODS
A ll media, glasswear, p las tics  and instruments were s te r i l is e d  by 
autoclaving or f i l t e r in g  (0.22ym m il l ip o re  f i l t e r )  or were obtained 
p re s te r i l ise d . S te r i le  procedures were carried out in a Bassair flow 
cabinet. Cells were grown in an atmosphere of 5% C0£/95% a i r  a t 37°C 
in a Flow Laboratories model 3MH tissue cultu re incubator.
Induction o f hamster l i v e r s .
A 29% (w/v) so lu tion o f arochlor 1254 in corn o i l ,  prepared by fo rc ­
ing the mixture through a 19 gauge syringe needle, was in jected in to  
male Syrian hamsters in trape ritonea ly  (500mg/kg). A fte r  5 days the 
l iv e rs  were removed and induction monitored as an increase in re la t iv e  
l i v e r  weight.
Preparation o f s te r i le  S9 hamster l i v e r  f ra c t io n s .
Hamster l iv e rs  were excised asep tica lly  and washed in 2 volumes o f 
0.54mM Tris/HCl bu ffe r ,  ph 7.4, A 50% homogenate in Tris/HCL bu ffe r 
was prepared and the postmitochondrial supernatant (10,000g, S9 f ra c t io n )
iso lated as previously described (page57 ).
Cell growth experiements.
2Stock ce lls  were grown in 175cm incubation flasks in 100ml Earle ’ s 
minimal essential medium (MEM) containing L-glutamine (2mM), non-ess­
en tia l amino acids (1% v /v ) ,  12,000 units pen ic i l l in /s trep tom yc in  
and 10% foeta l c a l f  serum, u n t i l l  confluent. The ce lls  were detached 
by incubating them in 30ml 0.25% tryps in  in PBS fo r  15min at 37^C.
/r
A fte r  washing the ce lls  were suspended in  growth medium (0.5x10 /5m l).
V ia b i l i t y  was assesed using trypan blue exclusion. Aliquots (5ml) o f
2
the ce ll suspension were transfered to 25cm incubation flasks and 
allowed to adhere overnight. The material under inve s tiga tio n , or an 
equal volume of PBS, was then added and ce ll  growth monitored as 
fo llows. Using a scalple blade, 2 crosses were cut in to  the under side 
o f each incubation f lask  and used to a lign a g ra ticu le  placed in 
one eye piece o f a tissue cultu re microscope. A mean count o f ce l ls  
in the 2 areas was then determined. The re la t iv e  increase in ce l l  
growth was obtained by d iv id ing  the number o f ce l ls  at time X by the 
number at time 0. This was then p lo tted against time (h).
The procedure was modified when the e f fe c t  o f in v i t r o  generated met­
abolites o f practo lo l on ce l l  growth was investigated. Practolol 
(lml of a lOmM so lu t io n ) ,  S9 fra c t io n  (to  a f in a l  concentration of 
10% w /v), cofactors (NADP 0.5mM, ICA 15mM, ICDH 5 un its ) and Tris/HCl
bu ffer (to  give a f in a l  volume o f 5ml) were mixed in 25ml conical
2flasks on ice. The medium was decanted from the 25cm incubation flasks 
and the f ib ro b la s t  monolayer washed once with PBS. The practo lo l metab­
o l i t e  generating system was added to the f ib rob la s ts  and the c e l ls  in c ­
ubated fo r  lh at 37°C in a CO2 incubator. The practolo l/S9 system was 
then discarded, the ce ll  layer washed twice with PBS, 5ml o f growth 
medium added and ce ll  growth monitored as described above. Cell counts
were carried out before and a f te r  the incubation to see i f  i t  had 
any immediate e f fe c t  on ce ll v ia b i l i t y .
RESULTS.
The e ffe c t  of* passage number on the rate o f growth o f normal human 
skin f ib rob la s ts  (DTqPh) growth and the action of p ra c to lo l .
P i lo t  experiments showed tha t practo lo l in h ib ite d  f ib ro b la s t  growth.
In order to standardise conditions fo r  fu ture experiments the e f fe c t  
of passage number on the rate o f ce l l  growth and the in h ib i to ry  action
_3
of practo lo l (10 M), measured at 72h, was investigated. The rate o f 
growth was uniform over passage numbers 7-18 although some va r ia t ion  
was observed when ce l ls  from e a r l ie r  passages (5 and 6) were used.
( f ig .  5,1). The in h ib i to ry  e f fe c t  o f practo lo l decreased s l ig h t ly  (30%) 
with increasing passage number although there appeared to be some 
re la tionsh ip  between the rate o f growth and in h ib i t io n  by p rac to lo l.  
This was p a r t ic u la r ly  noticeable when ce l ls  from passages 5 and 6 were 
used. In a l l  subsequent experiments ce l ls  were used from passages 7-12. 
The e f fe c t  o f p ra c to lo l , propranolol and paracetamol on PT^P^ growth.
Practolol ( f ig .  5 , 2 ) ,  propranolol ( f ig .  5, 3) and paracetamol ( f ig .  5 , 4 )  
a l l  inh ib ited  ce l l  growth in a dose dependent fashion. The concen­
t ra t io n  of practo lo l required to in h ib i t  growth by 50% (ID^q) was
-3
1.45x10 M. Corresponding values fo r  propranolol and paracetamol were 
0.16x10 and 0.7x10 respective ly , ( f ig .  5, 5 ) .  I f , a f t e r  the rate 
of growth had s ta b i l is e d ,  the ce lls  were exposed to a drug free med­
ium the in h ib i t io n  of growth was reversed.with a l l  3 compounds,(figs.54 
6 and 7). No change in v i a b i l i t y ,  assayed as trypan blue uptake, was 
observed at any concentration o f practo lo l or paracetamol used.
Figure 5 , 1 .
Passage Number
The e ffe c t o f passage number on the rate o f DTgP  ^ f ib ro b la s t  growth ( o )  
and i t s  in h ib i t io n  by practo lo l ( lx lO “ ^M) ( # ) . <
Parameters were measured a f te r  72h. (Results o f increase in ce l l  
number are the mean o f t r ip l i c a te  samples.)
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Dose response curve fo r  in h ib i t io n  o f DT2PH growth by p rac to lo l.
( ♦ =  PBS con tro l,  A =  0.5, □= 1.0, 0= 1.67, •=  3.33xl0"3M)
(Results are the mean + SD, n=3)
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Dose response curve fo r  in h ib i t io n  o f DT2Ph growth by propranolol.
( ♦=  PBS contro l. 0 =  0.5, A = l .o  and @= 2 .0x l0 “ 4M)
(Results are the mean + SD, n=3)
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Dose response curve fo r  in h ib i t io n  o f DT2Ph growth by paracetamol.
( ^  = PBS con tro l,  0 =  0.5, a =  1.0, ©= 1.5 and n=2.0xl0"^M)
(Results are the mean + SD, n=3)
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Plot o f percent in h ib i t io n  o f DT^Ph growth against concentration (M) 
fo r  practolo l ( O ) ,  propranolol { & )  and paracetamol ( a ).
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Experiment demonstrating the re v e rs ib i l i t y  of practo lo l in h ib i t io n
of DToP^ | growth. (❖  = PBS con tro l,  1.67 and a = 3.33x10“ ^M)
(Results are the mean + SD, n=3)
Figure 5, 7.
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Experiment demonstrating the re v e rs a b i l i ty  o f propranolol and
paracetamol in h ib i t io n  o f DT9PU growth. ( ® = PBS con tro l,  a  =
-3 -30.5x10 M paracetamol and n = 0.1x10 M propranolol).
(Results are the mean + SD, n=3).
I t  was not possible to use propranolol concentrations o f greater
_3
than 0.5x10 M as the f ib ro b la s ts ,  w ith in  24h, appeared to lose 
th e i r  cytoplasm or rounded up and became detached from the f la sk .
The e ffe c t  o f p ra c to lo l ,  propranolol and paracetamol on growth o f 
psoriasis skin (PS^ ) f ib ro b la s ts .
Practolol (ID5Q 0.4xl0~^M), propranolol (ID^q 0.03x10 ^M) and
-3paracetamol (ID^g 1.35x10 M) a l l  inh ib ited  ce l l  growth in a dose 
dependent manner ( f i g . 5 , 8 ) .
The e f fe c t  o f in v i t r o  generated metabolites o f practo lo l on ce l l  growth.
No difference in the rate o f growth o f e ith e r ce ll  type could be 
detected between ce l ls  incubated with p ra c to lo l,  the S9 fra c t io n  and 
cofactors ,and those incubated with practo lo l and the S9 f ra c t io n  only, 
using normal or arochlor induced hamster l i v e r  prepara tions,(tab le  
5, 1 ). Some ce lls  were lo s t  during the incubation but th is  was not
re lated to treatment and did not influence the subsequent rate of 
growth.
the e f fe c t  o f s truc tu ra l analogues o f practo lo l on ce ll  growth.
None of the analogues used, ie ,  the desacety l,b isether, 3-hydroxy
-5te r t ia r y  amine and propane d io l derivatives o f practo lo l (1.7x10 M) 
had any e f fe c t  on growth of e ith e r ce ll  type (Table 5, 2).
DISCUSSION.
P rac to lo l, propranolol and paracetamol a l l  in h ib ite d  the growth o f 
human skin f ib rob la s ts  in a dose dependent, revers ib le  fashion in  v i t r o . 
Whilst the ID^g fo r  practo lo l was considerably higher (about 100 fo ld  
with DT^ P^ j ce l ls  and 20 fo ld  using PS^  c e l ls )  than the level reported 
to occur in the blood or sa liva o f humans (Reeves et al 1978, F itzgera ld
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Table 5, 1.
The e f fe c t  o f in v i t r o  generated metabolites o f practo lo l on
DT2Ph and PS^  f ib ro b la s t  growth. 
*
Hamster l i v e r  
S9 fra c t io n .
Cofactors Relative increase 
growth, (72h).
DT2PH
in cel 1 
PS1
Control 2.7+ 0.25 3.1+ 0.20
II + 2.8+ 0.30 3.4+ 0.30
Arochlor induced - 2.7+ 0.15 2.8+ 0.45
n ii + 2.3+ 0.45 3.2+ 0.35
(Results are the mean + SD, n=4)
Table 5, 2.
The e ffe c t  o f chemical analogues on DTqP^  and PS^  f ib ro b la s t  .growth.
Analogue (1.7x10 ^M) Relative increase in ce ll  growth ( 72h),
DT2PH PS1
PBS (contro l) 3.'5+ 0.20 3.0+ 0.15
des acetyl 4.5+ 0.75 2.7+ 0.30
proprane dio l 2.9+ 0.35 3.1+ 0.35
te r t ia r y  amine 3.2+ 0.30 3.0+ 0.40
bis ether 2.7+ 0.55 2.5+ 0.45
3-hydroxy 3.9+ 0.50 2.9+ 0.05
(Results are the mean+ SD, n=3. Representitive o f 2 experiments).
- 1 2 2 -
and Scales 1968,Bodem et al 1972), tissue levels o f the drug could be 
high enough (NB they are 5 fo ld  higher in the beagle (Scales and 
Cosgrove 1970)) fo r  some in h ib i t io n  o f f ib ro b la s t  growth to occur 
in vivo. In contrast, in v i t r o  generated metabolites o f p ra c to lo l,  
using normal or arochlor induced hamster l iv e rs ,  had no e f fe c t  on 
f ib ro b la s t  growth implying tha t reactive metabolite formation may 
not be necessary fo r  growth. Amos et al successfully used hamster l i v e r  
preparations, comparable to those used in the present inve s t iga t io n , 
to generate m etabo lite /prote in complexes that bound spec if ic  antibodies 
in the serum o f practo lo l patients with the oculomucocutaneous syndrome. 
(Amos et al 1978). I t  seems reasonable to assume tha t metabolites 
formed during these experiments were s im ila r  q u a l i ta t iv e ly  to those 
which have been claimed to form haptens in adversely effected patients . 
In support o f the contention tha t metabolites of practo lo l are not 
responsible fo r  the e f fe c t  on f ib ro b la s t  growth, the s truc tu ra l an­
alogues o f practo lo l also had no e f fe c t  under the conditions used. A
-5concentration o f 1.67x10 M o f the s truc tu ra l analogues was used in 
these studies, about 1% of the dose of practo lo l needed to in h ib i t  
ce ll growth by 50%. Reeves et al (1978) reported that no sing le met­
abo lite  o f practo lo l exceeded 2% o f  recovered a c t iv i t y  in human vo l-  
14unteers given C practo lo l o ra l ly .  In view o f the l i k e ly  blood and
serum levels o f p ra c to lo l,  and m e ta b o li te s , i t  is probable tha t the
concentration o f analogues used reflected the in vivo s i tu a t io n .
*
Whilst an e f fe c t  due to a novel metabolite cannot be. ruled out these 
resu lts  ind icate th a t , in v iv o , metabolites o f p ra c to lo l,  e ith e r  at 
the s i te  o f formation or system ica lly , are un like ly  to influence 
f ib ro b la s t  growth.
Fibroblasts derived from skin taken from an uninvolved area o f a 
psoriasis pa tien t, a c l in ic a l  condition characterised by ce l l
p r o l i te ra t io n , were more sensitive  than normal ce lls  to practo lo l
and propranolol but were less sensitive  towards paracetamol. Whilst
not proving tha t f ib rob la s ts  taken from patients with p ro l i fe ra t iv e
skin conditions are always more sensitive  to 3-receptor blocking
drugs than ce lls  from people without skin complaints these resu lts
<
do ind icate that in h ib i ta ry  e ffec ts  on f ib rob la s ts  due to the two 
3- receptor blocking agents and paracetamol do not always pa ra l le l 
each other and that some people may be more sensitive  to such drugs 
than others.
CHAPTER 6.
4
THE EFFECT OF PRACTOLOL, IN VITRO GENERATED METABOLITES 
OF PRACTOLOL AND CHEMICAL ANALOGUES ON HUMAN SKIN 
FIBROBLAST COLLAGEN SYNTHESIS.
INTRODUCTION.
P rac to lo l, propranolol and paracetamol inh ib ited  the growth of 
human f ib ro b la s ts  in a dose dependent, revers ib le , fashion, although 
the concentrations needed were higher than would generally be expec- 
ted to occur in v ivo . In v i t r o  generated metabolites o f practo lo l 
and chemical analogues were without e f fe c t  suggesting tha t the adverse 
e ffects  observed in patients were due to the parent compound. PS^  
ce l ls  were more sensitive to in h ib i t io n  by practo lo l and propranolol 
but less sensitive  to paracetamol. This find ing  indicated tha t in h ib ­
i t io n  due to the 3-receptor blocking drugs and paracetamol do not 
always pa ra l le l each other and tha t some people are more sens it ive  to 
3-receptor blocking drugs than others.
I t  is  possible tha t a spe c if ic  ce l l  function could be e ffected at a
much lower concentration o f the chemicals than ce ll  growth. In view 
of i t s  importance in re la tionsh ip  to f ib ro b la s t  function , collagen 
synthesis is  a l i k e ly  ta rge t. Goldberg et al (1980) fo r  example dem­
onstrated tha t in h ib i t io n  o f ce ll growth and collagen synthesis are 
not always linked or even fo llow  the same pattern.
Green and Goldberg (1964) reported tha t human skin f ib rob la s ts  in
cultu re re ta in  the a b i l i t y  to synthesise collagen fo r  well over 20 
passages. This process was dependent on an adequate supply o f ascorbic 
acid, now known to be necessary fo r  pro line hydroxylation 
(Stassen et al 1973), and pro line . Harrington et al (1973) also added 
in su lin  to th e ir  cultures to aid v ia b i l i t y  and transport across the 
ce ll membrane, (Trowel 1 1959). Collagens are characterised as having 
a high content of g lyc ine, proline and, uniquely, hydroxyproline 
derived from pro line . Collagen synthesis can be assayed therefore by
measuring the incorporation o f radio!abelled pro line in to  collagenase 
sensitive prote in over a fixed incubation period, (Green and Goldberg 
1964, V is tica  et al 1977). This approach enables the incorporation 
of pro line in to  the d i f fe re n t  soluble peptides and collagens to be 
followed. This can be important when investiga ting  lesions using 
diseased tissue such as inflammed gingival f ib rob las ts  (Narayanan 
et al 1978) or the e f fe c t  o f chemicals on collagen synthesis, fo r  
example hydralazine ( Chen et al 1977),as much o f the hydroxyproline 
containing proteins remain in the medium (Green and Goldberg 1964).
Layman et al .(1971), however demonstrated tha t collagen extracted 
from the ce ll  layer o f cu lt iva ted  human skin f ib rob la s ts  was s im ila r  
to tha t extracted from human skin in i t s  ra t io  o f hydroxyproline 
to p ro line , chain composition, s o lu b i l i t y  and resistance to proteo­
l y t i c  d igestion. This was not so fo r  hydroxyproline containing pep­
tides iso lated from the medium. Changes in collagen synthesis are 
re flected in the amount o f collagen deposited in the ce l l  laye r,
(Layman et al 1971) and. Harrington et al (1973) measured collagen in 
that compartment using a chemical assay fo r  hydroxyproline a f te r  acid 
digestion of the ce l l  mat. This method would appear to be sa t is fa c to ry  
fo r  the measurement o f gross changes in collagen synthesis.
Fibroblasts from patients have been used to measure collagen synthesis 
in such conditions as scleroderma (LeRoy et al 1974, Buckingham et al 
1978) and rheumatoid a r t h r i t i s  (P r ie s t ly  1980) and to investigate  
the mode o f action o f such drugs as D-penicillamine and sodium s a l ic y la te  
(P r ie s t ly  1980) and sodium gold thiomalate (Goldberg et al 1980).
Normal ce l l  l ines have also been used to monitor the e ffec ts  o f ind­
u s tr ia l  chemicals on collagen synthesis, fo r  example lead (V is t ica  
et al 1977) polyvinyl chloride dust (Richards et al 1975) and drugs
such as local anaesthetics (Eichhorn and Peterkofski 1979), hydral­
azine (Chen et al 1977) and des ferioxamine (Hunt et al 1979).
Enhancing and in h ib i to ry  e ffec ts  have been reported (Goldberg et al 
1980, P r ie s t ly  1980) ind ica ting  tha t th is  system would be su itab le
fo r  investiga ting  the e ffec ts  o f practo lo l and i t s  metabolites 
on collagen synthesis in v i t r o .
Financial constraints prevented the use o f rad io labelled pro line  fo r  
measuring collagen formation which was assayed by measuring to ta l 
hydroxyproline levels in the ce ll  layer a f te r  acid hydrolysis.
Although ascorbic acid is  needed fo r  optimal collagen synthesis Aleo 
et al (1974) suggested that in some circumstances differences in c o l l ­
agen formation might only be observed in an ascorbic acid d e f ic ie n t 
medium. Experiments were also carried out therefore using a medium in 
which ascorbic acid had been . le ft  out.
METHODS.
Routine cu ltu r ing  o f ce l ls  and preparation o f the hamster l i v e r  S9 
fractions were performed as described previously (see chapter 5).
DNA ana lys is .
DNA analysis was carried out according to the method of Burton (1956). 
The ce ll samples were spun down at 1500g and 4°C fo r  lOmin using a 
MSE Coolspin cen tr ifuge, washed once in 2ml o f 0.5M perch lo ric  acid 
and then heated fo r  lOmin at 80°C in  1ml o f 1M perch lo ric  acid. A 
stock solu tion was prepared by d issolv ing a known weight o f c a l f  thymus 
DNA in 0.t)lM sodium hydroxide. Standard tubes containing 0-20pg o f DNA 
and 1ml o f 1M perch loric  acid were s im i la r ly  heated. Once the samples 
had cooled, 2ml o f a 200:1 diphenyl amine/2% acetaldehyde reagent was
added,(diphenyl amine reagent:- 1.5% diphenyl amine w/v and 1.5% 5N 
sulphuric acid in g lac ia l acetic acid). The tubes were then l e f t  at 
room temperature overnight to allow the colour to develop and the 
absorbance read at 600nm. The DNA concentration was read d i re c t ly  
from the ca lib ra t io n  curve.
Hydroxyproline Analys is .
The hydroxyproline assay is  based on the method o f Woessner (1961).
The ce ll sample was spun down at 1500g fo r  lOmin at 4°C in 2ml glass 
centrifuge tubes and the supernatant discarded. Hydrochloric acid 
(250 1/ 5N) was added to each tube which was then sealed using an 
oxygen/coal gas flame. The tubes were incubated overnight at 120°C, 
opened and the contents transferred to 10ml glass te s t  tubes. The 
hydrolysate was bought to pH 6.0-8.0 by adding 250ul o f 5N sodium hydrox­
ide and then adjusting the ph using d ilu ted  hydrochloric acid or 
sodium hydroxide. Chloramine T (1ml) was added, the solutions vortex 
mixed and l e f t  at room temperature fo r  20min, (chloramine T reagent:- 
0.05 M chloramine T, 20% d is t i l l e d  water, 30% methyl ce lluso lve and 50% 
hydroxyproline bu ffe r ph 6.0. Hydroxyproline b u f fe r : -  0.238 M c i t r i c  
acid monohydrate, 0.96 M anhydrous sodium acetate, 0.85M sodium hydroxide. 
1.2% g lac ia l acetic acid v/ v) .  Excess chloramine T was then neu tra l­
ised by adding 1ml 3.15 M perchloric  acid. A fte r  a fu r th e r 5min at 
room temperature 1ml of 20% p-dimethylamine-benzaldehyde in methyl - 
cellusolve (w/v) was added, the solutions mixed and heated at 60°C 
fo r  20min to develop the chromophore. The tubes were cooled fo r  5min 
in cold water and the absorbance read at 557nm.
Collagen "synthesis experiments.
Stock ce l ls  wsre grown as previously described and detached by incu- 
bating with tryps in . A liquots o f the ce ll  suspension (5ml, 0.5x10 c e l ls ) ,
in growth medium,containing foeta l c a l f  serum, were added to 50mm 
tissue cu ltu re  Petri dishes and allowed to reach confluency, 
normally about 3 days. The medium was then changed to one containing 
donnor c a l f  serum (DCS) and the ce lls  allowed to eq u il ib ra te  fo r  2 
days. Collagen synthesis was in i t ia te d  (day 0) by incubating the ce lls  
with DCS medium supplemented with lmg/ml L -p ro line , 50/ig/ml ascorbic 
acid and 1 unit/m l in su lin  BP, (collagen stim ula ting medium). The 
medium, plus any compound under inves tiga tion , was renewed every two 
days. The material under inves tiga tion , or an equivalent volume of 
PBS, was added on day 0 and collagen synthesis assayed on day 9 unless 
other wise stated. Collagen synthesis was assayed as fo llows. The 
incubation medium was decanted and the P e tr i  dish placed over a ten- 
p la te. The ce ll  layer was divided in h a lf  using a scalpel blade and 
one h a lf  analysed fo r  DNA and the other fo r  hydroxyproline. Values 
are expressed as yg hydroxyproline/lOOyg DNA.
In some experiments collagen synthesis was in i t ia te d  on day 0 and the 
chemical under investiga tion  added some days la te r .  These experiments 
were designed to see i f  p re in i t ia t io n  o f collagen synthesis had any 
e f fe c t  on the drugs action.
The method was modified s l ig h t ly  when the e f fe c t  o f in v i t r o  generated 
metabolites o f practo lo l on collagen formation was studied. P rac to lo l,  
the S9 fra c t io n  and cofactors were mixed in 25ml conical flasks as 
previously described (see chapter 5). The growth medium (FCS) was 
deccinted from the P e tr i dishes and the ce lls  washed once with PBS.
The metabolite generating system was added and the ce lls  incubated 
fo r  lh at 37°C in a CO^  tissue culture incubator. The medium was then 
discarded, the ce lls  washed twice with PBS and 5ml of the DCS, collagen 
stim ulating medium added.
14The e f fe c t  of practo lo l on C leucine uptake by DTpP^ f ib ro b la s ts .
_3
Cells were incubated with 0.5x10 M practo lo l fo r  9 days. On day 8 lyCi 
o f 14C leucine was added to each Petr i dish and l e f t  fo r  24h. On day 
9 lml o f the medium was removed,for counting the a c t iv i t y  o f the med­
ium, and the ce ll layer washed twice with PBS. The ce ll monolayer was4
then divided in h a lf  and one h a lf  analysed fo r  hydroxyproline. The
other h a lf  was digested (lml ce lluso lve , 24h,37°C) and added to 10ml
14of Dimilune s c in t i l l a t io n  f lu id .  C a c t iv i t y  was counted using a
Packard Tri-carb  l iq u id  s c in t i l l a t io n  spectrophotometer. Uptake o f 
14C leucine was expressed as counts per minute (cpm) in the cells/cpm 
ce lls  + medium.
14Uptake and retention o f C practo lo l by DTqP^  f ib ro b la s ts . •
F ibroblast cultures were established as previously described and
14collagen synthesis in i t ia te d  on day 0. On days 3 or 6, 0.2 yCi C 
-3practo lo l (0.5x10 M) was added and renewed every 2 days w ith the
collagen stim ulating medium. On day 9 lml o f the medium was counted fo r
ra d io a c t iv ity  and h a lf  the f ib ro b la s t  monolayer analysed fo r  hydroxy-
14proline and the other h a lf  fo r  C a c t iv i t y  as described above.
RESULTS.
Analysis o f DNA.
The DNA ca lib ra t io n  curve was l in e a r  over the range 0-20yg DNA 
( f ig .  6,1 ). The re la tionsh ip  between DNA content and ce ll number was 
investigated by assaying DNA in known numbers of c e l ls .  There was a
g
linea r re la tionsh ip  up to at least 2x10 ce lls  ( f i g . 6,2).
Figure 6, 1.
absorbance 
(§00 nM)
0.05 -
0
Ug DNA
DNA ca lib ra t io n  curve using c a l f  thymus DNA. (Results are the 
mean + SD, n=3).
Figure 6, 2.
jig  DNA
T
2 0 -
T
'i.
0 0.5 1.0 1.5 2.0
Cell no (x  106)
Graph showing the re la tionsh ip  between f ib ro b la s t  number and 
DNA content, (Results are mean + SD, n=3)
Analysis o f hydroxyproline.
A constant and reproducable dose response curve was obtained fo r  
hydroxyproline concentrations o f 0-20pg/incubation, ( f i g . 6,3 ).
The e f fe c t  o f practo lo l on DTqP^  collagen synthesis.
Collagen synthesis was in i t ia te d  and at day 0,and every 2 or 3 days 
a f t e r , t r ip l i c a te  incubations were analysed fo r  DNA and hydroxyproline. 
I t  was not possible to keep cultures rou tine ly  fo r  longer than 9 days 
a f te r  in i t ia t io n  o f collagen synthesis as more prolonged cu ltu r ing  
often le<i to detachment o f the ce l ls  from the Petr i dish. Collagen 
levels were re la t iv e ly  stable during the f i r s t  5 days a f te r  i n i t i a t io n  
and then rose rap id ly  over the next 4 days ( f i g . 6,4 ). This increase
_3
was not due to continued ce ll d iv is ion  ( f i g . 6,5 ). Practolol (1.67x10 
inh ib ited  th is  increased collagen production and by day 9 synthesis 
was only about 25% of tha t seen with control cultures with a real in ­
crease, compared to day 0, of 2yg hydroxyproline by practo lo l treated
fib rob la s ts  and lOpg by control ( f i g s . 6, 5A and 5B ).
-5 -3P rac to lo l, over the range 5x10 -1.8x10 M, inh ib ited  collagen syn-
_3
thesis in a dose related manner with an ID ^  o f 0.8x10 M. Concen­
tra t ions  o f 1x10 7- 5xl0~^M had no e f fe c t  ( f ig .  6, 6)
The e f fe c t  of p re in i t ia t io n  o f collagen syntheis on the in h ib i to ry  
e f fe c t  o f practolo l on DTqP^  collagen formation.
Collagen synthesis was in i t ia te d  on day 0 and on days 0,5,7 and 9
_3
practo lo l (1.67x10 M) was added. DNA and hydroxyproline levels 
were assayed a f te r  9 days. The in h ib i to ry  effectiveness of p racto lo l 
was not reduced by p re in i t ia t io n  of collagen formation. When both 
collagen production and percent in h ib i t io n  were p lo tted against length 
o f exposure to practo lo l a l in e a r re la t ionsh ip  was found ( f i g . 6,7 ).
In a second experiment f ib rob la s ts  were stimulated to synthesise
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The e ffe c t o f p re in i t ia t io n  o f collagen synthesis on the in h ib i to ry  
e f fe c t  o f practo lo l (1.67x10“ 3M) using DT2P^  f ib ro b la s ts .  (Results 
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Collagen synthesis = © . Percent in h ib i t io n  = 0 .
collagen from days 0 to 4 or from the equivalent o f days 5 to 9, in
_3
the presence or absence o f practo lo l (1.67x10 M). S im ilar amounts o f 
collagen were formed during each 4 day period by control c e l ls .  Pract­
o lo l also inh ib ited  collagen production to the same degree during each 
period (table 6, 1).
The e ffe c t  o f ascorbic acid defic iency on the in h ib i to ry  action o f 
practo lo l on DT^P^ collagen synthesis.
I f  ascorbic acid was ommitfce^from the stim ula ting medium there was
a s l ig h t  increase in collagen synthesis by control cultures over the
9 days (day 0'= 4.15+ 0.6 yg hydroxyproline/100 yg DNA, day 9 = 10.0
+ 4.5 yg hydroxyproline/100 yg DNA) but no change in practo lo l (0 .75 '
xlO ^M) treated cultures (day 9 = 3.25+ 1.0 yg hydroxyproline/lOOyg DNA).
14Uptake and binding o f C practo lo l by DTqP^  f ib ro b la s ts .
14There was no d ifference in to ta l C uptake by f ib ro b la s t  cultures 
incubated fo r  3 days (0.65%) or 6 days (0.73%) a f te r  in i t i a t io n  o f 
collagen synthesis although collagen production was in h ib ite d  to a 
greater extent in those cultures exposed to practo lo l fo r  6 days 
(tab le 6, 2).
14The e f fe c t  o f practo lo l on C leucine uptake'by DT£P  ^ f ib ro b la s ts .
14 - 3Uptake o f C leucine over days 8-9 was in h ib ite d  by 33% by 0.5x10 M
prac to lo l.  Collagen synthesis, over the 9 day period was in h ib ite d  by
36% (tab le  6, 3).
The e f fe c t  o f propranolol and paracetamol on DT^P^ collagen synthesis.
-4 ~ -3Both propranolol (1x10 M) and paracetamol (1x10 M) inh ib ited  c o l l ­
agen formation by about 80% over the 9 day incubation period (tab le
6, 4 ).
Table 6, 1.
The e f fe c t  o f prolonging the e q u i l ib ra t io n  stage (before in i t i a t io n
of collagen synthesis) on collagen formation and the in h ib i to ry  
e f fe c t  o f practo lo l using DT^ P^ j c e l l s .
period of collagen y g hydroxyproline/lOOy g DNA ^ in h ib i t io n
synthesis.-------------------------- --------- - --------------------------------------  due to p ra c to lo l.
control practo lo l
(1.67xlO-3M)
days 0-4 32.3+4.0 20.8+3.0 36%
(n=5) (n=5)
days 5-9 27.8+4.4 16.1+2.2 41%
(n=6) (n=6)
(Results are the mean + SD, n= number of rep lica tes ).
Table 6, 2.
14The uptake and binding o f C,practolo l by DTqP  ^ f ib ro b la s ts .
_  .
days exposed to C uptake. % uptake yg hydroxyproline
practo lo l ( counts/min
(0 .2pc i , 0.5x10_3M) x lO '3^.
0   ’  ---- 9.21+0.40 (100%)
3 1.83+0.2 0.73% 7.67+ 0.40 ( 83%)
6 1.63+0.6 0.65% 5.35+ 0.30 ( 58%)
(Results are the mean + SD, n=5).
Table 6, 3.
14The e f fe c t  o f practo lo l on uptake of C leucine by DT^P  ^ f ib ro b la s ts .
treatment 14C leucine uptake 
* over days 8-9
_3
(counts/min.xlO )
%uptake pg hydroxyproline 
(formed over 9 days)
control 112.7+11.40 6.35% 8.0+1.50
practo lo l 75.3+3.90 4.25 % 5.0+0.9
(0.5x10~3M)
s.
% in h ib i t io n due 33% 36%
to practolo l •
(Results are the mean + SD, n=5)
Table 6 , 4 .
The e ffe c t  of p ra c to lo l,  propranolol and paracetamol on DTgP^ 
collagen synthesis.
treatment pg hydroxyproline/lOOpg DNA % in h ib i t io n
control 116.25+1.50 0
practolo l 40.15+5.5 65%
(1.67x10’ 3M)
Propranolol 21.40+4.0 82%
(1x10~4M).
paracetamol 27.75+5.0 76%
(1x10"3M)
(Results are the mean + SD,n=3).
The e f fe c t  of in v i t r o  generated metabolites o f practo lo l on DTqP^
collagen formation.
In v i t r o  generated metabolites o f p ra c to lo l,  using normal or arochlor 
induced l iv e r  preparations, had no e f fe c t  on collagen synthesis 
(table 6 , 5 ) .
%
The e ffe c t of chemical analogues of practo lo l on DTgP  ^ collagen 
synthesis.
Chemical analogues of p ra c to lo l ,  the b ise ther, desacetyl, te r t ia r y
amine, 3-hydroxy and propane diol d e r iva t ive s , had no e f fe c t  on c o l l -
-5agen formation at a concentration o f 1.70x10 M (table 6, 6).
The e f fe c t  o f p ra c to lo l,  propranolol and paracetamol on PS^  col 1agen 
formation.
A ll three compounds inh ib ited  collagen formation by PS^  f ib ro b la s ts
(table 6, 7). The ID^q fo r  p ra c to lo l,  calculated from the data given
-3 -4above, was 0.25x10 M and fo r  propranolol 0.18x10 M. There was a
s l ig h t  reduction in the in h ib i t io n  induced by paracetamol.
The e f fe c t  o f in v i t ro  generated metabolites o f practo lo l and chemical 
analogues o f practo lo l on PS^  collagen production.
----------  ■ ■■■-■— ■ ■■— ............ ........... ■ —* ■ ■-  - - i i —......
Neither chemical analogues o f practo lo l ( f ig .  6, 8) or in v i t r o  gen­
erated metabolites (tab le  6, 9) had any e f fe c t  on collagen formation 
under the conditions used.
DISCUSSION.
Practolol. inh ib ited  the synthesis of collagen by human skin f ib ro b la s ts
_3
in a dose dependent fashion ( ID^q fo r  DT^P  ^ ce l ls  0.8x10 M, PS^  c e l ls
_3
0.25x10 M). Collagen synthesis was more sensitive to in h ib i t io n  than 
f ib ro b la s t  growth (ID^q fo r  DT^ P^ j ce l ls  1.45x10 ^M, PS^  c e l ls  0.4x10 ^
Table 6, 5.
The e f fe c t  o f in v i t ro  generated metabolites o f practo lo l on DTgPp 
collagen synthesis.
source o f S9 fra c t ion pg hydroxyproline/lOO g DNA
- cofactors + cofactors
control l iv e rs 63.1+10 .0 61.4+3 .5
arochlo.r induced 65.1+3.5 57.7+4 .0
1i vers
(Results are the mean + SD, n=4)
Table 6, 6 .
The e f fe c t  of chemical analogues o f practo lo l on DT^P  ^ collagen 
synthesis.
chemical. concentration pg hydroxyproline/lOOpg DNA
experiment 1 experiment 2
PBS control 59 .6+10.0 80 .6+1 .0
practo lo l 1 .67 x1 0 '3M 23.8+6.7 30.8+1 .0
propane diol 1 .70x10‘ 5M 62.3+4.5 85 .1+12 .0
3-hydroxy 1 48.4+1 .0 78 .2+4 .5
des acety l II 43.5+3 .0 77 .3+22.0
t e r t i a r y  amine u nd 92.3+7 .0
bis  e ther II nd 76.2+1 .0
(Results are the mean + SD, n=3)
Table 6, 7.
The e f fe c t  of p ra c to lo l,  propranolol and paracetamol on PS^  
collagen formation.
Compound yg hydroxyproline/lOOyg DNA %inhib ition
control 44.0+9.0 0
practo lo l
( 0 . 1 x 1 0 ' 3M) 47.0+0.5 0
p ra c to lo l“ 
( 0 .5 x 1 0 '3M) 7.0+1.5 84%
propranolol
( 0 . 0 1 x 1 0 ' 3M) 30.36+4.5 30%
propranolol
( 0 .0 5 x10"3M) 6.6+ 0.40 85%
paracetamol
( I x10"3M) 15.75+5.5 64%
(Results are the mean + SD, n=4).
Table 6, 8.
The e f fe c t  of chemical analogues o f practo lo l on PS-1 collagen
synthesis.
<
chemi cal concentration yg hydroxyproli ne/lOOyg DNA
experiment 1. experiment 2.
PBS control 48.0+5.0 64.0+3.0
practolo l 0.5x10” 3M 12.7+5.0 9.6+ 1.5
propane d io l 1 .7 x1 0 '5M 50.6+3.5 45.0+10.0
3-hydroxy II 45.3+3.0 61.0+4.5
des acetyl II 42,3+8.0 52.3+10.5
te r t ia r y  amine II 44.9+4.5 30.0+2.5
bis ether II 48.1+6.0 42.5+4.0
(Results are the mean + SD, n=3).
Table 6, 9 .
_3
The e f fe c t  o f in v i t r o  generated metabolites o f practo lo l (0.5x10 M) on 
PSl  collagen synthesis.
source o f S9 fra c t io n  yg hyjiroxyproline/TOOyg DNA
+ cofactors - cofactors
control l iv e rs  55.3+3.5 57.0+7.5
arochlor induced 51.5+2.0 56.0+5.0
1i vers
(Results are the mean + SD, n=4)
with a reduction in the ID^q o f about 40% with both ce ll types, pre­
in i t i a t io n  o f collagen synthesis did not a l te r  the in h ib i to ry  action 
o f practo lo l ind ica ting  tha t exposure time and drug concentration were 
the main factors in fluencing the degree o f in h ib i t io n .  The in h ib i to ry  
action of practo lo l was not altered by incubating ce lls  in an ascorbic 
acid free medium. In contrast to the e ffec ts  o f practo lo l i t s e l f ,  in 
v i t r o  generated metabolites o f practo lo l had no e f fe c t  on collagen 
formation supporting the suggestion made in chapter 5 .tha t reactive 
metabolites of p ra c to lo l,  ie metabolites formed at the s i te  o f the 
reaction and capable o f binding to p ro te in , probably play no part in 
the e ffec ts  on f ib ro b la s t  function . The find ing  tha t chemical analogues 
of practo lo l were also inactive  at the concentrations used fu r th e r
supports the idea that practo lo l i t s e l f  is  the active compound. Pract-
14o lo l inh ib ited  both collagen formation and C leucine uptake by DTgP  ^
f ib rob las ts  to the same extent ind ica ting  tha t i t  may act by a lte r in g  
amino acid a v a i la b i l i t y ,  possibly via a membrane e f fe c t .  The re la t iv e ly  
low concentrations o f practo lo l tha t accumulated w ith in  the c e l ls  tend 
to support the view that practo lo l may exert i t s  main e f fe c t  on the 
plasma membrane d ire c t ly .  Collagen synthesis is  only about 55-60% more 
sensitive to in h ib i t io n  tha t ce l l  growth (see above). Thus i t  remains 
to be seen whether in h ib i t io n  o f collagen synthesis is  the major ad*- 
verse e f fe c t  o f low doses o f practo lo l on human f ib ro b la s ts .
Both propranolol and paracetamol inh ib ited  collagen synthesis demon­
s tra t ing  tha t the in h ib i t io n  by practo lo l was not spec if ic  fo r  th is  
drug. In common with DT£P  ^ c e l ls ,  PS^  f ib rob la s ts  were also not e ffe c ­
ted by in . v i t r o  generated metabolites or chemical analogues. However 
there were more sensitive  to practo lo l and propranolol but showed l i t t l e  
change in s e n s i t iv i t y  towards paracetamol. S im ilar d ifferences in
s e n s i t iv i ty  were observed when the e f fe c t  o f the drugs on ce ll  growth 
was investigated. I t  is  c lear tha t there is  some var ia tion  in the res­
ponse to the two 3-receptor blocking drugs used in th is  study and tha t 
s e n s i t iv i t y  towards drugs whose structures are c losely re lated to tha t
of p ra c to lo l,  such as paracetamol, need not pa ra l le l tha t o f the 
%
3-receptor blocking agents.
CHAPTER 7.
EXPERIMENTS AIMED AT INVESTIGATING THE EFFECT OF PRACTOLOL 
ON PRODUCTION OF A FACTOR BY HAMSTER PERITONEAL MACROPHAGES 
CAPABLE OF INFLUENCING HUMAN SKIN FIBROBLAST COLLAGEN
SYNTHESIS.
INTRODUCTION.
Practolol inh ib ited  the growth o f ,  and collagen synthesis by, human
skin f ib rob la s ts  in v i t r o , (see chapters 5 and 6). Collagen synthesis
was more sensitive  to in h ib i t io n  by practo lo l than ce ll growth but 
*
the concentration o f the drug needed was s t i l l  a fac to r o f 10 to 50 
fo ld  higher than that reported to occur in v ivo . I t  was possible how­
ever tha t low concentrations o f practo lo l had an in d ire c t  action on 
collagen synthesis via the modulation o f mediator release from a 
second, regu la to ry ,ce ll such as the macrophage.
Heppleston and Styles (1967),fo r  example, demonstrated, in v i t r o , 
tha t mouse macrophages synthesised a fa c to r  tha t stimululated chick
f ib ro b la s t  collagen synthesis when exposed to s i l i c a  and Burrel and 
Anderson (1973) tha t rabb it macrophages could release a fa c to r  cap­
able o f stim ula ting human f ib ro b la s t  collagen production when incubated 
with s i l i c a .  A ll ison  e t al (1977), using d if fu s io n  chambers contain­
ing macrophages and s i l i c a ,  showed tha t s tim u la tion o f f ib ro b la s t  
function could also occur in v ivo . As Burrel and Anderson (1973) 
had shown that human f ib ro b la s t  collagen synthesis could be stimulated 
by a fac to r derived from macrophages of a d i f fe re n t  species i t  was 
decided to see i f  hamster macrophages released such a fa c to r  and i f  
practolo l could, at concentrations having no d ire c t  e f fe c t  on f ib r o ­
b last functions, modify or stimulate i t s  synthesis.
I t  was suggested in chapter 6 tha t practo lo l could exert i t s  e ffec ts  
on ce ll growth and collagen synthesis by acting on the plasma membrane. 
I f  practq lo l had an e f fe c t  on macrophage function i t  could also be via 
a membrane action. In order to detect such changes i t  was decided to 
measure macrophage Fc receptor numbers in control and practo lo l treated 
c e l ls .  Some antibodies o f the IgG class can bind to macrophages via a 
receptor fo r  the Fc part o f the immunoglobulin molecule (Hay et al
1972, Berken and Benacerraf 1966). Rhodes (1975) suggested
that the number o f these receptors varied with the state o f ac t iva t ion  
of the macrophage. For example inflammatory ce l ls  had a larger number 
of Fc receptors than resident peritoneal macrophages. M i l le r  and 
Kagan (1976) reported tha t c ro c id o l i te  induced a 9% increase in Fc 
receptors and an increase in a f f in i t y  fo r  the Fc ligand in macro­
phages dusted with the mineral. They postulated tha t such a change 
in the molecular organisation o f the membrane could re su lt  in an a l t ­
eration in i t s  an t ig e n ic i ty  and ac tiva t ion  o f the humoral response.
METHODS
Iso la tion  and cultu re o f hamster peritoneal macrophages.
S te r i le  procedures were observed throughout the iso la t io n  and inc ­
ubation o f the macrophages. Animals were k i l le d  by cervica l d is loca tion* 
the skin covering the abdomen cut and 15ml o f a 12mM lidnocaine s o l­
ution in Joklics medium 'injected in to  each peritoneum. A fte r  20min the 
wash was removed through a small inc is ion  in the abdomen and transfered 
to p la s t ic  universal containers. The peritoneum was washed with a fu r th e r  
10 of Joklics medium and the washes combined. The ce lls  were spun down 
fo r  20min at room temperature and lOOg using a MSE bench centrifuge.
The ce ll p e l le t  was washed once in DCS growth medium (see chapter 6)
g
and the ce lls  suspended at 5x10 cells/5ml in the same medium. The ce ll  
suspension (5ml) was then added to 90mm tissue cu ltu re  pe tr i  dishes and 
incubated fo r  20min in a tissue cultu re incubator to allow the macro­
phages to" adhere. Unadhered ce lls  were washed o f f  using 2x5ml o f 
Joklics medium and 5ml o f DCS growth medium added. A fte r 3h p racto lo l 
was added to the culture and the ce lls  incubated overnight (24h).
The media were then removed, f i l t e r e d  through 0.22y m il l ip o re
f i l t e r s  in to  p la s t ic  universal containers and stored at -20°C u n t i l  
needed. The ce lls  were disrupted by freeze/thawing several times in 
5ml o f DCS growth medium and the solu tion f i l t e r e d ,  f i r s t  through 
a 3pm filte r  and then a 0.22ym f i l t e r  and the so lu tion stored at -20°C. 
Sens it isa t ion*o f sheep red blood c e l ls .
A known packed volume o f sheep red blood ce lls  (SRBC) was . placed 
in a 20ml glass centrifuge tube, washed three times with PBS and 
made up to :5% v /v in  the same bu ffe r (SRBC were centrifuged fo r  lOmin 
at 350g and room temperature). Equal volumes o f the ce ll suspension 
and a 1:500 d i lu t io n  o f rabb it anti SRBC serum (Ambroceptor), were 
mixed and incubated at 37°C fo r  lh on a ro tary  mixer, washed once in 
PBS and made up to a 3% (v/v) suspension. The sensitised ce l ls  were used 
w ith in  24h o f preparation.
Measurement o f macrophage Fc receptors by EA Rosette formation.
g
Peritoneal macrophages (2x10 /2ml DCS medium) were added to s te r i le  
glass cover s l ips  (12mm, No.l) placed in wells in a 24 well Limbro 
dish and the adherent ce l l  population iso lated as before. A fte r  in c ­
ubating with practo lo l the ce lls  were washed with PBS and 2ml o f sen­
s it ise d  SRBC added. These were incubated at 37°C fo r  45min, washed 
gently in PBS, fixed in Bouins reagent and stained with haematoxylin 
and eosin. Rosette formation was assessed as pos it ive  i f  a macrophage 
had more than 2 adherent SRBC attached to i t .
Haematoxylin and eosin s ta in in g .
Cells were washed in PBS and fixed fo r  30min in Bouins reagent. A fte r  
washing in d is t i l l e d  water the ce l ls  were stained fo r  3min in haematox­
y l i n ,  blued in tap water and stained with eosin fo r  lmin. They were then 
washed, seqOentiaUy in  70%, 90%, absolute ethanol and xylene and 
mounted in buffered g lyce ro l.
Experiments to investigate  the e ffe c t o f control and practo lo l
treated macrophage incubation media and ce ll  contents on DT^P  ^
f ib ro b la s t  collagen synthesis.
F ibroblast cultures were set up as previously described and c o l l ­
agen synthesis in i t ia te d  on day 0. On day 5 macrophage medium, from 
control or practo lo l treated cu ltu res, was added to a f in a l  concen­
t ra t io n  o f 40% v/v. Cell contents were added to a f in a l  concentration 
o f 20% v/v also on day 5. In su l in ,  ascorbic acid and pro line  were 
added to the collagen stim ula ting medium to ensure the correct con- 
centrations in the f in a l  incubation volume. This was renewed, together 
with macrophage medium or ce ll contents, on day 7. On day 9 the ce ll  
layer was analysed fo r  DNA and hydroxyproline.
RESULTS
The e ffe c t  o f hamster macrophage incubation medium and ce ll  contents 
on collagen synthesis by DT^P^ f ib ro b la s ts ,  the possible influence 
of p ra c to lo l .
Hamster peritoneal macrophages did not secret, or s tore, any fac to r 
capable of in fluencing collagen synthesis in v i t r o  at the concen­
t ra t io n  o f ce l l  contents or incubation medium used. Practolol (1.25 
-4xlO M) did not induce the release or synthesis o f a fib rogenic
fac to r or e f fe c t  collagen synthesis in any other way under the
conditions o f the experiment (tab le 7, 1.'). The f in a l  concentration
-5of practolo l in the f ib ro b la s t  cutures was 2.5x10 M (ce ll  contents
-5experiments) and 5x10 M (macrophage incubation medium experiments).
Table 7, 1.
Experiments to investigate the e f fe c t  o f control and practo lo l
treated,hamster macrophage incubation media and ce ll contents 
on DT2Ph collagen synthesis.
Treatment pg hydroxyproline/lOOpg DNA
experiment 1 experiment 2
control 116.5+15 80.6+ 1.0
incubation medium 86.67+10 78.3+ 8.4
incubation medium 117.0+11.8 77.6+ 8.0
practo lo l treated.
ce ll contents 100.0+3.6 75.5+ 20
ce ll contents 100.3+7.4 81.8+ 13.4
practo lo l treated
(Results are the mean + SD, n=3)
The e f fe c t  o f practolo l on hamster macrophage Fc receptor expression.
Practolol caused a dose related decrease in the number o f Fc receptors,
_3
measured by EA rosette formation, with an ID ^  o f 1.3x10 M, ( f ig  7 ,1 . /2 ) .
DISCUSSION.
Although practo lo l had no apparent e f fe c t  on the synthesis o f a 
fibrogenic fac to r by hamster macrophages, f t  did induce a reduction 
in the number o f Fc receptors. As mentioned in the Introduction, an 
increase in Fc" receptor number is  associated with macrophage ac t iva t io n . 
The reverse re la tionsh ip  has not been shown, ie a decrease in Fc rec­
eptor number is  correlated with a decrease in macrophage a c t iv i t y ,  but 
such a re la tionsh ip  might be antic ipated. In support o f th is  concept 
M^rland and M0rland (1982) reported tha t chronic consumption o f ethanol 
induced a decrease in the phagocytosis o f sheep erythrocytes by ra t  
peritoneal macrophages in v i t r o , a process dependent upon Fc receptors, 
and that th is  change was’ related to an increased s u s c e p t ib i l i ty  to 
endotoxin. The authors suggested tha t these e ffec ts  re flec ted  a gen­
eral depression o f macrophage a c t iv i t y .
The Fc receptor is  important in mediating opsonization, phagocytosis, 
antibody mediated c y to to x ic i ty  and, possib ly, in determining qual­
i ta t iv e  and quantative aspects o f local inflammatory responses (Walker 
and Demus 1975, G r i f f in  et al 1975, Passwell e t al 1980).
Kavai et al (1980) demonstrated tha t human monocyte Fc receptors 
regenerated w ith in  4-8h a f te r  shedding due to cold treatment. I f  these 
receptors are con tinua lly  turning over then the in h ib i to ry  action o f 
p ra c to lo l,  in depressing Fc receptor number, could be a re f le c t io n  of 
the general e f fe c t  on protein synthesis id e n t i f ie d  in the previous
Figure 7, 1.
•.
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EA r o s e t t e  formation using contro l  hamster macrophages. Fc re c ep to r  
number was assessed a f t e r  24h incubat ion .
Figure 7, 2.
% Rosette formation 
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The e f fe c t  of practo lo l on hamster peritoneal macrophage Fc 
receptor expression.(Results are the mean ±  SD, n=3)
200 ce lls  were counted on each o f three s lides .
Macrophages were incubated fo r  24h with practo lo l and EA rosette 
formation measured.
Chapter. Both leucine uptake and collagen synthesis were inh ib ited  by
_3
about 70% by 1.67x10 M p rac to lo l.  I t  is  notable tha t a s im ila r  degree 
o f in h ib i t io n  of receptor expression was observed in the presence of 
the same concentration o f p rac to lo l.  However, as the ID^q fo r  in h ib ­
i t io n  of hamster macrophage Fc receptor expression was s im ila r  to
4
that fo r  in h ib i t io n  o f ce l l  growth o f DT^P^ f ib rob las ts  (1.3 and 1.4
_3
xlO M respective ly) i t  is  probable that receptor changes re f le c t  
gross a lte ra t ions  in macrophage function.
CHAPTER 8
4
THE EFFECT OF PRACTOLOL, PARACETAMOL AND PROPRANOLOL 
on d i2ph MORPHOLOGY AFTER IN VITRO EXPOSURE.
INTRODUCTION
During experiments to investigate  the e f fe c t  of p ra c to lo l,  pro­
pranolol and paracetamol on ce ll  growth i t  was noted tha t morph­
ological changes occured which d if fe red  depending on the drug used.
No changes were observed when DT^P^ ce lls  were exposed to in, v i t ro  
generated metabolites or chemical analogues. The a lte ra t ions  in 
morphology were investigated in more de ta il and the resu lts  reported 
in  th is  Chapter.
METHODS
Fibroblasts were grown in 50mm tissue cu ltu re  P e tr i dishes fo r  l ig h t  
microscopy studies o f growing c e l ls .  When ce lls  were needed fo r  
s ta in ing or electron microscope investigations theij were grown on 
mellanex s tr ip s  placed in the P e tr i  dishes.
Staining fo r  neutral l ip id .
The ce ll monolayer was rinsed once in PBS and fixed in Bouins reagent 
fo r  30min. A fte r  r ins ing  in d is t i l l e d  water and 60% isopropyl a lc ­
ohol there were stained fo r  lOmin with o i l  red 0, rinsed with 60% 
isopropyl alcohol, to d i f fe re n t ia te  the s ta in , and rinsed with d is t ­
i l l e d  water. Counterstaining was carried out using Mayers haematoxylin 
(2min). The ce lls  were f in a l l y  washed in running tap water and mounted 
in buffered g ly c e ro l.
Staining fo r  carbohydrate.
Cells were washed in PBS and fixed in a c i t ru s  acid bu ffe r fo r  2min, 
rinsed in d is t i l l e d  water and stained with 1% periodic acid fo r  5min. 
A fte r  r ins ing with d is t i l l e d  water they were stained with Schiffs
reagent (Feulgen) fo r  20min, washed fo r  20min in running tap water 
and counter stained in ce lestine blue (2min). The f ib rob la s ts  were 
f i n a l l y  washed in d is t i l l e d  water fo r  5min and mounted in buffered 
g lyce ro l.
Staining fo r  protein (haematoxylin and eosin)
_ c4
Cells were stained according to the method described in chapter 7. 
Preparing ce lls  fo r  electron microscopy.
Fibroblasts were washed in PBS and placed at 4°C in p la s t ic  un i­
versal bo tt les  containing 2.5% glutaraldehyde in 0.1 mol cacodyl ate 
bu ffer pH 7.2. A fte r 3h the samples were dehydrated in alcohol and 
embedded in a 1:1 mixture o f epon 812 and a ra ld ite  502. U ltra  th in  
sections were cut on a LKB Ultrotome 3 and stained using a saturated 
solu tion o f uranyl acetate in 50% ethanol. Counter s ta in ing was per­
formed using a 2.6% solu tion o f lead n i t ra te  in c i t ra te  bu ffe r. 
Sections were viewed and photographed using an AEI, EM 6B trans­
mission electron microscopy.
RESULTS.
The e f fe c t  of practo lo l on the morphology o f OT^P  ^ f ib ro b la s ts .
Practolol induced the formation o f cytoplasmic vacuoles during the 
f i r s t  24h of exposure. These then regressed at low concentrations 
(5xlO” ^M) but persisted fo r  days at high doses (3.3x10 ^M). Photographs 
of control and practo lo l treated cu ltu res , using a l ig h t  microscope, 
are shown, in f ig  8, 1A/1B and f ig  8, 2A/2B respective ly. The time 
taken fo r  the vacuoles to appear and th e i r  duration was dose depend­
ent (tab le 8, 1). I f  the ce l ls  were allowed to recover, by incubating 
them in a drug free medium, they responded to a second exposure in a
-101-
Figure 8, 1.
A. Low power photograph o f control DT^P^ ce lls  using a 
phase contrast lens.
Cells were cultured fo r  24h. Lens:- 10/.25
t
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The f ib rob la s ts  are mostly spindle shaped with long 
processes. An e l ip t ic a l  nucleus can ju s t  be seen.
B. High power photograph o f control DT^P  ^ ce lls  using a 
phase contrast lens.
Cells were incubated fo r  93h. Lens:- 20/.32
Cellsshow the cha rac te r is t ic  spindle shape. The nucleus can
be c le a r ly  seen and contains two or three nuc leo li.
1VL
-163-
High power photograph o f practo lo l treated DT^P  ^ ce lls  
using a phase contrast lens.
Cells were cultured in a drug free medium fo r  93h and
*
then fo r  24h with 3.3x10 p ra c to lo l . L e n s 20/.32 
Vacuolation caused the ce lls  to swell and become round­
ed. Although some vacuoles appear to have formed w ith in  
the nucleus they are probably in the cytoplasm over- 
ly ing  i t .
High power photograph o f OT^P  ^ ce lls  recovering a f te r  
practo lo l treatment. Phase contrast lens.
_3
Cells were incubated with 3.3x10 M practo lo l fo r  24h 
and then transfered to a drug free medium, The photo­
graph was taken 24h la te r  and shows the reduction in vac­
uole number and size. Lens:- 20/.32

Table 8, 1.
The e f fe c t  o f practo lo l on the formation o f cytoplasmic vacuoles
in f ib ro b la s ts .
time a f te r  exposure 
to practo lo l (h).
percent vacuole formation 
1.67xlO’ 3M 3.3xlO~3M
practolo l practo lo l
2 5+ 4 20+ 7
16 18+9 100
24 * 57+ 12 100
39 11+9 100
68 0 100
96 0 100
(Results are the mean + SD, n=3). 100% vacuole formation 
occured when a l l  the ce lls  contained vacuoles.
Table 8, 2.
The e ffe c t  of preexposure to practo lo l on vacuole formation in DTqP^  
f ib rob las ts  on a subsequent exposure to p ra c to lo l .
time a f te r  exposure 
to practolo l (h).
percentage vacuol e formation.
f i r s t  exposure 
to 1.67x10’ 3M 
practolo l
second exposure 
to 1.67x10’ 3M 
practo lo l
2 0 4+ 4
,16 12+ 7 17+ 11
24 49+ 15 47+ 13
40 15+ 8 11+ 6
(Results are the mean + SD, n=3. Cells were incubated with practo lo l
fo r  96h follou>4 by 24h in a drug free medium and then 40h with p ra c to lo l.
Vacuole formation was followed during each incubation period with p ra c to lo l.
s im ila r  fashion ( f ig .  8, 3 ) ( table 8, 2). Vacuole formation was not 
related to any overt signs o f membrane damage as trypan blue, added
to the growth medium with practolo l or a f te r  development o f the
vacuoles, was not taken up by the c e l ls .  The vacuoles did not sta in
fo r  neutral l i p id ,  carbohydrate or protein.
Transmission electron microscope studies o f practo lo l treated ce lls  
revealed that there was no membrane surrounding the vacuoles and that 
the rest o f the ce ll was normal in appearence (control ce l ls  f ig  8, 4. 
practolo l treated ce lls  f ig  8, 5 . ) .  Some ce lls  developed l i p id  dep­
os its  a f te r  they were transfered to a practo lo l free growth medium 
( f ig  8, 6A/6B).
The e f fe c t  o f propranolol on DT^P  ^ morphology.
_3
Fibroblasts treated with low (0.1x10 M) concentrations o f propranolol 
developed perinuclear granules ( f ig  8, 7.) which gradually disappeared
_3
on withdrawal o f the drug. Exposure to high (0.5x10 M) Propranolol 
resulted in the ce lls  rounding up and becoming detached from the Petri 
dish ( f ig  8, 8 .) .
Electron microscope studies showed tha t f ib rob la s ts  exposed to propranolol 
developed myeloid type bodies, the number and severity  of which was 
dose related ( f ig  8, 9A/9B).
The e ffe c t o f paracetamol on DTpP  ^ morphology. -
Cells exposed to paracetamol appeared to be normal as assessed 
l ig h t  and electron microscopic studies ( f ig  8, 10A/10B). Transfering 
ce ll cultures to a drug free medium did not re su lt  in any morphological 
a lte ra t io n  ( f ig  8, 11).
Figure 8, 3.
The e f f e c t  of preexposure to p rac to lo l  on vacuole formation by DT^P^
f i b r o b l a s t s  reexposed to p r a c t o l o l .
-3Cel ls  were incubated with 3.33x10 M p rac to lo l  fo r  24h and then in a 
drug f ree  medium u n t i l  the  vacuoles had reg ressed .  They were then
_3
reexposed to 3.3x10 M prac to lo l  . The photograph was taken 24h l a t e r .  
Lens:-  20/ .32
- 168-
Figure 8 , 4 .
Transmission electron photomicrograph of acontrol DT^P  ^ cel 1. 
Cells were incubated fo r  93h. Magnification 30,000.
The appearence is  tha t o f a quiescent c e l l .  There is  com­
para tive ly  l i t t l e  rough endoplasmic reticulum (re) with 
narrow cisternae. A few mitochondria (m) and an area con­
ta in ing  golgi apparatus (g) can also be seen. L ip id drop­
le ts  (1) and lysosomes ( ly )  are scarce. Cytoplasmic f i l a ­
ments ( c f i )  are present throughout the cytoplasm.
Figure 8, 5.
Transmission electron photomicrograph o f a practo lo l treated
DT2Ph ce11-
Cells were incubated fo r  96h in growth medium and fo r  24h
_3
in the presence o f 3.3x10 M p rac to lo l.  Magnification 15,000. 
Cytoplasmic vacuoles (v) can be seen in the upper o f the 
two c e l ls .  There is  no membrane and the contents are not 
electron dense. A small vacuole can be seen (T) in the top 
of the lower ce l l  which appears to be causing the plasma 
membrane to balloon out. I t  is  not possible to say i f  th is  
was due to a cytotoxic reaction ie a bleb, or ju s t  to the 
chance o f a vacuole occuring at the ce ll surface. The rest 
o f the ce l l  appears normal.
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The e ffe c t  of practo lo l withdrawal on DT^P^ morphology. 
Cells were incubated fo r  93h in growth medium and then
_3
fo r  24h with 3.3x10 M p rac to lo l.  The f ib rob la s ts  were 
then incubated inadrug free medium fo r  a fu r th e r 24h. 
Magnification 15,000.
There appears to be an increase in the number o f l ip id  
droplets in the cytoplasm. Remnants o f vacuoles can be 
seen scattered through out the cytoplasm but they do not 
appear to be associated with any p a r t ic u la r  organelle.
The e f fe c t  o f practo lo l withdrawal on OT^P  ^ morphology. 
Cells were treated as above. This photograph shows the 
bottom r ig h t  part of the the ce ll in 8, 5A at a magnif­
ica tion  o f 45,000.
Apart from the increase in l i p id  droplets the ce ll  is 
normal in appearance.
'> • jw

Figure 8, 7.
High power photograph o f propranolol treated Dl^P^ 
f ib rob la s ts  using a phase contrast microscope.
Cells were incubated fo r  93h in growth medium and then fo r  
24h with 0.1x10 propranolol. Lens:- 20/.32 
Perinuclear granules (png) can be seen in a l l  the ce l ls .  
These are confined to the ce l l  body and do not appear to 
have caused the f ib ro b la s ts  to swell up or d is to rted  them 
in any way.
Figure 8, 8 .
Low power photograph of tT^P^ ce lls  treated with a high 
concentration o f propranolol taken using a phase contrast 
microscope.
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Cells were incubated with 0.5x10 M propranolol fo r  24h. 
Lens:- 10/.25 . Most ce l ls  rounded up and became de­
tached from the incubation f lask . Remnants o f some dead, 
adherent,cel Is can also be seen.

- 1 / 4 -
Transmission electron photomicrograph of propranolol
treated_DT2PH f ib ro b la s ts .
Cells were incubated fo r  93h in growth medium and then
* -3fo r  24h with 0.1x10 M propranolol. Magnification 22,500
Myeloid type bodies (my) can be observed, apparantly 
forming 1° lysosomes (1°). These electron dense bodies 
are probably the perinuclear granules seen using the 
phase contrast microscope. The mitochondria and rough 
endoplasmic reticulum appear normal.
Transmission electron photomicrograph o f propranolol 
treated DT^P^ f ib ro b la s ts .
Cells were incubated fo r  93h in growth medium and then 
fo r  43h with 0.1x10 ^M propranolol. Magnification 15,000 
The cytoplasm has been disrppted to a greater extent 
by the longer incubation period. 2° lysosomes (2°) con­
ta in ing  p a r t ia l ly  digested matter can now be seen.
9A
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Figure 8, 10.
Transmission electron photomicrograph of propranolol 
treated DTgP  ^ f ib ro b la s ts .
Cells were grown fo r  93h in growth medium and then fo r  
* -3
24h with 0.1x10 M propranolol. Magnification 30,000. 
Myeloid type bodies consisting o f concentric layers of 
membranes and electron dense 1° lysosomes (1 °)occupy 
most o f the cytoplasm.
10
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Figure 8, 11.
The e f fe c t  of paracetamol on morphology.
_3
Cells were incubated with 2x10 M paracetamol fo r  47h. 
Magnification 22,500.
Apart fom the s l ig h t  increase in l i p id  droplets the ce ll 
is s im ila r  in appearance to control f ib rob la s ts  ( f ig .
8, 4 .) .
Figure 8, 12.
The e f fe c t  o f paracetamol on DT^P  ^ morphology.
-3Cells were incubated fo r  93h with 2x10 M paracetamol. 
Magnification 45,000.
The ce lls  had a normal morphological appearance.(The 
rough endoplasmic reticulum may have p ro l i fe ra ted  between 
47 and 93h incubation periods but th is  is  only an im­
pression and was never quan t if ied ).

-  X  /  Z ) ~
Figure 8, 13.
Cel ls  were t r e a t ed  with 2x10 "M paracetamol for  93h and then grown for  
a f u r t h e r  24h in a drug f r ee  medium. Magnif icat ion 45,000.
These c e l l s  d i f f e r e d  l i t t l e  from those t r e a t e d  cont inuous ly with 
paracetamol for  47h or 93h.
DISCUSSION.
Control f ib ro b la s ts ,  using both l ig h t  and electron microscopy, 
showed charac te r is t ics  associated with an inactive  c e l l .  They were 
mostly spindle shaped with an e l ip t ic a l  nucleus containing two or 
three nu c leo li.  Using the electron microscope the nucleus could be 
seen to be mainly smooth with occasional indentations containing 
d i f fu s e  chromatin. The cytoplasm was also typ ica l o f an inactive  
ce ll containing few cisternae o f rough endoplasmic reticulum.
There were no clear changes in the morphology o f practo lo l treated 
ce lls  apart fom the formation of cytoplasmic vacuoles which regressed 
on withdrawal o f the drug. S im ila r ly ,  paracetamol induced no changes 
in ce ll morphology which could be observed e ith e r at the l ig h t  or 
election microscope leve l.  Propranolol on the other hand induced the
formation of myeloid type bodies with the accompanying formation of
what appeared to be 1° and 2° lysosomes, probably the perinuclear
particles seen using t h e l ig h  microscope.
Vacuole formation in ce l ls  exposed to practo lo l was both time and dose 
dependent but th is  was not a protective response to some adverse e f fe c t  
o f practo lo l as a second exposure to the drug, a f te r  the ce l ls  had 
recovered from a f i r s t ,  e l ic i te d  the same pattern of vacuole forma­
t ion  as the f i r s t  exposure. Vacuole formation was not re lated to 
membrane damage as trypan blue, added with practo lo l or a f te r  devel­
opment of the vacuoles, did not enter the c e l ls .  I t  would also 
appear to be un like ly  tha t the vacuoles function as storage vesicles 
as neither carbohydrate, neutral l i p id  or protein could be detected 
using normal s ta in ing methods. As f ib ro b la s ts ,  under the conditions 
o f these experiments, synthesiselow levels o f collagen (chapter 6)
i t  is also un like ly  tha t the ce l ls  accumulated collegen precursors. 
Eichhorn and Peterkofsky (1979) reported that local anaesthetics 
induced vacuole formation in a f ib ro b la s t  l in e .  The appearance and 
disappearance o f the vacuoles followed the same time course and 
was associated with a rounding up o f the ce lls  and loss o f the 
ce l ls  processes. Local anaesthetics possess membrane s ta b i l is in g  prop­
e r t ie s  which, i t  was suggested,could be important fo r  vacuole form­
ation. Propranolol, but not p ra c to lo l , possesses such a c t iv i t y  so tha t 
i t  is  un like ly  tha t the same mechanism is involved in the case o f 
practo lo l and,.local a<\cvesthetics.
Futher investigations in to  the biochemical basis fo r  the d i f fe re n t  
morphological actions o f propranolol and practo lo l may help to determine 
why treatment with propranolol is  not associated with the severe 
side e ffects  observed in susceptible practo lo l patients.
FINAL DISCUSSION.
L i t t l e  is  established about the mechanism(s) by which practo lo l 
induced severe adverse reactions in some patients . Epidemiological, 
immunological and pharmacological studies have been unable to id e n t i fy
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conclusively any fac to r which could provide the basis fo r  understand­
ing the "oculomucocutaneous syndrome" (Davies 1980).
As discussed in the In troduction , there is  no experimental evidence
to support the idea , put forward by a number o f authors (N istrup- 
Madsun and S0ndergaard 1977, Brown e t al 1974 and Raftery and Denman 
1973), tha t practo lo l could prevent deactivation o f a ta rge t ce ll  ie . 
the f ib ro b la s t ,  leukocyte or lymphocyte, by blocking a r ise  in  cAMP 
in the presence o f adrenergic agonists. Indeed the reports demonstrating 
tha t such ce lls  possess 82 but not 3i-adrenergic receptors suggest tha t 
such a pharmacological mechanism would be extremely u n l ik e ly ,  par­
t ic u la r ly  as propranolol does not give r ise  to such severe side 
e ffects  as p rac to lo l.
Pharmacokinetic studies revealed no differences between practo lo l 
patients with and without side e ffec ts  and a control volunteer (Reeves 
et al 1978). Extensive animal feeding t r i a l s  have fa i le d  to demon­
s tra te  any o f the reactions observed in practolol treated patients 
which, taken with the human studies, would suggest tha t a d ire c t  tox ic  
reaction is  not the primary cause o f the practo lo l syndrome.
S im ila r ly ,  evidence fo r  an immune mechanism is inconclusive. Changes 
in T -ce ll a c t iv i t y  in adversely 'effected patients reported by Behan et 
al (1976) could not be confirmed by Amos and Bridgen (1976) and, when 
occurring were probably due to the disease and not the cause o f i t  
(Pugh et al 1976).
Although autoantibodies were detected in the sera of many practo lo l 
treated patients ne ither the antibody t i t r e n o r  i t s  s p e c i f ic i ty  
appeared to be correlated with any p a r t ic u la r  manifestation o f the 
syndrome (Davies 1980).
The one pos it ive  f ind ing  was tha t o f Amos et al (1977, 1978) who 
reported the presence of antibodies to in v i t ro  generated metabolites 
o f practo lo l in the sera o f adversely affected practo lo l pa tien ts . 
Although the immunological s ign if icance o f these antibodies is  not 
c lea r, they were not correlated to any p a r t ic u la r  disease and were 
also detected,in the serum o f patients with no adverse reactions, 
the study did show however tha t practo lo l could be metabolised in vivo to 
products capable o f binding to macromolecules to form haptens.
I t  was postulated in the Introduction tha t the antigenic metabolite(s) 
could have had a d ire c t  e f fe c t  on a ta rget c e l l ,  inducing changes 
which triggered the adverse response. As a f ib ros ing  reaction was 
such a prominent component o f the practo lo l syndrome the f ib ro b la s t  
was a log ica l choice fo r  such an inves tiga tion . -  
The s tructure o f the antigenic metabolite(s) had been p a r t ia l ly  
elucidated by Amos et al (1977) and Amos (1979) and i t  was decided to 
fu r th e r characterise th is  compound using the novel immunological 
approach described by Amos e t al (1978). The radioimmunoassay system 
used by Amos et al (1978) was evaluated along w ith other possible 
methods, using a model system and covalent binding assays carried out 
to confirm generation o f protein bound practo lo l metabolites in the 
in  v i t r o  incubation system used. I t  did not prove possible however 
to measure antimetabolite antibodies in the sera o f practo lo l 
pa tients . These negative results  were confirmed
by co llabora tive  experiments w ith workers who had carried out the 
o r ig ina l studies. Follow up investigations provided support fo r  
the idea that the sera containing antimetabolite antibodies had been 
a l l  used up during the o r ig ina l investigations although i t  was 
also possible tha t the sera had deteriorated during storage.t
4
The co llabora tive  experiments indicated that the assay system used 
in the o r ig ina l studies was not reproducible. The standard deviation 
observed between duplicates was very high (+90%) and the percent 
binding between the two co llabora tive  experiments varied from 0.2% 
in  the f i r s t  experiment to 20% in the second. The o r ig ina l workers 
accepted binding values of greater than 10% o f the antigen as in d i ­
cating spec if ic  binding and reported values of up to 80%. Covalent 
binding studies, using the equilibrium  d ia lys is  method, reported here 
show a probable maximum binding o f 3nMol/mg prote in . This was calcu­
lated as being equivalent to 1 practo lo l metabolite bound per 6 HSA 
molecules ie 17% o f the HSA molecules in the in v i t ro  microsomal 
incubation would bind practo lo l metabolites. As the only rad ioactive 
HSA prec ip ita ted in the Farr assay used by Amos et al (1978) was tha t 
which was bound to the antigenic metabolite(s) maximum binding 
values should be 17% o f the added antigen mixture. I t  is  possible 
tha t metabolites,or practo lo l i t s e l f ,  complexed non-covalently to HSA 
contributed to the antigen/antibody binding but i t  is also possible 
tha t some o f the reported binding was an a r t i f a c t  o f the method used. 
The low concentration o f hapten binding was probably the reason why 
animals in jected with the protein bound metabolites o f p racto lo l did 
not synthesise antimetabolite antibodies although they did respond to 
the microsomal protein and is o c i t ra te  dehydrogenase present in the 
incubation system.
Two metabolites o f p racto lo l had d e f in i te ly  been id e n t i f ie d  during 
animal experiments, the des-acetyl and the 3-hydroxy deriva tives.
(Reeves et al 1979). The des-acetyl metabolite o f practo lo l had also 
been shown by Amos (1979) to p a r t ia l ly  in h ib i t  binding o f the a n t i -  
metabolite antibody and the in  v i t ro  generated antigen complex. I t
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was decided therefore to use the des-acetyl de riva tive  and other 
analogues of p ra c to lo l,  including the 3-hydroxy form,in in  v i t r o  
experiments to determine the effec ts  o f these compounds on f ib ro b la s t  
functions. Neither the model compounds nor in v i t r o  generated metabolites 
had any e f fe c t  on e ith e r  ce l l  growth or collagen synthesis ( a t the 
concentrations used) whereas practo lo l inh ib ited  both parameters in 
a dose dependent manner despite the fa c t tha t i t  was not taken up by 
the f ib rob las ts  to any great extent (0.7%). Practolol also in h ib ite d  
the uptake and incorporation o f leucine by these ce lls  to the same 
extent as the in h ib i t io n  o f collagen synthesis. These resu lts  are 
consistent with the idea tha t practo lo l depresses protein synthesis 
by l im i t in g  substrate a v a i la b i l i t y ,  possibly via an e f fe c t  on the plasma 
membrane. DT^P  ^ ce l ls  were less sensitive  to the in h ib i to ry  actions o f 
practo lo l than PS^  ce lls  however (5 fo ld )  demonstrating tha t there 
is  considerable va r ia tion  in the response to practo lo l although i t  is  
not possible to say i f  th is  va r ia t ion  is  re lated to s u s c e p t ib i l i ty  
to p ro l i fe ra t iv e  conditions such as psorias is.
The in h ib i to ry  actions on growth and collagen synthesis were also 
observed when propranolol and paracetamol were used. However, where­
as PSj ce l ls  were more sensitive towards propranolol, p a ra l le l in g  
the changes observed with p ra c to lo l,  they were s l ig h t ly  less sens it ive  
towards paracetamol. I t  appears tha t the two 8-receptor blocking 
drugs exert th e ir  e ffec ts  by a mechanism d if fe re n t  to tha t o f paracetamol. 
As discussed above i t  would appear to be un like ly  tha t the actions of
practo lo l and propranolol are mediated via 8-adrenergic receptors.
I t  is possible tha t differences in th e ir  associated properties, ie
propranolol is  l i p id  soluble and practo lo l has sympathomimetic a c t iv i t y ,
could play a ro le in th e i r  actions. This implies tha t the two 3-
adrenergic receptor blocking drugs in h ib i t  ce l l  function via d i f fe re n t  
*
mechanisms and tha t the pa ra lle l responses observed with the two 
are co incindenta l. Morphological studies, using both the l ig h t  and 
transmission electron microscope, provide some support fo r  th is  idea. 
Paracetamol had no obvious e f fe c t  on f ib ro b la s t  morphology at any 
of the concentrations used. Practolol on the other hand induced the 
formation of cytoplasmic vacuoles, the number and time course of 
which was dose dependent. Vacuole formation did not re su lt  in any 
appreciable change in f ib ro b la s t  s tructure as observed using trans­
mission electron microscopy and was not re lated to damage o f the plasma 
membrane, assessed using trypan blue, and was not involved with storage 
o f neutral l i p id ,  carbohydrate or prote in . Propranolol treated ce lls  
developed perinuclear granules which appeared, using the electron 
microscope, to be lysosomes formed from fused myeloid type bodies,
concentric c irc les  of membranes. Propranolol was also found to be
-3cytocidal at 0.5x10 M whereas practo lo l at concentrations up to 
-33.3x10 M, causing almost 100% in h ib i t io n  of ce l l  growth, appeared to 
cause no permanent damage.
The actions o f practo lo l on f ib ro b la s t  growth and collagen synthesis 
occured at concentrations higher than those reported to occur in the 
plasma of patients ( l-2ug /m l) (Reeves et al 1978, F itzgera ld and Scales 
1968 and Bodem et al 1972). However practo lo l can accumulate in some 
tissues such as the eye, skin and small in te s t ine  (Lindup et al 1979) 
in a time and dose dependent fashion. Such an accumulation could res­
u l t  in the formation o f an e ffe c t ive  concentration o f p racto lo l 
in v ivo . I t  was possible however tha t practo lo l exerted i t s  main
e ffe c t  upon the f ib ros ing  response in d ire c t ly  via a mediator ce ll
such as the macrophage. The secretion o f a collagen stim u la ting  fac to r
by peritoneal macrophages exposed to mineral dusts has been reported
by a number o f authors (Heppleston and Styles 1967, Burrel and
Anderson 1973 and A ll iso n  et al 1977). Hamster peritoneal macrophages
did not synthesise any such fac to r  however and practo lo l did not
stimulate the synthesis o f one. Practolol did in h ib i t  Fc receptor
expression, probably re f le c t in g  a general reduction in macrophage
a c t iv i t y  and demonstrating that the e ffec ts  o f th is  drug are not
confined to e ith e r the f ib ro b la s t  or to human c e l ls .  The ID™ Tor50
the e f fe c t  on Fc receptor number was s im ila r  to tha t fo r  in h ib i t io n  
of f ib ro b la s t  growth. I t  is u n l ike ly  therefore that th is  e f fe c t  is  
the primary one of p ra c to lo l,  ra ther i t  probably re f le c ts  a common 
disruption of macrophage metabolism.
The overall conclusion from the resu lts  obtained is  tha t the p racto lo l 
syndrome is due to the parent compound and not a metabolite* Further, 
the action o f practolol- is probably an in h ib i to ry  one, not s tim u la tory  
as postulated in the Introduction. Moreover, the f ib ro b la s t  is  probably 
not the primary target fo r  p rac to lo l.  I f  these proposals are correct 
then several questions remain to be answered. F irs t  what is  the primary 
ta rget fo r  practo lo l? Second, what factors could be involved in determ­
ining s u s c e p t ib i l i ty  to the drug? Third, why are such side e ffec ts  not 
observed with other 3-receptor blocking drugs? Las tly , why were animal 
experiments unable to predict the problems associated with practo lo l 
therapy?
Both ocular and peritoneal reactions are associated with loss o f secretory 
ce ll function be i t  the lacrimal gland, conjunctival goblet c e l ls  or 
the peritoneal mesothelium (Rahi e t al 1976, Myllarniemi and 
Leppaniemi 1981).
Damage to other organs is  also characterised by u lceration (nasal
and o ra l)  damage to the cochlear and to the pleural membrane (Wright
1975). I t  is  possible tha t a d ire c t  tox ic  e f fe c t  on secretory ce ll
functions is  the primary action of p rac to lo l.  The in h ib i t io n  o f
leucine uptake by f ib rob la s ts  in v i t r o  supports th is  idea which is' «
strengthened by the report tha t oral administration o f practo lo l to 
rats in h ib i ts  in te s t in a l mucosal glycoprotein synthesis,(Okine et al 
1982). The need fo r  practo lo l to accumulate in vivo to an e ffe c t ive  
concentration might explain the re la t iv e ly  long la te n t period before 
adverse reactions became apparent,(eye e ffec ts  23.4 +14 months, Wright 
1975)( sclerosing p e r i to n i t is  34+ 15 months, Marshall et al 1977a). 
However accumulation o f a tox ic  concentration o f practo lo l would not 
explain the delayed reactions reported by, fo r  example, Allan and 
Cade 1975 and Marshall et al 1977b. The in v i t r o  studies reported 
in th is  thesis demonstrate tha t the e ffec ts  o f acute exposure to p ract­
o lo l (up to 4 days) are revers ib le , however i t  appears tha t chronic 
practo lo l therapy resu lts  in lesions which can be expressed, or 
continue to be expressed, a f te r  withdrawal o f the drug. That is ,  there 
is  some change, analogous to in i t i a t io n  in  the two stage model o f 
carc inogenic ity , which upon appropriate s t im u la tion , allows the f ib ro s i  
reaction to manifest i t s e l f .  S im ilar ideas have been put forward to 
account fo r  the action o f hydrocortisone on f ib rob la s ts  from patients 
with adult or juvenile-onset diabetes m e ll i tus  and the action o f 
phenytoin on human gingival f ib rob la s ts  (Rowe e t al 1977, Hassell and 
G ilbe rt 1983).
S u sce p t ib i l i ty  could depend on the rate of accumulation o f p racto lo l 
and the concentration needed to in h ib i t  secretory ce l l  function .
Although the work o f Reeves et al (1978) indicates tha t there are no 
differences in the pharmacokinetics of practo lo l in d i f fe re n t  pa tien ts , 
they administered only one dose o f the drug. Chronic treatment may 
re su lt  in d i f fe re n t  rates o f accumulation,reflecting small d ifferences 
in the rates o f uptake and excre tion ,and,possib ly ,varia tions in bind­
ing s ites  in Ihe d i f fe re n t  tissues. I t  is  also not unreasonable to 
assume that the differences in s u s c e p t ib i l i ty  reported fo r  f ib ro b la s ts  
w i l l  also be re flected by other ce ll types. Chapman e t al (1980) rep­
orted tha t hydrocarbon hydrolase a c t iv i t y  in the jejunum, l i v e r  and 
lesion free epidermis o f psoriasis patients was reduced compared to 
control values. I t  is  possible tha t practo lo l susceptible patients 
also have a genetic lesion predisposition to the adverse actions o f 
p ra c to lo l,  th is  genetic defic iency being present in a l l  tissues but 
the pattern o f adverse reactions re f le c t in g  the s ites  o f accumulation 
o f the drug. In th is  conection the work o f Takeichi (1980) and 
Bjorkholm et al (1980),suggesting tha t hypertension and ischemic heart 
disease could be re lated to an immunological dysfunction ,is  pe rt inen t. 
Propranolol exhibited the same in h ib i to ry  actions on f ib ro b la s t  growth 
and collagen synthesis in v i t r o  as practo lo l ( th is  thesis) but did 
not in h ib i t  in te s t in a l mucosal glycoprotein synthesis in the ra t  (Okine 
et al 1982). Okine et al suggested tha t the reason practo lo l had an 
e f fe c t  on glycoprotein synthesis and propranolol ( and also ateno lo l) 
had no e f fe c t  was that practo lo l is  read ily  absorbed from the gut and 
has a greater b io a v a i la b i l i t y  than the other drugs used in th e i r  
experiments. S im ilar considerations could be the reason why propranolol 
does not /induce adverse reactions in patients despite being more active 
than practo lo l i_n v i t r o .
Practolol induced none o f the signs o f the"oculomucocutaneous syndrome" 
in animals during chronic feeding t r i a l s  (Case et al 1978) using doses 
higher than that reported by Okine et al (1982) to cause in h ib i t io n  o f
protein synthesis (50-200mg/kg). The s ign if icance o f th e i r  find ing 
is therefore unclear but could be in terpreted as supporting the 
idea that a predisposing fac to r is  necessary fo r  expression of the 
adverse reactions. Experiments using spontaneously hypertensive rats 
could help evaluate th is  hypothesis as well as the possible ro le 
of associated'immunological changes in the development o f the 
practolo l syndrome.
Although the work carried out fo r  th is  thesis has posed more new
questions than i t  has answered several aspects o f the mechanism
involved in the practo lo l syndrome have been c la r i f ie d .
F i r s t  i t  apears tha t p racto lo l and not one o f i t s  metabolites is  
responsible fo r  the adverse reactions associated with i t s  adm in istra tion. 
Second, the lesion involved is  l i k e ly  to be one o f in h ib i t io n  as opposed 
to the stim ulation o f various functions proposed by most authors.
Third, p ra c to lo l,  via an e f fe c t  on the plasma membrane, could e f fe c t
protein synthesis and hence those ce lls  which are most ac t ive , such
as those with a secretory function , would be most effected and, maybe, 
more sensitive to the in h ib i to ry  actions o f p rac to lo l.
Lastly , the d ifference in the s u s c e p t ib i l i ty  o f ce l ls  from
d if fe re n t  people to the in h ib i to ry  e f fe c t  o f practo lo l could be one 
of the predisposing factors in v ivo .
The p o s s ib i l i ty  arises tha t by using f ib rob la s ts  from patients with 
a va r ie ty  of id iopath ic  and drug induced cond it ions,predisposing ‘ 
factors could be id e n t i f ie d .  Such a panel of c e l ls ,  w ith d i f fe re n t  
s e n s i t iv i t ie s  to drugs could be used to screen new drugs fo r  po ten tia l 
side effec ts  and to id e n t i fy  those potentia l patients who would be most 
at r is k  of developing untoward side e ffec ts .
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